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1 Summary 
Tumor angiogenesis is essential for the growth of solid tumors as their proliferation and 
survival is dependent on consistent oxygen and nutrient supply. Anti-angiogenic treatments 
represent a therapeutic strategy to inhibit tumor growth by preventing the formation of new 
blood vessels leading to starvation of the tumor. One of the best characterized 
anti-angiogenic therapeutics is the monoclonal antibody bevacizumab (Avastin), which 
targets and neutralizes VEGF leading to disruption of the VEGF signaling pathway. Until 
today, bevacizumab has found its way into clinical practice and has gained approval for 
treatment of different types of cancer including colorectal cancer, non-small cell lung cancer, 
breast cancer and renal cell carcinoma. Signaling of VEGF is mediated through VEGF 
receptors, mainly VEGFR2, which are primarily located on the cell surface of endothelial 
cells. However, there has been evidence that expression of VEGF receptors can also be 
found on tumor cells themselves raising the possibility of autocrine and/or paracrine signaling 
loops. Thus, tumor cells could also benefit from VEGF signaling, which would promote tumor 
growth. The aim of this study was to investigate if bevacizumab has a direct effect on tumor 
cells in vitro. To this end, tumor cell lines from the NCI-60 panel derived from four different 
tumor types were treated with bevacizumab and angiogenic gene and protein expression as 
well as biological outputs including proliferation, migration and apoptosis were investigated. 
Most of the experiments were performed under hypoxia to mimic the in vivo state of tumors. 
Overall, there was a limited measurable effect of bevacizumab on treated tumor cell lines 
according to gene and protein expression changes as well as biological functions when 
compared to endothelial controls. Minor changes in terms of proliferation or gene regulation 
were evident in a single tumor cell line after VEGF-A blockade by bevacizumab, which 
partially demonstrated a direct effect on tumor cells. However, the overall analysis revealed 
that tumor cell lines are not intrinsically affected in an adverse manner by bevacizumab 
treatment.  
Besides the functional analysis of tumor cells, embryonic stem cell derived endothelial cells 
were characterized to delineate vascular Hey gene functions. Hey and Hes proteins are the 
best characterized downstream effectors of the evolutionary conserved Notch signaling 
pathway, which mainly act as transcriptional repressors regulating downstream target genes. 
Hey proteins play a crucial role in embryonic development as loss of Hey1 and Hey2 in mice 
in vivo leads to a severe vascular phenotype resulting in early embryonic lethality. The major 
aim of this part of the thesis was to identify vascular Hey target genes using embryonic stem 
cell derived endothelial cells utilizing a directed endothelial differentiation approach, as ES 
cells and their differentiation ability provide a powerful in vitro system to study developmental 
processes. To this end, Hey deficient and Hey wildtype embryonic stem cells were stably 
transfected with an antibiotic selection marker driven by an endothelial specific promoter, 
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which allows selection for endothelial cells. ESC-derived endothelial cells exhibited typical 
endothelial characteristics as shown by marker gene expression, immunofluorescent staining 
and tube formation ability. In a second step, Hey deficient ES cells were stably transfected 
with doxycycline inducible Flag-tagged Hey1 and Hey2 transgenes to re-express Hey 
proteins in the respective cell line. RNA-Sequencing of Hey deficient and Hey 
overexpressing ES cells as well as ESC-derived endothelial cells revealed many Hey 
downstream target genes in ES cells and fewer target genes in endothelial cells. Hey1 and 
Hey2 more or less redundantly regulate target genes in ES cells, but some genes were 
regulated by Hey2 alone. According to Gene Ontology term analysis, Hey target genes are 
mainly involved in embryonic development and transcriptional regulation. However, the 
response of ESC-derived endothelial cells in regulating Hey downstream target genes was 
rather limited when compared to ES cells, which could be due to lower transgene expression 
in endothelial cells. The limited response also raises the possibility that target gene 
regulation in endothelial cells is not only dependent on Hey gene functions alone and thus 
loss or overexpression of Hey genes in this in vitro setting does not influence target gene 
regulation. 
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2 Zusammenfassung 
Tumorangiogenese ist essential für das Wachstum von Tumoren, da ihr Überleben und ihre 
Proliferation von einer dauerhaften Versorgung mit Sauerstoff und Nährstoffen abhängig 
sind. Anti-angiogene Therapeutika inhibieren das Wachstum von Tumoren, indem sie die 
Bildung von neuen Blutgefäßen unterbinden, was zu einem „Verhungern“ des Tumors führt. 
Zu den am besten untersuchten anti-angiogenen Therapeutika gehört der monoklonale 
Antikörper Bevacizumab (Avastin), welcher den Wachstumsfaktor VEGF bindet und 
neutralisiert, was schließlich zu einer Unterbrechung des VEGF-Signalweges führt. 
Bevacizumab wird aktuell zur Behandlung verschiedener Tumortypen, unter anderem 
Colonkarzinom, nicht kleinzelliges Lungenkarzinom, Brustkrebs und Nierenzellkarzinom in 
der Praxis angewandt. VEGF bindet an VEGFR2 und andere VEGF-Rezeptoren, welche 
primär an der Oberfläche von Endothelzellen lokalisiert sind. Dennoch gibt es Hinweise, dass 
die Expression von VEGF-Rezeptoren nicht ausschließlich auf Endothelzellen begrenzt ist, 
sondern auch auf Tumorzellen nachgewiesen werden konnte. Die tumorale Expression von 
VEGF-Rezeptoren ermöglicht eine direkte autokrine und/oder parakrine Stimulation von 
Tumorzellen. Tumorzellen könnten dadurch selbst vom VEGF-Signalweg profitieren, was 
das Tumorwachstum fördern würde. Das Ziel dieser Arbeit war es, zu untersuchen, ob 
Bevacizumab in vitro einen direkten Einfluss auf Tumorzellen ausübt. Dazu wurden 
verschiedene Tumorzelllinien von vier unterschiedlichen Tumortypen aus der NCI-60 
Sammlung mit Bevacizumab behandelt und anschließend die Gen- und Proteinexpression 
von angiogenen Markern sowie biologische Funktionen wie Proliferation, Migration und 
Apoptose untersucht. Die Experimente wurden hauptsächlich unter Hypoxie durchgeführt, 
um den in vivo Status von Tumoren nachzuahmen. Insgesamt war ein direkter Effekt von 
Bevacizumab auf Tumorzellen im Vergleich zu Endothelzellen nicht nachweisbar. Gen- und 
Proteinexpression sowie biologische Funktionen waren in Tumorzellen nach 
Bevacizumab-Behandlung bis auf wenige Ausnahmen unverändert. Geringe Veränderungen 
in der Proliferationsrate sowie in der Genregulation nach Inhibition von VEGF durch 
Bevacizumab konnten jeweils in einer einzelnen Zelllinie nachgewiesen werden, wodurch 
zumindest teilweise eine direkte Wirkung von Bevacizumab auf Tumorzellen gezeigt werden 
konnte. Dennoch zeigt die umfassende Analyse der verschiedenen Tumorzellen, dass die 
Bevacizumab-Behandlung sich insgesamt nicht negativ auf Tumorzellen auswirkt und diese 
nicht intrinsisch beeinflusst werden.  
Neben der funktionellen Analyse von Tumorzellen wurden Endothelzellen, die aus 
embryonalen Stammzellen gewonnen wurden, charakterisiert, um anhand derer die Rolle der 
Hey Gene in der vaskulären Entwicklung näher zu bestimmen. Hey und Hes Proteine sind 
die am besten charakterisierten nachgeschalteten Effektoren des evolutionär konservierten 
Notch-Signalweges. Als Transkriptionsfaktoren sind Hey Proteine an der Regulation von 
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Zielgenen beteiligt, wobei sie meist als transkriptionelle Repressoren fungieren. Hey Proteine 
spielen eine sehr wichtige Rolle während der Embryonalentwicklung, da der gemeinsame 
Verlust von Hey1 und Hey2 in Mäusen in vivo einen vaskulären Phenotyp hervorruft, der in 
sehr früher embryonaler Letalität endet. Das Hauptziel dieser Arbeit war es, vaskuläre Hey 
Zielgene mit Hilfe von Endothelzellen, die aus embryonalen Stammzellen differenziert 
wurden, zu identifizieren. Die Fähigkeit embryonaler Stammzellen verschiedene Zelltypen zu 
bilden, liefert dabei ein wertvolles in vitro System, um entwicklungsbiologische Prozesse zu 
analysieren. Dazu wurden Hey-defiziente und Hey-Wildtyp embryonale Stammzellen mit 
einem antibiotischen Selektionsmarker versehen, dessen Expression von einem 
Endothel-spezifischen Promoter kontrolliert wird und daher die Selektion von Endothelzellen 
erlaubt. Die differenzierten Endothelzellen wiesen typische endotheliale Charakteristika auf, 
was durch Markergen-Expression, Immunfluoreszenzfärbungen und der Bildung 
netzwerkähnlicher Strukturen gezeigt werden konnte. In einem zweiten Schritt wurden 
Doxyzyklin-induzierbare Flag-markierte Hey1 bzw. Hey2 Konstrukte stabil in Hey-defiziente 
Zellen integriert, um Hey1 bzw. Hey2 kontrollierbar zu re-exprimieren. Die Zielgensuche 
mittels RNA-Seq Analyse lieferte viele Hey Zielgene in embryonalen Stammzellen, jedoch 
weitaus weniger Zielgene in ausdifferenzierten Endothelzellen. Zusammengefasst zeigten 
Hey1 und Hey2 eine redundante Regulation von Zielgenen in embryonalen Stammzellen, 
wobei einige wenige Gene alleine durch Hey2 reguliert wurden. Die Gen-Ontologie Analyse 
zeigte, dass diese Zielgene hauptsächlich an der embryonalen Entwicklung und der 
transkriptionellen Regulation von anderen Genen beteiligt sind. Dennoch war die Anzahl der 
Hey regulierten Gene in Endothelzellen weitaus geringer als in embryonalen Stammzellen. 
Das könnte auf eine geringere Transgen-Expression in Endothelzellen im Vergleich zu 
embryonalen Stammzellen zurückzuführen sein. Die weitaus geringere Anzahl an Hey 
Zielgenen in Endothelzellen lässt außerdem vermuten, dass die Regulation von Zielgenen in 
Endothelzellen nicht ausschließlich von der Funktion der Hey Gene abhängig ist. Die 
Regulation von Hey Zielgenen in Endothelien wurde durch den Verlust bzw. die 
Überexpression von Hey1 und Hey2 in dem angewandten in vitro System nur geringfügig 
beeinflusst.  
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3 Introduction 
3.1 Anti-angiogenic therapy of human tumor cells 
3.1.1 Tumor angiogenesis 
The growth of tumor cells is dependent on consistent oxygen and nutrient supply, which are 
provided by blood vessels. The formation of blood vessels is a two-stage process, involving 
vasculogenesis and angiogenesis. During vasculogenesis the primary vascular plexus is 
formed from the mesoderm by differentiation of angioblasts, which subsequently build 
primitive blood vessels. Vasculogenesis mainly occurs during early development. After 
vasculogenesis the primary plexus is remodeled by a process named angiogenesis. During 
angiogenesis more endothelial cells are generated and new capillaries are formed e.g. by 
sprouting from pre-existing vessels (Risau, 1997). The formation of blood vessels form 
pre-existing ones is not only restricted to early development, but also occurs in adult 
organisms regulating physiological processes, e.g. wound-healing. Angiogenesis also occurs 
in pathological processes leading to a severe formation of vessels, e.g. in tumor growth. 
Tumor growth is dependent on persistent blood vessel growth, which allows tumors also to 
metastasize and to spread. Tumor fragments or tumor cells, which are placed into avascular 
sites, are able to attract new capillaries from the existing host vascular network, which 
demonstrates the dependency of tumor cell growth from blood vessels (Hanahan and 
Folkman, 1996, Gimbrone et al., 1972). Inadequate blood and thus oxygen supply can lead 
to tissue hypoxia, a massive reduction of the normal tissue oxygen tension. Tissue hypoxia 
often emerges as a consequence of acute and chronic vascular diseases as well as cancer. 
Most solid tumors develop low oxygen regions and are able to adapt to the hypoxic 
environment in contrast to healthy tissue. Therefore, tumor cells undergo genetic and 
adaptive changes, which allow them to survive and to proliferate even under hypoxic 
conditions. Low intratumoral oxygen levels can affect several biological parameters and often 
lead to a more aggressive and malignant phenotype of tumors. Because of its strong 
association with tumor progression and malignancy, tumor hypoxia has evolved to an 
important therapeutic target in cancer treatment (Harris, 2002, Hockel and Vaupel, 2001). In 
response to the hypoxic environment a variety of biological processes including cell 
proliferation, cell migration, apoptosis, switch from an aerobic to an anaerobic metabolism as 
well as angiogenesis are affected. In tumor cells, one of the main responses to hypoxia is the 
production of growth factors, which induce angiogenesis (Harris, 2002). Hypoxia-induced 
biological processes are controlled by HIF-1 (Hypoxia-inducible factor-1), which is the major 
transcription factor regulating gene expression in mammalian cells in response to hypoxia. 
This basic-helix-loop-helix transcription factor consists of HIF-1α and HIF-1β subunits, which 
activate transcription of hypoxic sensitive genes upon heterodimerization under hypoxia 
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(Wang et al., 1995). One of the major hypoxic sensitive genes is vascular endothelial growth 
factor (VEGF), which is strongly induced under hypoxa (Harris, 2002). Besides VEGF other 
angiogenic genes like VEGF receptors, VEGFR1 (FLT-1) and VEGFR2 (FLK-1), as well as 
the co-receptor Neuropilin1 (NRP1) are involved in the process of tumor angiogenesis and 
thus of particular interest in this study.  
3.1.2 Angiogenic pathway molecules 
Vascular endothelial growth factor A (VEGF-A) is the major inducer of angiogenesis and also 
plays an important and essential role in tumor angiogenesis. Signaling through its receptors 
presents the best characterized pathway in angiogenesis (Ferrara and Kerbel, 2005). VEGF 
was identified in 1989 by Ferrara and collaborators, which described VEGF as a secreted 
molecule mediating endothelial cell growth and angiogenesis (Leung et al., 1989, Ferrara 
and Henzel, 1989, Keck et al., 1989). The VEGF family consists of  seven subtypes including 
VEGF-A, VEGF-B, placental growth factor (PLGF), VEGF-C and VEGF-D from mammals as 
well as parapoxvirus genome encoded VEGF (viral VEGF, also denoted as VEGF-E) and 
snake venom-derived VEGF, also referred as VEGF-F. All VEGF family members are 
secreted glycoproteins, which contain a cystein knot motif with three intertwined disulfide 
bridges. VEGF members function as ligands and are able to bind to corresponding tyrosine 
kinase receptors like VEGFR1 (FLT-1), VEGFR2 (FLK-1) and VEGFR3 (FLT-4) and 
non-tyrosine kinase receptors, Neuropilin1 (NRP1) and Neuropilin2 (NRP2). NRP1 and 
NRP2 serve as co-receptors for VEGF binding. Binding of VEGF subtypes is highly selective 
for specific receptors and occurs with different binding affinities, which reflects the diversity of 
the VEGF family in biological functions (Yamazaki and Morita, 2006).  
The best characterized and most important member of the VEGF family is VEGF-A. Human 
VEGF-A is located on chromosome six and contains eight exons. Due to alternative splicing 
different isoforms of VEGF-A with varying exon content are generated, which can differ in 
their functional properties as well as in their expression pattern (VEGF-A121, VEGF-A145, 
VEGF-A148, VEGF-A165, VEGF-A183, VEGF-A189 and VEGF-A206). Amongst all isoforms of 
VEGF-A, VEGF-A165 is known as the predominant and best characterized isoform. In 
general, expression of VEGF-A is often increased in several pathologies including cancer 
and thus is investigated in detail for its function in cancer progression (Harper and Bates, 
2008). VEGF-A has been described as the major ligand for VEGFR2 (FLK-1, KDR) and 
signaling through VEGFR2 plays an essential role in the development of the vascular system 
and the process of angiogenesis (Millauer et al., 1993). VEGFR2 is a 200-230 kDa tyrosin 
kinase receptor, which is primarily located on the cell surface of endothelial cells. According 
to its high binding affinity for VEGF-A it is the major mediator of the mitogenic, angiogenic 
and permeability-enhancing effects of VEGF-A (Ferrara and Kerbel, 2005). VEGFR2 
contains a series of immunoglobulin-like domains in the extracellular region and a conserved 
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intracellular tyrosine kinase domain (Lohela et al., 2009). Phosphorylation of the two main 
autophosphorylation sites of VEGFR2, Tyr1175 and Tyr1214, leads to activation of 
downstream pathways of the VEGF-A-VEGFR2 signaling axis. Activation of downstream 
intracellular signaling pathways are involved in the regulation of biological processes like 
migration, vascular permeability, survival and proliferation as illustrated in Fig. 1 (Takahashi 
and Shibuya, 2005). 
Another tyrosine kinase receptor involved in angiogenesis is VEGFR1 (FLT-1). VEGFR1 is a 
180 kDa protein, which is also activated through binding of VEGF-A, but in addition can also 
be stimulated by PLGF. VEGFR1 is expressed on vascular endothelial cells, but also on 
non-endothelial cells like macrophages and monocytes as well as haematopoietic stem cells 
(Takahashi and Shibuya, 2005). Although expression of VEGF receptors in general is mainly 
found on endothelial cells, there has also been evidence for expression on tumor cells for 
non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and breast cancer (BC) (Duff 
et al., 2006, Seto et al., 2006, Ghosh et al., 2008). Tumor cells expressing VEGF receptors 
on their cell surface could benefit from autocrine or paracrine signaling loops of VEGF-A 
signaling to enhance tumor growth and survival. A co-receptor of the VEGF pathway, 
Neuropilin1 (NRP1), is a 130 – 135 kDa cell surface glycoprotein, which is activated by 
binding of specific isoforms of VEGF-A (Soker et al., 1996). Binding of VEGF-A165, but not 
VEGF-A121, is able to activate NRP1 signaling, which indicates that signaling through NRP1 
is isoform-dependent on VEGF-A. Besides VEGF-A other members of the VEGF family like 
PLGF can function as ligands for NRP1. In addition, as a co-receptor for VEGF signaling, 
NRP1 is able to enhance VEGF-A binding to VEGFR2. Expression of NRP1 is not primarily 
present on endothelial cells, but also can be found to a great extent on the cell surface of 
tumor cells of breast and prostate carcinoma as well as melanoma (Soker et al., 1996, Soker 
et al., 1998).  
A scheme of VEGF-A signaling through its receptors VEGFR1 and VEGFR2 as well as its 
co-receptor NRP1 is presented in Fig. 1.  
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Fig. 1 Interactions of VEGF family members with VEGF receptors and NRP co-receptors 
(modified from Takahashi and Shibuya, 2005). VEGF family members bind to their receptors with 
different binding specificity (indicated by the arrows). Binding of VEGF to VEGFR2 leads to 
dimerization of the receptor and to autophosphorylation of the main phosphorylation sites (Y1214, 
Y1175) inducing downstream signaling pathways, which are involved in regulation of cell migration, 
vascular permeability, cell survival and cell proliferation (detailed downstream signaling pathways are 
presented in a review from Takahashi and Shibuya, 2005). 
3.1.3 Biological function of VEGF-A 
VEGF plays a very crucial role during angiogenesis and in normal blood vessel development 
as shown by VEGF deletion studies. (Carmeliet et al., 1996, Ferrara et al., 1996). VEGF 
deletion in mice revealed that already the loss of a single allele of VEGF resulted in early 
lethality between embryonic day 11 and 12 due to impaired angiogenesis and reduced 
blood-island formation. Furthermore, endothelial cell differentiation is delayed in VEGF 
knockout mice and most steps of early vascular development are impaired (Ferrara et al., 
1996). Besides vascular development and blood vessel formation, VEGF is also involved in 
many pathological conditions like the growth of solid tumors, hematological malignancies, 
inflammatory disorders and pathologies of the female reproductive tract (Ferrara, 2004). A 
functional involvement of VEGF in angiogenesis and tumorigenesis was shown by VEGF 
depletion in embryonic stem cells and subsequent injection into nude mice. VEGF deficient 
cells were impaired in their growth in vivo and exhibited a decreased ability to form tumors in 
nude mice, which indicated that even in a pluripotent system VEGF is essential for 
tumorigenesis (Ferrara et al., 1996). Involvement of VEGF in tumorigenesis is also apparent 
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from in vitro studies, as several tumor cell lines secrete VEGF-A in cell culture (Ferrara et al., 
1992). Secretion of VEGF from tumor or endothelial cells supports the theory of an autocrine 
or paracrine stimulation of neighboring cells. Paracrine stimulation enhances angiogenesis 
by secretion of angiogenic growth factors or cytokines like PDGF, EGF, TNF-α and IL-1β 
from endothelial cells, which leads to induced VEGF mRNA transcription in tumor cells 
(Ferrara and Davis-Smyth, 1997). Subsequently, the release of growth factors from tumor 
cells like VEGF can activate VEGF signaling on host cells, e.g. endothelial cells. Spread and 
proliferation of endothelial cells lead to vessel extension and recruitment of supporting cells, 
like pericytes, to form a new vascular network (McMahon, 2000). In contrast, autocrine 
stimulation can exert a direct effect on tumor cells. If tumor cells express VEGF receptors on 
their cell surface, autocrine stimulation can lead to enhanced VEGF signaling, which in turn 
promotes tumor growth (McMahon, 2000). Besides secretion of VEGF from tumor and 
endothelial cells, VEGF expression is also demonstrated in tumor tissue of human tumors 
including lung and breast cancer cells by immunohistochemistry. Intensity of VEGF staining 
is variable between different tumor samples from very high to very low expression, but there 
is no significant correlation between the amount of VEGF expression and the degree of 
tumor progression (Volm et al., 1997, Yoshiji et al., 1996). Furthermore, the possibility of an 
autocrine VEGF signaling loop is supported by VEGF receptor expression on the cell surface 
of tumor cells and thus not only restricted to the surrounding vasculature.  
3.1.4 The complexity of cancer 
Besides cardiovascular diseases, cancer is the second most common death in Germany. 
According to data from the Federal Statistical Office more than 26 % of all deaths in 
Germany in 2011 were related to cancer. As the number of new cases is still increasing, the 
search for therapeutic agents targeting cancer is an essential component of today’s research 
to promote prevention and treatment of cancer. The major problem of treating cancer is its 
complexity when compared to other diseases, as it does not underlie a universal defined 
cause and as it can originate in almost every organ of the human body. Different organs of 
the human body are affected to varying degree and also differentially affected in males and 
females. The most common cancer disease worldwide in males is lung cancer and in 
females breast cancer. Colorectal cancer is the third most commonly diagnosed cancer in 
males and the second one in females, while renal cell carcinoma occur less frequently in 
both, males and females (Jemal et al., 2011). Because of differences in origin and 
progression of cancer it is impossible to treat it with a universal therapy. In addition, cancer 
cells are often able to metastasize and to spread all over the body, which makes therapy 
even more difficult. Initial assumptions about the cause of cancer were described by Theodor 
Boveri in 1914, who linked chromosomal changes, as numerical and structural aberrations of 
chromosomes, to the origin of cancer (Boveri, 2008). Besides chromosomal aberrations also 
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genomic changes like mutations in oncogenes and tumor suppressor genes have been 
described as a major cause of cancer. Oncogenes and tumor suppressor genes mainly 
function as important regulators of cell division, cell proliferation, apoptosis and cell cycle 
control and thus, mutations can result in deregulation and uncontrolled proliferation of cancer 
cells (Croce, 2008, Levine and Oren, 2009). Alterations in cell physiological processes like 
self-sufficiency in growth signals, insensitivity to growth-inhibitory signals, evasion of 
apoptosis, limitless replicative potential, tissue invasion and metastasis as well as sustained 
angiogenesis have also been linked to the complexity of cancer (Hanahan and Weinberg, 
2000). Tumor cells have developed resistance against tightly controlled physiological 
processes, which facilitates their proliferation and tumor growth.  
Although no unique therapy to cure cancer is available, a common useful therapeutic 
approach is chemotherapy. Chemotherapy aims at either killing cancer cells or preventing 
cancer cells from proliferation. The large disadvantage of chemotherapeutic agents is their 
impact on malignant as well as healthy tissue, which has led to the discovery and the 
development of novel anticancer drugs. Anticancer drugs specifically inhibit molecules of 
pathways, which are essential for tumor progression. These new approaches of targeting 
cancer, e.g. by preventing the building of new vessels has extended the traditional view of 
targeting cancer only by chemotherapy (Ramaswami et al., 2013). Targeting angiogenesis is 
one of the novel tumor therapy approaches, which has already been investigated over the 
past decade (Ferrara et al., 2004).  
3.1.5 Bevacizumab – a monoclonal antibody for anti-angiogenic treatment and 
cancer therapy 
Anti-angiogenic therapy was first described as a novel cancer treatment approach targeting 
angiogenesis by Judah Folkman about 40 years ago (Folkman, 1971). Even earlier it was 
evident that the growth of solid tumors is closely connected to new vessel growth and 
vascular supply (Algire et al., 1950). The association between growing malignant tumors and 
new vessel growth has led to intensive research on anti-angiogenic targets as well as on the 
development of anti-angiogenic drugs. The first anti-angiogenic agent targeting blood vessel 
supply of tumors was bevacizumab, a humanized monoclonal antibody against VEGF. 
Bevacizumab was developed by Ferrara et al. in 1997 by humanization of the mouse 
anti-VEGF monoclonal antibody A.4.6.1. It binds and neutralizes all VEGF-A isoforms and 
bioactive proteolytic fragments, thereby limiting the interaction between VEGF and VEGF 
receptors. The impaired interaction of VEGF and VEGF receptors results in disruption of the 
VEGF pathway and thus tumor angiogenesis. Since 1997 bevacizumab has been passed 
through several clinical trials from phase I to phase III studies and was finally approved by 
the Food and Drug Administration as a first-line treatment for metastatic colorectal cancer in 
February 2004. In several phase II studies bevacizumab was combined with 
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chemotherapeutic agents, e.g. 5-fluoruracil/leucovorin and irinotecan, which resulted in 
prolonged survival of patients with colorectal and non-small cell lung cancer (Ellis and 
Hicklin, 2008). Until today, bevacizumab has proven efficacy in clinical applications in 
combination with chemotherapy for colorectal cancer (Hurwitz et al., 2004), non-small cell 
lung cancer (Sandler et al., 2006), breast cancer (Miller et al., 2007) and in combination with 
interferon treatment for renal cancer (Escudier et al., 2007). Clinical trials and case studies 
for treatment of patients with bevacizumab and chemotherapeutic agents lead to prolonged 
survival and progression free survival but do not increase overall survival of patients. Several 
open-label phase I and phase II studies identified a number of adverse side effects including 
thrombosis, bleeding, proteinuria and hypertension, which were caused by bevacizumab 
treatment, but overall it is well tolerated by the patients (Ferrara et al., 2005). Although 
application of bevacizumab could efficiently improve response rates and prolong survival of 
patients, further research is needed in the field of anti-angiogenic treatments to enhance 
overall survival. Tyrosine kinase inhibitors of VEGFR1 and VEGFR2 (sorafenib, sunitinib) are 
already under investigation and part of clinical trials and applications (Escudier et al., 2009, 
Motzer et al., 2009). Targeting other members of the VEGF pathway, e.g. PLGF and NRP1, 
could also improve efficacy in case of resistance that develop from existing treatments (Ellis 
and Hicklin, 2008). Combination therapies simultaneously targeting ligands and receptors of 
the VEGF signaling pathway would be beneficial for cancer therapy. In addition, the 
identification of new biomarkers and the development of new drugs targeting angiogenic 
pathway molecules are required to improve anti-angiogenic treatment.  
3.1.6 Tumor cell lines for the experimental research of cancer 
A useful tool to study the impact of anticancer drugs in vitro is the availability of a wide 
variety of human tumor cell lines. A group of specific immortal human tumor cell lines derived 
from nine different tissues, known as the NCI-60 panel from the National Cancer Institute, 
build the basis of tumor related cell culture research since decades. Cell lines from the 
NCI-60 panel were systemically characterized according to their genetics and genomics by 
the Cancer Genome Project to improve their utility and interpretation of data in terms of drug 
discovery. Furthermore, the experimental use of tumor cell lines from the NCI-60 panel 
provides the possibility to relate recently achieved data with new data. To this end, 
experiments in this study were performed with tumor cell lines derived from the NCI-60 
panel. More detailed information is provided at 
http://dtp.nci.nih.gov/branches/btb/characterizationNCI60.html. An overview of all 60 tumor 
cell lines of the panel is given at: http://cancer.sanger.ac.uk/cell_lines/cbrowse/nci.  
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3.1.7 Aim of the thesis – part I 
The major goal of this part of my thesis was to investigate potential direct effects of 
bevacizumab on human tumor cells in vitro. As VEGF receptors can be present on the cell 
surface of human tumor cells, secretion of VEGF-A could lead to an autocrine or paracrine 
stimulation of tumor cells. Anti-angiogenic agents like bevacizumab could therefore have 
additional antitumoral effects besides their impact on endothelial cells.  
Tumor cell lines from the NCI-60 panel derived from four different tumor types (NSCLC, 
CRC, RCC and BC) were used to study changes in angiogenic gene and protein expression 
after bevacizumab exposure. In addition, alterations of cellular responses like proliferation, 
migration and apoptosis, due to bevacizumab treatment, were measured in a larger number 
of tumor cell lines. 
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3.2 The role of Hey genes during vascular development 
3.2.1 Blood vessel development and function of the endothelium 
The first organ to develop during embryogenesis is the blood vessel system. The formation 
of blood vessels is a two-stage process, including vasculogenesis and angiogenesis. During 
vasculogenesis the primary vascular plexus is formed from the mesoderm by differentiation 
of angioblasts into blood islands. Central cells of the blood islands give rise to embryonic 
blood cells, while peripheral cells of the blood islands differentiate into endothelial cells. 
Subsequently, endothelial cells build the primary vascular plexus, which is remodeled to form 
the extraembryonic yolk sac vasculature. Intraembryonic vascular development is initiated by 
differentiation of hemangioblasts into the vascular primary plexus, which builds the aorta and 
the cardinal vein. After vasculogenesis, a more complex vascular network is formed by 
interaction of endothelial cells with mural cells and by generation of new capillaries, e.g. by 
sprouting of vessels from pre-existing ones, a process called angiogenesis. The complete 
vasculature is formed by intensive remodeling after specification of arterial and venous blood 
vessels (Risau, 1997, Flamme et al., 1997, Choi, 2002, Park et al., 2013).  
The inner surface of blood vessels is lined with vascular endothelial cells. Endothelial cells 
mainly function as a physical barrier between vessel walls and the intravascular space 
controlling the exchange of oxygen and nutrients between blood and tissues. A precise 
organ-specific oxygen supply results from the selective permeability of endothelial cells, 
which is due to their heterogeneity. Endothelial cells can mainly be sub-divided into three 
different phenotypes according to their morphology and their vascular permeability: 
continuous, fenestrated and discontinuous endothelium. Continuous endothelial cells are 
connected to each other with tight junctions and exchange of substances between blood and 
tissue mainly occurs through specific transport mechanisms. Fenestrated and discontinuous 
capillaries exhibit a higher permeability. The different phenotypes of endothelial cells exhibit 
various functions and show a different organ distribution. Continuous endothelium for 
example can be found in the central nervous system, where it functions as the so-called 
blood-brain barrier controlling diffusion of molecules into the brain. Discontinuous endothelial 
cells are primarily found in tissues with high filtration, secretion and absorption, e.g. in the 
kidney, and are more permeable for low molecular hydrophilic molecules. Thus, the 
differentiation into a specific endothelial phenotype is adapted to the specific needs of the 
organ and occurs through interaction of endothelial cells and the surrounding tissue (Risau, 
1995). 
3.2.2 The canonical Notch signaling pathway 
The Notch signaling pathway is a central regulator of gene expression, which controls cell 
fate determination and cell differentiation processes. It plays a very crucial role in embryonic 
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development as demonstrated by several knockout studies. Loss of ligands and receptors of 
the Notch signaling pathway often result in early lethality of the mouse embryo. In humans, 
mutations of Notch ligands and Notch receptors are associated with several diseases like 
Alagille syndrome, CADASIL, T-cell leukemia, aortic valve calcification and other 
cardiovascular diseases (Fischer and Gessler, 2007). Notch signaling is highly conserved 
throughout different species from Caenorhabditis elegans, Drosophila melanogaster to 
vertebrates and mammals. In mammals, there are four Notch receptors (Notch1-4), while 
Caenorhabditis elegans exhibits only two (LIN-12, GLP-1) and Drosophila melanogaster only 
one receptor (Notch). Notch receptors are transmembrane proteins, which are activated by 
binding of a ligand, another transmembrane protein, of a neighboring cell (Delta, Serrate, 
Jagged). Thus, activation of Notch signaling requires direct interaction between two cells. 
The interaction with Notch ligands on the neighboring cell is mediated by epidermal growth 
factor (EGF)-like repeats. The binding of a ligand to the Notch receptor on the neighboring 
cell results in two proteolytic cleavages. The first cleavage is catalyzed by an ADAM 
metalloprotease, while the second cleavage is mediated by γ-secretase, which leads to the 
release of the Notch intracellular domain (NICD). γ-secretase is an enzyme complex 
consisting of presenilin, the catalytic subunit, and three transmembrane proteins, nicastrin, 
APH1 and PEN-2. The Notch intracellular domain is translocated to the nucleus, where it 
interacts with a CSL DNA-binding protein complex named CBF1/RBPkJ in mammals (LAG-1 
in Caenorhabditis elegans, Su(H) in Drosophila melanogaster). In addition, co-activators like 
Mastermind in Drosophila melanogaster and mammals (LAG-3 in Caenorhabditis elegans) 
as well as the histone acetylase p300 and the Ski-interacting protein (SKIP) are recruited by 
Notch to promote transcription of target genes (Bray, 2006). Transcription of target genes is 
suppressed by association of the RBPkJ complex with co-repressors. To initiate transcription 
of target genes co-repressors are released upon binding of the Notch intracellular domain. 
Amongst others, the most and best studied downstream target genes of Notch signaling are 
Hairy and Enhancer-of-split genes in Drosophila melanogaster and Hes and Hey genes in 
mammals (Fischer and Gessler, 2007).  
A scheme of the canonical Notch signaling pathway is presented in Fig. 2. 
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Fig. 2 Scheme of Notch signaling (modified from Fischer and Gessler, 2007). Ligands of the 
Delta (Dll) orJagged (Jag) family induce intramembrane cleavage of the Notch receptor (Notch). The 
intracellular domain (green colored circle) replaces transcriptional co-repressors (rep) with activators 
(act) enabling transcription of Hes and Hey genes by RBPkJ. 
3.2.3 Hey basic helix-loop-helix transcription factors 
Two of the best characterized downstream target genes of the canonical Notch signaling 
pathway are the mammalian Hes and Hey genes. Hes and Hey genes are closely related to 
the Hairy and Enhancer-of-split genes in Drosophila melanogaster according to their domain 
organization (Fischer and Gessler, 2007). All members contain a basic helix-loop-helix 
domain and an Orange domain. Within the basic domain, Hey proteins differ from Hes 
proteins, as they contain a glycine residue instead of a proline residue. Because of this 
amino acid change Hey proteins cannot bind to N-box sequences (CACNAG) in promoters 
and preferentially bind to E-box sequences (CACGTG) instead (Nakagawa et al., 2000). The 
C-terminal part of Hey proteins contains a YRPW (Y) motif, followed by a TEIGAF (T) motif 
and thus differs from Hes proteins, which contain a WRPW (W) motif. The structure of Hes 
and Hey proteins and their domain organization is shown in Fig. 3.  
 
Fig. 3 Structure of Hes and Hey proteins and their domain organization (modified from Fischer 
and Gessler, 2007). Hes and Hey proteins contain a basic (b) helix-loop-helix (HLH) domain and an 
Orange (Or) domain. They differ in their C-terminal part as Hes proteins contain a WRPW (W) motif 
and Hey proteins contain a YRPW (Y) motif followed by a TEIGAF (T) motif. 
In mammals, a new subfamily of the hairy-related basic helix-loop-helix (bHLH) proteins with 
three members, Hey1, Hey2 and HeyL, was identified in 1999 by Leimeister et al. 
Mammalian Hey proteins are also known as Hrt, Hesr, Herp and Chf (Leimeister et al., 1999, 
Nakagawa et al., 1999, Kokubo et al., 1999). Hey genes encode transcriptional regulators, 
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which mainly function as repressors. Regulation of transcription occurs by interaction of Hey 
proteins with other basic helix-loop-helix proteins or by recruitment of additional 
co-repressors. For transcriptional regulation Hey proteins can bind to the DNA, which is 
mediated by their basic domain, whereas their helix-loop-helix domain is essential for 
homo- and heterodimerization (Massari and Murre, 2000). Both, Hey and Hes proteins, can 
form homo- as well as heterodimers and bind to similar DNA-sequences to repress target 
gene transcription, whereby heterodimers show higher and stronger DNA binding affinity and 
repression activity than homodimers (Iso et al., 2001). The stability of heterodimers can be 
increased by the Orange domain, which is also necessary for additional protein interactions 
(Leimeister et al., 2000). In Hes proteins, transcriptional repression is mainly mediated by the 
WRPW (W) motif in the C-terminal part, as it can recruit the co-repressor TLE (Grbavec and 
Stifani, 1996). In contrast, the C-terminal YRPY (Y) motif of Hey proteins is not able to 
mediate transcriptional repression. Repressive functions of Hey proteins are mainly caused 
through direct interaction between the helix-loop-helix domain and other repressive proteins 
like the mSin3 complex, which includes HDAC1 and HDAC2. This complex is associated with 
additional co-repressors like N-CoR and SMRT (Iso et al., 2001). Furthermore, transcriptional 
repression can also be mediated by interaction with SIRT1, which has been shown at least 
for Hey2 and Hes1 (Takata and Ishikawa, 2003). Any function of the C-terminal TEIGAF (T) 
motif has not been elucidated so far. 
3.2.4 Expression and function of Hey genes during cardiovascular development 
As downstream effectors of the Notch signaling pathway, Hey genes play an important role 
during embryonic development as shown by several knockout studies in mice. The single 
loss of Hey2 in mice reveals a strong cardiac phenotype, which leads to embryonic lethality 
during the first ten days of life. Hey2 knockout mice show ventricular and atrioventricular 
septum defects with massive hypertrophy and cardiomyopathy (Donovan et al., 2002, 
Gessler et al., 2002, Sakata et al., 2002). In contrast, deletion of either Hey1 or HeyL does 
not result in any cardiac phenotype, but the combined loss of Hey1 and HeyL in turn shows a 
similar phenotype as the single loss of Hey2 (Fischer et al., 2007). Besides cardiac 
phenotypes, Hey deletion also causes vascular phenotypes in mice. The combined loss of 
Hey1 and Hey2 leads to early lethality at embryonic day 9.5 due to impaired angiogenic 
remodeling and impaired arterial cell fate determination. Hey1 and Hey2 deficient embryos 
suffer from massive bleeding in the trunk and in the head region and show truncated and 
less well organized blood vessels. The size of large blood vessels in knockout embryos is 
often strongly reduced or the dorsal artoae and the cardinal veins are even absent (Fischer 
et al., 2004). The lethal vascular phenotype as a result of the combined loss of Hey1 and 
Hey2 emphasizes their important role in embryonic vascular development. At later 
developmental stages Hey1 and Hey2 expression in blood vessels is restricted to endothelial 
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cells of the arteries and to smooth muscle precursor cells, but no expression can be found in 
endothelial cells of veins. As downstream effectors of active Notch signaling Hey proteins are 
involved in arterial cell fate determination and the complex process of the development of the 
vascular system (Fischer et al., 2002). 
3.2.5 The role of Notch signaling and Hey genes in endothelial cell specification 
Loss of Hey1 and Hey2 in mice leads to a lack of arterial cell fate determination, which 
emphasizes the importance of Hey proteins in determining endothelial cell specification 
(Fischer et al., 2004). Arterial cell determination is mediated by Hey proteins as shown by 
overexpression of Hey2 in zebrafish (Zhong et al., 2001) as well as in human endothelial 
cells (Chi et al., 2003). Overexpression of Hey2 diminishes vein formation and induces 
expression of artery-specific genes. The arterialization process initiated by Notch signals is 
counteracted by CoupTFII, also known as Nr2f2. CoupTFII is a major regulator of venous 
endothelial cells, which inhibits Notch signaling and the expression of arterial specific genes. 
In contrast, loss of CoupTFII leads to the induction of Notch signaling and the expression of 
arterial marker genes in veins (You et al., 2005). However, little is known from the literature 
about the antagonism and a possible direct interaction between CoupTFII and Hey proteins. 
Differentiation of arterial endothelial cells is stimulated by VEGF, which may act upstream of 
Notch signaling. VEGF binds to the VEGF receptor 2 and leads to expression of Dll4, which 
activates Notch signaling (Lawson et al., 2002). As a result of activated Notch signaling 
expression of its downstream target genes Hey1 and Hey2 is induced. Expression of Hey1 
and Hey2 in arterial cells has been linked to the hypoxic response, as VEGF was strongly 
increased in Hey1/2 double knockout embryos compared to controls indicating that these 
embryos suffer from hypoxia (Fischer et al., 2004). In endothelial cells and endothelial 
progenitor cells hypoxia leads to induction of Hey1 and Hey2 as well as to the induction of 
the Notch ligand Dll4 (Diez et al., 2007). Increasing amounts of Dll4 enhance Notch signaling 
and Hey gene expression, which determines the arterial phenotype of endothelial cells. 
Furthermore, Hey expression is also able to suppress CoupTFII and thus venous cell fate 
determination (Diez et al., 2007). The converse negative regulation of Hey and CoupTFII 
emphasizes an important role of both pathways in regulating arterial versus venous 
endothelial cell fate determinations (Wiese et al., 2010). A schematic model of arterial versus 
venous endothelial cell specification is shown in Fig. 4. 
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Fig. 4 Schematic model of arterial versus venous endothelial cell specification (modified from 
Wiese et al., 2010). VEGF binds to the Vegfr2/Nrp1 heterodimer that leads to expression of Dll4 and 
activation of Notch receptors. The Notch target genes Hey1 and Hey2 are induced upon active Notch 
signaling leading to arterial endothelial cell specification by additionally suppressing venous 
endothelial cell development. In contrast, expression of CoupTFII is able to suppress Nrp1 leading to 
reduced Notch signaling.  
3.2.6 Notch signaling and Hey gene functions in embryonic stem cells and 
endothelial cells 
The combined loss of Hey1 and Hey2 leads to a severe vascular phenotype during 
embryonic development and results in early lethality in vivo. The lethal phenotype in vivo 
requires a system to study the role of Hey genes during development in vitro. A commonly 
used system to study developmental processes dependent on specific gene functions is 
based on the use of embryonic stem cells and their differentiation ability. Embryonic stem cell 
cultures were first established in the 1980s. Stem cells were isolated from the inner cell mass 
of a developing blastocyst from mice and could be further cultured in vitro (Evans and 
Kaufman, 1981). Embryonic stem cells exhibit two major characteristics, namely their 
capacity of self-renewal and their pluripotent ability to differentiate into cells from all three 
germ layers including ectoderm, mesoderm and endoderm, which reflects in vivo embryonic 
development (Doetschman et al., 1985). To study developmental processes in vitro, 
embryonic stem cells can be used for the differentiation into specific cell types. Thereby, the 
use of genetically modified or knockout cells allows the investigation of the differentiation of 
ES cells in dependence of a specific gene. For this purpose, Hey deficient and Hey 
re-expressing embryonic stem cells were generated to study specific Hey gene functions 
during differentiation. Results obtained from earlier in vitro studies using Hey deficient ES 
cells further supported knockout studies of Hey deficient mice according to deregulation of 
cardiac related genes (Fischer et al., 2005). Furthermore, it has been shown that inhibition of 
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Notch signaling influences VEGF-induced arterialization and endothelial differentiation, which 
results in a phenotypic switch from arterial to venous endothelial cells (Lanner et al., 2007).  
3.2.7 Aim of the thesis – part II 
The major goal of the second part of my thesis was to identify vascular Hey target genes 
using an in vitro differentiation system with embryonic stem cells. The combined loss of Hey1 
and Hey2 leads to a severe vascular phenotype and early embryonic lethality in vivo. Thus, 
an in vitro system is needed to study Hey gene functions during vascular development. 
Hey1/2 deficient embryonic stem cells were stably transfected with an antibiotic resistance 
gene under the control of endothelial specific promoters (VE-Cadherin, Tie1) to establish a 
selection-based differentiation method for endothelial cells in a chemically defined medium. 
In a second step, Hey1 and Hey2 inducible plasmids were used to re-express either Hey1 or 
Hey2 in embryonic stem cells to study endothelial cell differentiation in the absence or 
presence of Hey genes. Finally, whole transcriptome analysis was performed in embryonic 
stem cells as well as in embryonic stem cell (ESC) derived endothelial cells to identify 
possible Hey downstream target genes.  
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4 Material 
4.1 Chemicals 
Chemicals were purchased from Roth GmbH, Sigma-Aldrich GmbH or AppliChem GmbH 
unless otherwise indicated. 
 
peqGOLD TriFastTM PeqLab 
SYBR Green Ambrex Bio Science 
4.2 Plasmids 
pTol2-ins-VE-Or-Blast and pTol2-ins-Tie1-blast 
Expression construct with miniTol2 flanking sites for target gene integration of VE-Cad-bsd or 
Tie1-bsd. 
 
 
 
pKate-NI-Tol2 
Expression construct for Tol2 transposase. 
 
pSB-FS-mHey1 and pSB-Flag-mHey2 
Expression construct with a doxycycline dependent transactivator (TA) to induce target 
gene expression upon addition of doxycycline. Inverted terminal repeats (IR/DR) are the 
recognition sites for the SB100X transposase for integration to a genomic target site. 
 
 
 
pCMV-(CAT)-T7-SB100X 
Expression construct for SB100X transposase. 
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4.3 Cell culture material 
4.3.1 Cell culture media and supplements 
0.25 % Trypsin-EDTA solution Sigma-Aldrich GmbH 
AccutaseTM Sigma-Aldrich GmbH 
Alpha-MEM Sigma-Aldrich GmbH 
bFGF Miltenyi Biotec GmbH 
BMP4 Miltenyi Biotec GmbH 
DMEM Sigma-Aldrich GmbH 
ECGS Sigma-Aldrich GmbH 
FBS PAN Biotech 
Glutamax (100x) Life Technologies GmbH 
Heparin Sigma-Aldrich GmbH 
Knockout-DMEM Life Technologies GmbH 
KnockOut™ Serum Replacement Life Technologies GmbH 
Leukemia inhibitory factor (LIF) Developmental Biochemistry,  
 University of Wuerzburg 
M199 Sigma-Aldrich GmbH 
Matrigel BD Biosciences 
mVEGF164 Developmental Biochemistry,  
 University of Wuerzburg 
Non-essential amino acids (100x) Sigma-Aldrich GmbH 
Nutridoma-CS Roche Diagnostics GmbH 
Penicillin/streptomycin PAA Laboratories GmbH 
RPMI-1640 Sigma-Aldrich GmbH 
ß-Mercaptoethanol PAN-Biotech GmbH 
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4.3.2 Eukaryotic cell lines 
4.3.2.1 Human tumor cell lines 
Human tumor cell lines were obtained from American Type Culture Collection (ATCC). 
Non-small cell lung 
cancer 
Colorectal  
cancer 
Renal cell 
carcinoma 
Breast  
cancer 
A549 COLO 205 786-0 MCF7 
EKVX HCC-2998 A498 MDA-MB-231 
HOP-62 HCT-116 ACHN HS-578T 
HOP-92 HCT-15 CAKI-1 BT-549 
NCI-H226 HT29 RXF-393 T-47D 
NCI-H23 KM12 SN12C MDA-MB-468 
NCI-H460 SW-620 TK-10  
NCI-H522 KM20L2 UO-31  
LXFL529  RXF-631  
  SN12K1  
4.3.2.2 Human endothelial cell lines 
HUVEC (human umbilical vein endothelial cells) PromoCell 
4.3.2.3 Mouse embryonic stem cell lines 
ΔHey1/2 (original name: A3d) Developmental Biochemistry, 
 University of Wuerzburg 
ΔHey1/2-(VE-Cad-bsd) 
ΔHey1/2-(VE-Cad-bsd)-pSB-FS-mHey1#1 
ΔHey1/2-(VE-Cad-bsd)-pSB-Flag-mHey2#3 
E14 Prof. Dr. Albrecht Müller, 
 MSZ, University of Wuerzburg 
E14-(Tie1-bsd) 
4.3.2.4 Mouse endothelial cell lines 
bEnd5 Prof. Dr. Georg Breier 
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4.4 Buffers and solutions 
10 x PBS 1.4 M NaCl, 27 mM KCl, 80 mM Na2HPO4, 18 mM 
KH2PO4 
10 x Repro Fast buffer 100 mM (NH4)2SO4, 200 mM Tris-HCl (pH 8.8), 100 mM 
KCl, 20 mM MgSO4, 1 % TritonX100, 1 % BSA 
10 x SDS running buffer 250 mM Tris, 192 mM Glycin, 1 % SDS, pH 8.3 
2 x SDS sample buffer 0,1 M Tris-HCl (pH 6.8), 4 % SDS, 0.25 % 
Bromphenolblue, 25 % Glycerin, 200mM DTT 
20 x SB buffer 200 mM NaOH, pH 8.0 (adjust with boric acid) 
50 x Base solution 1.25 M NaOH, 10 mM EDTA, pH 12.0 
50 x Neutralization solution 2M Tris-HCl, pH 5.0 
50 x TAE buffer 2 M Tris-AcOH (pH 7.5 – 8.0), 50 mM EDTA 
Cell lysis buffer 20mM HEPES pH 7.8, 500mM NaCl, 5mM MgCl2, 5mM 
KCl, 0.1% Sodium deoxycholate, 0.5% Nonidet-P40, 
10ug/ml Leupeptin, 10ug/ml Aprotinin, 1mM PMSF, 
200uM Na3VO4, 0.1M NaF 
DNA loading buffer 0.25 % Bromphenol blue, 10 mMEDTA, 15 % Ficoll 
ECL solution 100 mM Tris-HCl pH 8,0, 250 mM Luminol, 90 mM 
Coumaric acid,  
3 µl H2O2 (35 %) / 10 ml ECL  
RIPA buffer 50 mM Tris (pH 8.0), 1 % Nonidet P40, 0.5 % Sodium 
deoxycholate, 0.1 % SDS, 150 mM NaCl, 1x Protease 
inhibitor mix, 50 µg/ml PMSF 
TM staining solution 25 ml TM-buffer, 200 µl 10 % MgCl2, 10 mg Naphtol AS-
MX Phosphat, 25 mg Fast Red TR 
TM buffer 30 mM Tris, pH 9.0 (adjust with 1 M maleic acid) 
Transfer blotting buffer 25 mM Tris, 150 mM Glycin, 10 % Methanol (pH 8,3) 
4.5 Oligonucleotides 
Oligonucleotides were obtained from Sigma-Aldrich GmbH. Sequences of oligonucleotides 
are presented in 5‘-3‘ direction. 
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4.5.1 Human oligonucleotides for quantitative real-time PCR 
Gene Primer name Primer sequence 
GLUT1 huGLUT1-5’real GCTTTGTGGCCTTCTTTGAA 
 huGLUT1-3’real CAGAACCAGGAGCACAGTGA 
HPRT hHPRT_5’real_neu2 AAGATGGTCAAGGTCGCAAG 
 hHPRT_3’real_neu2 GTCAAGGGCATATCCTACAACAA 
NRP1 h-NP1-real5’ CAAAACCAGCAGACCTGGAT 
 h-NP1-real3’ CATTATGCCAACAGGCACAG 
VEGF total hVEGF-real1 TACCTCCACCATGCCAAGTG 
 hVEGF-real2 GCTGCGCTGATAGACATCCA 
VEGFA121 hVEGFA-3-f GTGTGTGCCCACTGAGGAG 
 hVEGFA-5,8a-r GCCTCGGCTTGTCACATTT 
VEGFA165 hVEGFA-5,7a-f AGATAGAGCAAGACAAGAAAATCCC 
 hVEGFA-7b8a-r CTCGGCTTGTCACATCTGC 
VEGFA189 hVEGFA-6a7a-f TATAAGTCCTGGAGCGTTCCC 
 hVEGFA-7b8a-r CTCGGCTTGTCACATCTGC 
VEGFR1 hVEGFR1-real5’ CTTCACCTGGACTGACAGCA 
 hVEGFR1-real3’ ACAGCTGGAATGGCAGAAAC 
VEGFR2 hVEGFR2-real-f ACAACCAGACGGACAGTGGT 
 hVEGFR2-real-r AGTCAGGCTGGAGAATCTGG 
 
4.5.2 Murine oligonucleotides for quantitative real-time PCR 
Gene Primer name Primer sequence 
Actc1 mActc1-real-for AGCTGTCTTCCCGTCCATC 
 mActc1-real-rev GCTCTGGGCTTCATCACCTA 
C1d mC1d-real-for GCATCCAGTGAAGCAGGAACT 
 mC1d-real-rev TTGGCAGCCTTCTTCTTGTCT 
Calcoco2 mCalcoco2-real-for GGAACAGCTCAGTGAGGAGC 
 mCalcoco2-real-rev CCCTCTGTGTTGCTTCCAGT 
CoupTFII mCoup-TF2-real5‘ AGTACTGCCGCCTCAAAAAG 
 mCoup-TF2-real3‘ CAGGTACGAGTGGCAGTTGA 
CoupTFIIalt mCoup-TF2-alt5‘ TTTCACCCGCCAAACTAAAG 
 mCoup-TF2-real3‘ CAGGTACGAGTGGCAGTTGA 
Cxxc1 mCxx1c-real-for CAGGGGCTACAAGAGGCTAC 
 mCxx1c-real-rev AGCTTGCAGACTGTCCACTG 
Ddit3 mDdit3-real-for GAGCCAGAATAACAGCCGGAA 
 mDdit3-real-rev TGGACCAGGTTCTGCTTTCA 
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Dll4 mDll4-real3‘ AGCTGGGTGTCTGAGTAGGC 
 mDll4-real5‘ AGAAGGTGCCACTTCGGTTA 
Dnajc4 mDnajc4-real-for GGCCTGCACTATGTTGCCTT 
 mDnajc4-real-rev CTGGCCCGAGTGTCATTGT 
EG434280 mEG434280-real-for TCCAGGCTAACCGGGATACA 
 mEG434280-real-rev CAGCCGCAGGTTTCCAGATA 
EphB4 mEphb4-real-for TACTGGGACATGAGCAACCA 
 mEphb4-real-rev ATTTTGAGGCTAGCGGGATT 
EphrinB2 m-ephrinB2-5’real CTCAACTGTGCCAGACCAGA 
 m-ephrinB2-3’real2 TATCCAGGCCCTCCAAAGA 
Esm1 mEsm1-real-for ATGGACGGGGTCAAGTGTG 
 mEsm1real-rev CATTCCATCCCGAAGGTGCC 
Fabp3 mFabp3-real-for AGGGAGCTAGTTGACGGGA 
 mFabp3-real-rev ACGCCTCCTTCTCATAAGTCC 
Fibronectin1 mFibronectin1-real5‘ AAGTGTGatccccATGAAGC 
 mFibronectin1-real3‘ CAGGTCTACGGCAGTTGTCA 
Hdac8 mHdac8-real-for CCACCGAATCCAGCAAATCC 
 mHdac8-real-rev TTCCACAAACCGCTTGCATC 
Hey1 (endogenous) mHey1-5’UTR CTGCAGTTAACTCCTCCTTGC 
 clik-race ATTCTCGTCCGCGCTCTCCTTTTCC 
Hey1 (transgene) pSB-FS-mHey1-for GCTCAAGCCACCCAGACTAC 
 clk2 CTGGCCAAAACCTGGGAC 
Hey2 (endogenous) mHey2-real-e1for AGTAGCTGCTCCTCCTTCGTC 
 mHey2-real-e2rev GTCGGTGAATTGGACCTCAT 
Hey2 (transgene) Flag-Tag-for GGATTACAAGGATGACGACGAT 
 mHey2-real-e2rev GTCGGTGAATTGGACCTCAT 
Hprt mHPRT-real-ex8 TGTTGTTGGATATGCCCTTG 
 mHPRT-real-ex9 ACTGGCAACATCAACAGGACT 
Hspg2 mHspg2-real-for TGTGAACATTCGCAAGCCCT 
 mHspg2-real-rev GGTGGTCACCGTTACACCTT 
Icam1 mIcam1-real for TTTGAGCTGAGCGAGATCGG 
 mIcam1-real rev AGAGGTCTCAGCTCCACACT 
Krt19 mKrt19-real-for AAGCAAGACCGAAGTCACGG 
 mKrt19-real-rev CAGCTGGACTCCATAACGGG 
Lefty1 mLefty1-real5’ GGCTCTGCTGGGCACTCTGGGCACT 
 mLefty1-real3’ GACACCAGGAACCTGCCTGCCACCTCTC 
Lefty2 mLefty2-real5‘ ACGCCGGACGGCAAGGGGCAG 
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 mLefty2-real3‘ CGAGGCCCCAGAAATGGCCACCCGA 
Mier3 mMier3-real-for GGAATGACAGCATGGACGGA 
 mMier3-real-rev GGCAACCGTTCTAGACCTCA 
Myl9 mMyl9-real-for GCAATGCCTTTGCCTGCTTT 
 mMyl9-real-rev TCCTCATCCGTGAATCGGTC 
Nanog mNanog-real5‘ TTGCCTAGTTCTGAGGAAGCA 
 mNanog-real3‘ GAGGAAGGGCGAGGAGAG 
Nptx2 mNptx2-real-for CTTAGCCGCTCCTTGCAAAC 
 mNptx2-real-rev AGCCCAGCGTTAGACACATT 
Oct4 mOct4-real5‘ CCGTGAAGTTGGAGAAGGTG 
 mOct4-real3‘ GAAGCGACAGATGGTGGTCT 
Perp mPerp-real-for CATTCTCTCGTTCTTCGCCCT 
 mPerp-real-rev TGAAGCCTGAAGGTCTGTGTG 
Psmb10 mPsmb10-real-for CTTTACTGCCCTTGGCTCTG 
 mPsmb10-real-rev AGCCCAGGTCACTCAGGAT 
Ptges mPtges-real-for CCAGTATTACAGGAGTGACCCAG 
 mPtges-real-rev ATGAGTACACGAAGCCGAGG 
Rarres1 mRarres1-real-for GAGCAATACAACCCCGAGCA 
 mRarres1-real-rev GCCGGTCTGGGTTTTTCATTC 
Serpine2 mSerpine2-real-for TGGAACCAAAGCTTCGGCAG 
 mSerpine2-real-rev GATGGCACCTGTGGGATTGT 
Skil mSkil-real_F  TGAGGAGCAGGAGAAAATGG 
 mSkil-real_R  AAGCTGCACACAGCAGACTC 
Smarca2 mSmarca2-real-for CAAACCGAGGCAAAGCCAAA 
 mSmarca2-real-rev CACGTCCAGGATGGTCACTC 
Sox1 mSox1-real-for AGTGGAAGGTCATGTCCGAG 
 mSox1-real-rev TGTAATCCGGGTGTTCCTTC 
Sox2 Sox2_fwd_mus AAGGGTTCTTGCTGGGTTTT 
 Sox2_rev_mus AGACCACGAAAACGGTCTTG 
Spred3 mSpred3-real-for CCATTGCCACAGTGGAGTCA 
 mSpred3-real-rev CAGTGAACGGTAGAAGCGGA 
Tie1 mTie1-real5‘ TGCAGACTTTGGCCTTTCTC 
 mTie1-real3‘ TGCCTCCAAGGCTCACTATC 
Tie2 tie2-for-real CTCGGCCAGGTACATAGGAG 
 tie2-rev-real ATAAACCCAGGAGGGCAAAT 
VE-Cadherin mVE-Cadherin_5’real GGATGTGGTGCCAGTAAACC 
 mVE-Cadherin_3’real ACCCCGTTGTCTGAGATGAG 
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Vegfr2 flk1-for-real GGCGGTGGTGACAGTATCTT 
 flk1-rev-real GTCACTGACAGAGGCGATGA 
4.5.3 Additional oligonucleotides 
The following oligonucleotides were used to confirm transgene integration into embryonic 
stem cells. 
Transgene Primer name Primer sequence 
Tie1-bsd mTie1-prom-3‘ TCTGGTTCATTCCAGATCATTGT 
 bGlob-3’UTR-rev GAGACTCCATTCGGGTGTTC 
VE-Cad-bsd Cherry-3for CACCATCGTGGAACAGTACG 
 blasticidin_R  CAAGATGCCCCTGTTCTCAT 
 
The following oligonucleotides were used for genotyping of embryonic stem cells (in one 
reaction). 
Genotype Primer name Primer sequence 
flox Hey1 clikATG GCGGGATCCACATGAAGAGAGCTCACCCAG 
 Clikseq2 TGAGATCTTGCAGATGACTGTG 
 Hey1flox-wt CACGCCGAGCACGCAAAG 
 Eagrev ACAAAGCAAAGCAGGCAGTC 
4.6 Antibodies 
4.6.1 Antibodies for western blot analysis 
Anti-cleaved PARP (Asp214) (552596) BD PharmingenTM 
Anti-Flag M2 (F3165) Sigma-Aldrich GmbH 
Anti-Neuropilin (H-286) (sc-5541) Santa Cruz Biotechnology 
Anti-ß-Aktin (C4) (sc-47778) Santa Cruz Biotechnology 
Anti-VEGFR1 (Flt1) (C17) (sc-316) Santa Cruz Biotechnology 
Anti-VEGFR2 (55B11) (2479) Cell Signaling 
Anti-Vinculin (V9131) Sigma-Aldrich GmbH 
Anti-α-Tubulin (T6074) Sigma-Aldrich GmbH 
Goat anti-Mouse IgG, Peroxidase conjugated, H+L (AP124P) Chemicon 
Goat anti-Rabbit IgG, HRP conjugated, H+L Chemicon 
4.6.2 Antibodies for immunofluorescence 
AlexaFluor488 donkey α-goat IgG (H+L) (A11055) Life Technologies GmbH 
AlexaFluor568 donkey α-goat IgG (H+L) (A11057) Life Technologies GmbH 
AlexaFluor568 goat α-rat IgG (H+L) (A11077) Life Technologies GmbH 
PECAM-1 (CD31) (sc-18916) Santa Cruz Biotechnology 
Material 
28 
VE-Cadherin (sc-6458) Santa Cruz Biotechnology 
4.6.3 Antibodies for flow cytometry 
CD304 (BDCA-4/Neuropilin-1)-APC, human Miltenyi Biotec 
CD309 (VEGFR-2/KDR)-APC, human Miltenyi Biotec 
4.6.4 Humanized monoclonal antibodies 
Avastin® (bevacizumab), 25.3 mg/ml F. Hoffmann-La Roche AG 
4.7 Enzymes and Kits 
ExperionTM DNA 1K Reagents and Supplies Bio-Rad Laboratories 
ExperionTM RNA HighSense Reagents and Supplies Bio-Rad Laboratories 
His-Taq-Polymerase, lot 10, 12 Developmental Biochemistry, 
 University of Wuerzburg 
mRNA Library Reagents Set for Illumina® New England Biolabs 
Multiplex Oligos for Illumina® Index Primer Set 1 New England Biolabs 
Plasmid Midi Kit Omega bio-tek 
Plasmid Mini Kit I Omega bio-tek 
RevertAidTM First Strand cDNA Synthesis Kit Thermo Scientific 
RneasyTM Purification Kit Qiagen 
Sera-Mag Oligo(dT)-Coated Magnetic Particles Thermo Scientific 
QIAquick Gel Extraction Kit Qiagen 
QIAquick PCR Purification Kit Qiagen 
4.8 Technical devices 
Hypoxia chamber (C-Chamber und Adapter Plate) BioSpherix 
Leica DMI6000 B  Leica Microsystems 
Mastercycler® ep realplex Eppendorf GmbH 
NanoDrop ND 1000 Spectrophotometer Fisher Scientific 
Nikon Eclipse TS100 Nikon GmbH 
Proox Model 110 BioSpherix 
Sunrise Absorbance Reader Tecan Group Ltd. 
Tristar LB 941 Berthold Technologies 
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5 Methods 
5.1 Cell culture 
5.1.1 Cell culture of human tumor cell lines and human endothelial cells 
Human tumor cell lines selected from the NCI-60 panel (4.3.2.1) were obtained from 
American Type Culture Collection (ATCC) and cultured in RPMI-1640 medium supplemented 
with 10 % FBS, 1 % Glutamax, 1 % penicillin and 1 % streptomycin as recommended by the 
NCI-Frederick Cancer DCTD Tumor Cell Line Repository. Cells were passaged using trypsin 
at about 80 % confluency. HUVECs (human umbilical vein endothelial cells) were cultured in 
M199 medium with 10 % FBS, 25 µg/ml heparin, 50 µg/ml ECGS and 1 % Glutamax on 
plates pre-coated with 0.2 % gelatin. 
5.1.2 Cell culture under hypoxic conditions and bevacizumab treatment 
Most of the experiments with human tumor and human endothelial cells were performed 
under hypoxia at 1 % O2. Therefore, cells were cultured in a special chamber inside the 
incubator (C-Chamber), which was flushed with a gas mixture of 95 % N2 und 5 % CO2 to 
reduce the oxygen level in the interior. The oxygen level was controlled by a device outside 
the chamber (Proox Model 110). Cells were cultured under serum-reduced conditions with 
1 % FBS for up to 96 hours and treated with 250 μg/ml bevacizumab (Avastin) and/or 
50 ng/ml recombinant human VEGF-A. 
5.1.3 Cell culture of mouse embryonic stem cells 
Mouse embryonic stem cells [E14-(Tie1-bsd), ΔHey1/2-(VE-Cad-bsd), 
ΔHey1/2-(VE-Cad-bsd)-Hey1, ΔHey1/2-(VE-Cad-bsd)-Hey2] were cultured in KO-DMEM 
medium supplemented with 15 % KnockOut™ Serum Replacement (KOSR), 1 % Glutamax, 
1 % penicillin, 1% streptomycin, 1 % non-essential amino acids, 0.1 mM 2-mercaptoethanol 
and 2000 units/ml Leukemia Inhibiting Factor (LIF) on plates pre-coated with 0.2 % gelatin. 
Medium was changed daily and the cells were passaged every second day by trypsinization. 
5.1.4 Establishment of stable mouse embryonic stem cell lines 
For the generation of stable mouse embryonic stem cell lines different plasmids were 
incorporated into the cells by either electroporation (pTol2-ins-VE-Or-Blast and 
pTol2-ins-Tie1-blast) or by transfection (pSB-FS-mHey1 and pSB-Flag-mHey2).  
5.1.4.1 Electroporation 
5 x 106 cells were electroporated with either 2 µg pTol2-ins-VeOr-Blast or 2 µg 
pTol2-ins-Tie1-blast and 12 µg pKate-NI-Tol2 (transposase) using program A024 (E14) or 
program A023 (ΔHey1/2) of the electroporation device Amaxa Nucleofector II according to 
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the manufacturer’s instructions. The cells were plated on two 10 cm dishes after 
electroporation. 
5.1.4.2 Transfection 
1 x 105 cells per well were seeded on a 12 well plate and transfected with the transfection 
reagent Metafectene Pro overnight. 0.6 µg of plasmid DNA (pSB-FS-mHey1 or 
pSB-Flag-mHey2) were co-transfected with 0.6 µg of pCMV-(CAT)-T7-SB100X 
(transposase) using 2.4 µl Metafectene Pro according to the manufacturer’s instructions. 
Before the mixture of the DNA and the transfection reagent was added to the cells, the 
medium in the cell culture well was reduced from 1.0 ml to 0.5 ml to facilitate integration of 
the transgene. On the next day cells were detached from the 12 well plate using Accutase 
solution and re-plated on a 6 well plate. Before starting the selection for stable clones cells 
were again detached and transferred to a 10 cm dish to limit the cell density on the plate and 
to prevent overgrowth as well as uncontrolled differentiation.  
5.1.4.3 Selection of stable clones 
Selection of stable clones, which have integrated the transgene, was started 48 hours after 
electroporation or transfection using 0.5 µg/ml puromycin or 150 µg/ml hygromycin 
depending on the respective antibiotic resistance gene. After seven to ten days of selection, 
stable clones arose on the culture plate and were picked in a well of a 48 well plate. 
Individual clones were grown up to a 10 cm dish and tested via PCR or western blot for 
stable integration of the transgene. 
5.1.5 Differentiation of mouse embryonic stem cells into endothelial cells 
For the differentiation of mouse embryonic stem cells into endothelial cells, cell culture plates 
were pre-coated with 0.5 % gelatin overnight. On day 0 of the differentiation between 2 x 104 
and 3 x 104 cells per well were seeded on a 6 well plate in serum-free ESC differentiation 
medium (induction medium) consisting of α-MEM supplemented with 20 % KnockOut™ 
Serum Replacement (KOSR), 1 % Glutamax, 1 % penicillin, 1 % streptomycin, 
1 % non-essential amino acids, 0.05 mM 2-mercaptoethanol, 5 ng/ml BMP4 and 120 ng/ml 
mVEGF164. Cells were incubated for four days (induction phase) without changing the 
medium. On day four of the differentiation, medium was changed using another chemically 
defined medium named Ldsk as published previously (Blancas et al., 2011). Ldsk medium 
consists of 70 % α-MEM and 30 % DMEM supplemented with 1 % Glutamax, 1 % penicillin, 
1 % streptomycin, 1 % non-essential amino acids, 0.1 mM 2-mercaptoethanol, 
2 x Nutridoma-CS, 50 ng/ml bFGF and 400 ng/ml mVEGF164. Again, the medium was not 
changed for another four days until day eight of differentiation. From day eight on, Ldsk 
medium was supplemented with 5 µg/ml blasticidin and changed every second day. 
Selection with blasticidin allows the enrichment of endothelial cells, while eliminating 
Methods 
31 
embryonic stem cells from the culture dish. At day 14 of the differentiation nearly all 
embryonic stem cells were eliminated and the resulting ESC-derived endothelial cells could 
be used for further experiments. For experiments with doxycycline inducible cell lines 
[ΔHey1/2-(VE-Cad-bsd)-Hey1, ΔHey1/2-(VE-Cad-bsd)-Hey2], cells were re-plated on a 6 
well plate and cultured in Ldsk medium for 48 or 72 hours in the presence of 1 µg/ml 
doxycycline to induce Hey transgene expression. 
5.2 Cell biological methods 
5.2.1 Cell proliferation assay 
Cell proliferation was assessed for up to 96 hours using MTT [3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide] staining as described previously (Mosmann, 1983). Briefly, 
between 2 x 103 and 5 x 103 cells/well (cell line/doubling time dependent) were seeded into 
96 well plates and incubated overnight to adhere. Medium was then replaced by fresh 
medium supplemented with bevacizumab or VEGF-A at the concentrations indicated 
depending on the application. After 24, 48, 72 or 96 hours of treatment 20 µl of MTT (5 mg/ml 
in PBS) was added and incubated for two hours at 37°C. The supernatant was removed and 
reaction products were solubilized for 1 hour in 10 % HCl, 0.1 % NP-40 in isopropanol. 
Absorbance was measured at 570 nm with a reference wavelength of 650 nm. 
5.2.2  Cell migration assay 
Cell migration was measured using the in vitro scratch assay as described previously (Liang 
et al., 2007). Briefly, cells were grown in 6 well plates to a confluent monolayer, before 
scraping in a straight line using a sterile P200 pipet tip. To remove debris, cells were washed 
once with PBS. Medium was changed to serum reduced +/- treatment and cells were 
incubated for up to 24 hours. Images of the scratch width were measured using ImageJ 
software at the same location after 6 and 24 hours of incubation. 
5.2.3 Tube formation assay 
To test the functionality of endothelial cells in vitro, the tube formation assay was performed 
as described previously (Arnaoutova and Kleinman, 2010). 50 µl of Matrigel per well were 
loaded on a 96 well plate. The plate was incubated for 30 min at 37°C to allow the Matrigel to 
polymerize. 15 x 103 cells in a total volume of 100 µl were plated into each well. Culture 
medium was supplemented with 50 ng/ml bFGF and 400 ng/ml mVEGF164. The formation of 
tubes was observed after four to 16 hours under an inverted microscope. 
5.2.4 Immunofluorescence 
For immunofluorescent staining, cells were cultured on coverslips pre-coated with 
0.2 % gelatin in a 24 well plate. Fixation was done using ice-cold methanol (100 %) for ten 
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minutes at room temperature. Depending on the antibody staining, cells were blocked with 
appropriate blocking reagents for 1 hour at room temperature (CD31: 10 % goat serum in 
PBS, VE-Cadherin: 5 % BSA in PBS). Primary antibodies were diluted 1:100 in PBS + 
1.5 % of the blocking reagent and incubated at 4 °C overnight. Secondary antibodies were 
diluted 1:1000 and incubated at room temperature for 1 hour in PBS + 1.5 % of the blocking 
reagent. Cells were washed three times with PBS after incubation of the primary and the 
secondary antibody for five minutes at room temperature. 
5.2.5 Alkaline phosphatase staining 
For alkaline phosphatase staining, embryonic stem cells were fixed with 
4 % paraformaldehyd for 20 minutes at room temperature. Cells were washed three times 
with TM buffer and subsequently stained with TM staining solution for 20 minutes. Afterwards 
cells were washed with PBS and then alkaline phosphatase positive cells were investigated 
under an inverted cell culture microscope. 
5.3 Molecular biological methods 
5.3.1 Molecular cloning 
Cloning of plasmids was done using standard molecular cloning methods. 
5.3.2 Reverse transcription and quantitative real-time PCR (qRT-PCR) 
Total RNA was extracted from subconfluent monolayers using peqGOLD TriFast according 
to the manufacturer’s instructions. cDNA was transcribed using 1 or 2 µg total RNA with the 
RevertAid First Strand cDNA Synthesis Kit and diluted in 500 µl DEPC-treated water. cDNA 
was amplified by qRT-PCR using a two-step PCR program of 40 cycles with denaturation at 
95°C for 15 s, annealing and extension at 60°C for 30 s, followed by a melting curve from 50 
to 95°C using a Mastercycler ep realplex. The following standard PCR master mix was used. 
13.30 µl ddH2O 
1.50 µl Ethylenglycol 
2.50 µl 10 x Repro Fast buffer 
0.25 µl dNTPs (25 mM) 
0.75 µl SYBR Green (1:2000) 
0.2 µl Taq-Polymerase (15 U/µl) 
0.75 µl Forward Primer (10 pmol/µl) 
0.75 µl Reverse Primer (10 pmol/µl) 
5.0 µl cDNA 
Relative quantification was done using ΔΔCt (cycle threshold) measurements on SYBR 
Green based fluorescence readings with HPRT as a housekeeping gene. 
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5.3.3 Isolation of genomic DNA and PCR analysis 
For genotyping and/or verification of stable transgene integration, cells were pelletized and 
incubated in 1 x base solution at 96°C for 20 minutes. Between 30 and 100 µl of base 
solution were added according to the size of the cell pellet. After cooling down of the sample, 
the same amount of 1 x neutralization solution was added and 1 µl of the sample was directly 
used as a template in the PCR reaction. PCR reaction was performed with the a three-step 
PCR program of 35 cycles with denaturation at 94°C for 30 s, annealing at 60°C for 30 s and 
extension at 72°C for 45 s, following a single incubation step at 72°C for 7 min. 
5.3.4 Agarose gel electrophoresis 
DNA fragments with a size of up to 600 bp were separated in 1 % agarose gels with 
SB-buffer for 15 minutes at 300 volt. For larger fragments with up to 20 kb, fractionation was 
done using 1 % agarose gels in TAE-buffer. Agarose gels were supplemented with 1 µg/ml 
ethidiumbromid and DNA was visualized under UV light. 
5.3.5  RNA-Sequencing 
For whole transcriptome analysis, total RNA was extracted using RneasyTM Purification Kit 
according to the manufacturer’s instructions. Starting material for the isolation of mRNA did 
contain between 1.5 and 5 µg of total RNA. Quality control of RNA was analyzed with 
ExperionTM RNA HighSens Chips. Isolation of mRNA was done with Sera-Mag 
Oligo(dT)-Coated Magnetic Particles according to the Illumina transcriptome sequencing 
library preparation protocol. The following preparation of the cDNA library was performed 
with the mRNA Library Reagents Set according to the sample preparation guideline from 
Illumina. mRNA was fragmented into 200 bp fragments at 94°C and afterwards transcribed 
into cDNA using random primers. cDNA was end-repaired, dA-tailed and Illumina sequencing 
adapters were attached. After each reaction cDNA samples were purified using QIAquick 
PCR Column Purification Kit. Adaptor-ligated DNA ranging from 200 - 300 bp was excised 
from an agarose gel and purified using QIAquick Gel Extraction Purification Kit. The 
adaptor-ligated cDNA library was enriched by PCR amplification with 12 cycles. Quality and 
quantification of the resulting cDNA library was measured using an ExperionTM DNA Chip. 
For RNA-Sequencing, various samples were multiplexed and analyzed on a single flow cell 
v4. After de-multiplexing of the samples, data were analyzed using bowtie 1.0.0 with 
standard parameters and aligned to the Mus Musculus genome (NCBI37/mm9) (Langmead 
et al., 2009). Genes with less than ten reads per million were excluded from further analysis. 
Noise expression was calculated from reads mapping to non-exonic regions of the genome 
and a gene was considered as expressed with a value of ≥ 2.26 reads per kilo base per 
million (RPKM), which was ten-fold higher than RPKM values for non-exonic regions of the 
genome. Regulated genes were identified using the R-package Deseq (Anders and Huber, 
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2010) and a gene was considered to be regulated if the fold change was ≥ 1.8 between the 
control and the induced sample, while the RPKM value had to be ≥ 2.26 in at least one 
sample. Heatmaps were generated using hierarchical clustering in Cluster 3.0 (De Hoon et 
al., 2002, Eisen et al., 1998) and were visualized using TreeView 1.1.6r2 (Saldanha, 2004). 
Gene Ontology (GO) term analysis was performed with DAVID 6.7 (Huang da et al., 2009) 
using the functional annotation clustering method allowing only to enrich for biological 
processes. Clusters were named based on interpretation of enriched GO annotations. A 
Cluster Enrichment Score of 1.3 was considered as significant (p-value ≤ 0.05). 
5.4 Protein biochemical methods 
5.4.1 Western blot analysis 
Cell pellets were either lysed in RIPA buffer or cell lysis buffer for up to four hours on ice or 
directly re-suspended in 2 x SB buffer and denaturated at 95°C for 5 minutes. Protein 
quantification was done using Bradford reagent, as described previously (Bradford, 1976). 
Proteins were separated by SDS-polyacrylamide gel electrophoresis. Usually, 
12 % SDS-polyacrylamide gels were used. For separation of larger proteins (> 90 kDa), 
polyacrylamide gels with lower percentages were used according to the size of the 
appropriate protein. After separation on a SDS-PAGE, proteins were transferred to a 
nitrocellulose membrane using a semi-dry blot chamber for 35 min at 360 mA and 25 V per 
gel. Transfer of larger proteins (> 90 kDa) was done using a wet-blot chamber at 100 mA and 
15 V overnight. Protein transfer was performed at 4°C.  
5.4.2  Flow cytometry 
Protein expression on the cell surface was determined by flow cytometry. Cells were 
harvested using Accutase solution and stained for Neuropilin1 or VEGFR2 with CD304- or 
CD309-APC conjugated antibodies according to the manufacturer’s instructions and 
measured by a BD FACS Canto II flow cytometer. Analysis was done using FlowJo software 
(version 8.8.6) to determine the percentages of positive cells.  
Propidium iodide stained cells were prepared by fixing the cells in 80 % ice-cold ethanol for 
up to 48 hours. Afterwards, cells were washed with PBS and re-suspended in 38 mM sodium 
citrate, 24 μg/ml Rnase A and 54 μM propidium iodide. After 30 minutes of incubation 
samples were measured with a flow cytometer. 
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6 Results 
6.1 Impact of bevacizumab treatment on human tumor cell lines in 
vitro 
Bevacizumab targets the vascular network of tumor cells and thus primarily acts on 
endothelial cells and not on tumor cells themselves. To investigate if bevacizumab also 
directly influences tumor cells, which express VEGF receptors, cells from different tumor 
entities were treated either with or without bevacizumab. In general, experiments were 
performed under hypoxic conditions to mimic the in vivo state of tumors. After bevacizumab 
treatment cells were analyzed for angiogenic gene and protein expression as well as for 
biological processes like proliferation, migration and apoptosis. According to publicly 
available microarray data and to preliminary gene expression data different cell lines from the 
NCI-60 panel, derived from four tumor types (NSCLC, CRC, RCC and BC), were selected 
according to high expression of angiogenic pathway genes (NSCLC: H522, HOP62; 
CRC: HCT-116, HT-29, KM12; RCC: A498; BC: HS-578 T, MDA-MB-231). 
Below, results of NSCLC and CRC cell lines as well as the endothelial control (HUVECs) 
were obtained by myself. Results of RCC and BC cell lines were kindly provided by Shannon 
Graver and for the sake of completeness additionally presented in this thesis. All results were 
published together as a single publication: Tumor cell response to bevacizumab single 
agent therapy in vitro. Cancer Cell International 2013 13:94 (Hein and Graver, 2013). 
6.1.1 Tumor cell and cell surface expression of VEGF receptors 
VEGF-A signaling is activated through different angiogenic receptors like VEGFR1, VEGFR2 
and Neuropilin1. Expression of receptors by tumor cells was determined by western blot 
analysis with HUVECs as a control. Cells were incubated under normoxia and hypoxia 
(1 % O2) and either treated with or without 250 µg/ml bevacizumab for 24 hours. Vinculin was 
used as a loading control and served as an internal standard between treated and untreated 
cells (Fig. 5). 
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Fig. 5 Protein expression of VEGFR1, VEGFR2 and NRP1.1 Protein expression of VEGFR1, 
VEGFR2 and NRP1 was determined in tumor cells and HUVECs under normoxia and after 24 hours of 
hypoxia with or without bevacizumab treatment. Vinculin was used as a loading control. n.d. = not 
determined 
 
1This figure was published similarly in Hein and Graver (2013), Tumor cell response to bevacizumab 
single agent therapy in vitro. Results of RCC and BC cell lines were kindly provided by Shannon 
Graver and for the sake of completeness additionally presented in this thesis. 
VEGFR1 was expressed by all cell lines with the exception of H522 as shown by two specific 
bands (Fig. 5). Incubation under hypoxia led to an increase of protein expression in the renal 
cell line A498, but treatment with bevacizumab did not further influence expression. In 
contrast, expression of VEGFR2, the main angiogenic receptor, was limited with only four 
tumor cell lines showing expression (H522, HOP62, HCT-116 and MDA-MB-231), while 
HUVECs, which served as a control, exhibited clear and strong expression of VEGFR2 (Fig. 
5). However, hypoxic conditions as well as bevacizumab treatment did not alter expression of 
VEGFR2. Neuropilin1, which serves as a co-receptor for VEGFR1 and VEGFR2, was 
expressed by all cell lines investigated to varying intensities, but again bevacizumab 
treatment and hypoxic incubation did not change expression of Neuropilin1 (Fig. 5).  
In addition, protein expression of VEGFR2 and Neuropilin1 was further evaluated on the cell 
surface by flow cytometry under normoxia and hypoxia with bevacizumab treatment (Fig. 6). 
Respective examples of unlabeled and labeled cells are shown for endothelial controls 
(HUVECs) and for two tumor cell lines, MDA-MB-231 (BC) and HCT-116 (CRC), in the FACS 
profile in Fig. 6A. Quantification of VEGFR2+ and NRP1+ cells for all tumor cell lines 
investigated, is presented in Fig. 6B and Fig. 6C. 
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Fig. 6 Cell surface protein expression of VEGFR2 and NRP1.1 Cell surface protein expression was 
analyzed by flow cytometry. Unstained cells under normoxic conditions were used as a control. 
HUVECs, MDA-MB-231 (BC) and HCT-116 (CRC) cells are shown as respective examples (A). 
Quantification of VEGFR2+ (B) and NRP1+ (C) cells. n.d. = not determined. 
 
1This figure was published similarly in Hein and Graver (2013), Tumor cell response to bevacizumab 
single agent therapy in vitro. Results of RCC and BC cell lines were kindly provided by Shannon 
Graver and for the sake of completeness additionally presented in this thesis. 
Although Neuropilin1 showed expression by western blot analysis in all cell lines 
investigated, cell surface expression was only evident for the cell lines MDA-MB-231 (BC) 
and A498 (RCC). HOP62 (NSCLC) and HS-578 T (BC) showed NRP1 cell surface 
expression to a lower degree with only 10 – 15 % positive cells (Fig. 6C). Cell surface 
expression of VEGFR2 was even more limited to only one tumor cell line (MDA-MB-231) and 
the endothelial positive control (HUVECs), while the percentages of positive cells remained 
below 10 % in the other cell lines investigated (Fig. 6B). In turn, neither hypoxic incubation 
nor bevacizumab treatment did change protein expression levels on the cell surface of tumor 
cells (Fig. 6).  
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6.1.2 Hypoxic induction of VEGF 
Activation of the transcription factor HIF-1 under hypoxia leads to a variety of gene 
expression changes, including induction of VEGFA and GLUT1. Hence, tumor cells were 
incubated under normoxia and hypoxia for 24 hours and VEGFA and GLUT1 expression 
levels were measured by quantitative real-time PCR (Fig. 7). 
 
Fig. 7 Hypoxic VEGFA and GLUT1 mRNA induction in tumor cells.1 Cells were incubated under 
normoxia and hypoxia for 24 hours and total RNA was extracted. Quantitative real-time PCR was 
performed with HPRT as housekeeping gene. Change in relative expression of VEGFA (A) and 
GLUT1 (B) is shown under hypoxia compared to normoxic controls. Results are an average of three 
biological repetitions. p-value ≤ 0.05 = *; p-value ≤ 0.01 = **, p-value ≤ 0.001 = ***. 
 
1This figure was published similarly in Hein and Graver (2013), Tumor cell response to bevacizumab 
single agent therapy in vitro. Results of RCC and BC cell lines were kindly provided by Shannon 
Graver and for the sake of completeness additionally presented in this thesis. 
Most of the tumor cell lines showed induction of VEGFA and GLUT1 upon hypoxic 
incubation, but to variable extent between different tumor cell lines (Fig. 7). VEGFA was 
significantly upregulated in one non-small cell lung cancer cell line (HOP62) and two 
colorectal cell lines (HCT-116 and HT-29) with up to 3-fold increase (Fig. 7A). GLUT1 mRNA 
levels were significantly upregulated in almost all tumor cell lines investigated, up to 4-fold 
with the exception of A498 (RCC) and MDA-MB-231 (BC), where GLUT1 remained 
unregulated after incubation under hypoxia (Fig. 7B). Induction of VEGFA and GLUT1 
demonstrates the responsiveness of tumor cell lines to the hypoxic environment and 
supports the theory of an autocrine or paracrine stimulation of surrounding tumor cells by 
VEGFA. 
6.1.3 Regulation of angiogenic pathway molecules upon bevacizumab treatment 
Although protein expression of angiogenic receptors like VEGFR1, VEGFR2 and NRP1 was 
rather limited as measured by western blot and flow cytometry, gene expression analysis 
was performed to detect possible changes on mRNA levels. Cells were incubated under 
hypoxia (1 % O2) and treated with or without bevacizumab for 24 hours. Gene expression 
analysis was performed by quantitative real-time PCR with HPRT as housekeeping gene. 
Fold changes were calculated from treated versus untreated cells. HUVECs were used as a 
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control and additionally incubated with rhVEGF to demonstrate activation of the respective 
receptors (indicated by *) (Fig. 8). 
 
Fig. 8 Gene expression analysis in bevacizumab treated tumor and endothelial cells.1 Change in 
relative expression of VEGFA isoforms (A), VEGFR1 (B), NRP1 (C) and VEGFR2 (D) in bevacizumab 
treated cells after 24 hours of hypoxia versus untreated hypoxic cells. Only cell lines with detectable 
expression are included. p-value ≤ 0.05 = *. 
* indicates HUVECs were in addition stimulated with rhVEGF in the absence of bevacizumab and 
normalized against untreated controls. 
 1This figure was published similarly in Hein and Graver (2013), Tumor cell response to bevacizumab 
single agent therapy in vitro. Results of RCC and BC cell lines were kindly provided by Shannon 
Graver and for the sake of completeness additionally presented in this thesis. 
Different isoforms of VEGFA result from alternative splicing (Harper and Bates, 2008) and 
could be influenced by bevacizumab treatment in a different manner. Thus, VEGFA189, -165 
and -121 were analyzed with exon specific primers and changes upon bevacizumab treatment 
were evaluated. Bevacizumab treatment did not change expression of VEGFA isoforms in all 
tumor cell lines investigated as well as in HUVEC controls (Fig. 8A). Addition of rhVEGF led 
to an increase of VEGFA expression in HUVECs, however with quite high standard 
deviations and therefore not to a significant extent (Fig. 8A). Expression analysis of VEGFR1 
on mRNA level confirmed expression data from protein analysis. Six tumor cell lines as well 
as the endothelial control (HUVECs) exhibited expression of VEGFR1. However, no 
significant change in expression was obvious after bevacizumab treatment. Addition of 
rhVEGF showed responsiveness of HUVECs to VEGF stimulation, as VEGFR1 was 
upregulated 2-fold (Fig. 8B). VEGFR2 was only expressed by four tumor cell lines (H522, 
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HOP62, HCT-116 and MDA-MB-231) and the HUVEC controls, but remained more or less 
unregulated after bevacizumab exposure (Fig. 8D). In line with the increase of VEGFR1 in 
HUVECs upon addition of rhVEGF, also VEGFR2 expression was increased, however not to 
a significant extent (Fig. 8D). The VEGF-A co-receptor Neuropilin1 was expressed by all 
tumor cell lines with the exception of H522, as already demonstrated by protein analysis 
(Fig. 8C). In general, a clear trend of downregulation of Neuropilin1 was observed upon 
bevacizumab treatment in HOP62, HCT-116, HS-578 T and MDA-MB-231 cells, but only to a 
significant extent in one breast cancer cell line (HS-578 T). This was in line with HUVEC 
controls, which also showed a downregulation and an opposing upregulation after addition of 
rhVEGF, respectively (Fig. 8C). 
In summary, gene expression analysis revealed no consistent impact on VEGF-A related 
genes upon bevacizumab treatment. In contrast, endothelial cells reacted to bevacizumab or 
rhVEGF treatment as expected. At least, regulation of Neuropilin1 in HS-578 T cells was 
comparable to the downregulation seen in endothelial cells.  
6.1.4 Effects of bevacizumab on biological functions 
Although bevacizumab treatment resulted in rather limited changes in gene and protein 
expression, downstream biological functions of the VEGF-A pathway like apoptosis, 
proliferation and migration were evaluated after bevacizumab treatment of tumor cells.  
6.1.4.1 Effects of bevacizumab on tumor cell survival 
In endothelial cells VEGF-A can act as a survival factor and protect cells from apoptosis. To 
figure out if bevacizumab can also influence tumor cell survival, cells were treated with 
bevacizumab and changes in apoptotic levels were investigated. First of all, changes on 
protein level of cleaved PARP were evaluated after 48 hours of bevacizumab treatment in a 
hypoxic environment against non-treated controls. Presence and higher amounts of cleaved 
PARP are associated with an increasing apoptotic cell population. In addition, cells were 
treated with staurosporine for 24 hours, which is able to induce apoptosis (Fig. 9). 
 
Fig. 9 Tumor cell (A) and endothelial cell (B) survival in bevacizumab treated cells.1 Levels of 
apoptosis were determined by western blot analysis using an antibody against cleaved PARP. ß-Actin 
served as a loading control. As a positive control all cell lines were treated with staurosporine 
(0.15 µM) for 24 hours to induce apoptosis. An example of KM12 (CRC) and HUVECs is shown. 
 1This figure was published similarly in Hein and Graver (2013), Tumor cell response to bevacizumab 
single agent therapy in vitro. Results of RCC and BC cell lines were kindly provided by Shannon 
Graver and for the sake of completeness additionally presented in this thesis. 
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As obvious from Fig. 9, staurosporine was able to induce apoptosis, which is shown for the 
colorectal cell line KM12 as a representative example. In comparison to the positive control 
expression level of cleaved PARP was rather low in all cell lines investigated and was more 
or less unchanged after bevacizumab treatment. Minor changes could be detected in H522 
and HOP62 cells with a slight decrease in expression of cleaved PARP, while A498 and 
HS-578 T cells showed a minor increase in levels of cleaved PARP after bevacizumab 
treatment (Fig. 9A). In HUVEC cells addition of bevacizumab slightly increased the level of 
cleaved PARP when compared to the non-treated as well as to the staurosporine treated 
control (Fig. 9B). Similar results were obtained by flow cytometry, where sub G1 levels were 
quantified according to propidium iodide positive cell populations (Fig. 10). 
 
Fig. 10 Tumor cell survival of bevacizumab treated tumor cells analyzed by flow cytometry.1 
Quantification of cellular sub G1 fraction after 48 hours of bevacizumab treatment. Cells were stained 
with propidium iodide and analyzed by flow cytometry. Averaged data from three experiments are 
shown. 
 1This figure was published similarly in Hein and Graver (2013), Tumor cell response to bevacizumab 
single agent therapy in vitro. Results of RCC and BC cell lines were kindly provided by Shannon 
Graver and for the sake of completeness additionally presented in this thesis. 
Again the two non-small cell lung cancer cell lines (H522 and HOP62) showed a slight 
decrease in apoptosis in line with results obtained from western blot analysis, but not to a 
significant extent. This trend was also evident in two colorectal cell lines, HCT-116 and 
KM12, but even to a lower degree. Consistent with western blot analysis, HS-578 T and 
A498 cells reacted to bevacizumab treatment with a slight increase in apoptosis indicated by 
higher percentages of cells in the sub G1 phase. However, changes in apoptotic levels 
observed by flow cytometry were not significant at all (Fig. 10). 
6.1.4.2 Effects of bevacizumab on tumor cell proliferation 
To further evaluate downstream functions of the VEGF-A pathway, proliferation rates of 
tumor cell lines were investigated. To challenge the system and due to high heterogeneity of 
different tumor cell lines, the number of cell lines per tumor type was increased (NSCLC: 9, 
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CRC: 6, RCC: 10, BC: 5) (Fig. 11). Proliferation was investigated for up to 72 hours under 
hypoxia with or without addition of bevacizumab. 
 
Fig. 11 Tumor (A) and endothelial (B) cell proliferation after bevacizumab treatment.1 
Proliferation of bevacizumab treated cells as a percentage of control. Tumor cells were cultured under 
hypoxia and serum starved conditions for 72 hours (A). For comparison HUVECs were stimulated with 
rhVEGF and treated with bevacizumab (B). p-value ≤ 0.05 = *. 
 
1This figure was published similarly in Hein and Graver (2013), Tumor cell response to bevacizumab 
single agent therapy in vitro. Results of RCC and BC cell lines were kindly provided by Shannon 
Graver and for the sake of completeness additionally presented in this thesis. 
HUVECs were used as endothelial controls and in addition stimulated with rhVEGF to show 
their dependence on VEGF, which led to higher proliferation rates. In contrast, when treated 
with VEGF and bevacizumab in combination, proliferation was decreased about 
77 % compared to untreated controls (Fig. 11B). In general, tumor cells did not show any 
measureable effect of decreased proliferation rates as shown for HUVECs, with the 
exception of some colorectal cell lines, e.g. HT29, KM12, HCT-15 (Fig. 11A). To emphasize 
minor changes observed in some of the colorectal cell lines, growth curves of representative 
examples under normal growth conditions (10 % FBS) and serum starved conditions 
(1 % FBS) with or without bevacizumab are shown in Fig. 12. Cell growth of the tumor cell 
line KM12 was slightly inhibited by bevacizumab after 48 and 72 hours (Fig. 12A), while cell 
growth of HCT-115 cells was nearly not affected (Fig. 12B). In contrast, both cell lines 
showed normal proliferation rates under non treated conditions with 10 % FBS (Fig. 12). 
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Fig. 12 Cell proliferation rates of colorectal cell lines KM12 and HCT-15. Cell proliferation was 
assessed for up to 72 hours under hypoxia. Cells were either cultured under standard growth 
conditions (10 % FBS) or serum starved conditions (1 % FBS) with or without bevacizumab.  
6.1.4.3 Effects of bevacizumab on tumor cell migration 
As VEGF-A can act as a motility factor in endothelial cells and influence their migratory 
capabilities, treatment with bevacizumab reduces migration in endothelial cells. Thus, 
blockade of VEGF-A by bevacizumab could also influence migration of tumor cells that are 
dependent on VEGF-A. Cell migration was investigated according to the in vitro scratch 
assay (Liang et al., 2007) under hypoxic and serum starved conditions with or without 
addition of bevacizumab. Dependent on rapid or less motile moving cell lines, migration of 
tumor cells was examined after six or 24 hours under hypoxia (Fig. 13). 
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Fig. 13 Tumor cell migration analysis of bevacizumab treated tumor (A) and endothelial cells 
(B).1 Migration was assessed under hypoxia after 6 or 24 hours depending on the motility of tumor 
cells. Endothelial cells were additionally treated with rhVEGF to demonstrate their responsiveness to 
VEGF. p-value ≤ 0.05 = *; p-value ≤ 0.01 = **. 
 
1This figure was published similarly in Hein and Graver (2013), Tumor cell response to bevacizumab 
single agent therapy in vitro. Results of RCC and BC cell lines were kindly provided by Shannon 
Graver and for the sake of completeness additionally presented in this thesis. 
Some colorectal cell lines (COLO205, KM12, SW620) showed absolutely no cell migration, 
even 24 hours after scratch initiation (Fig. 13A). In contrast, other cell lines (NSCLC: 
LXFL529, RCC: 786-0, ACHN, CAKI-1, RXF-393, UO-31, BC: BT-549) showed an active 
motility, which led to a complete closure of the scratch after 24 hours (data not shown). Thus, 
these cell lines were already investigated after six hours of migration (Fig. 13A). Taken 
together, tumor cell lines did not show any change in their migratory potential after 
bevacizumab treatment. In some tumor cell lines slight changes were evident upon 
bevacizumab treatment, but without being significant (Fig. 13A). In contrast, HUVECs 
reacted to VEGF addition with a significant increase in migration of cells, which supports the 
theory of VEGF-A being a chemo-attractant in endothelial cells. With addition of 
bevacizumab, migration of HUVECs was reduced to the same level as observed for the 
untreated controls (Fig. 13B). 
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6.2 In vitro differentiation of Hey deficient and Hey re-expressing 
endothelia to delineate vascular Hey gene functions 
As the combined loss of Hey1 and Hey2 in vivo leads to a vascular phenotype and results in 
embryonic lethality (Fischer et al., 2004), an in vitro system was established to determine the 
function of Hey genes in endothelia. Hey1/2 double knockout ES cells were stably 
transfected with plasmids coding for an antibiotic selection marker driven by an endothelial 
specific promoter as well as with Hey1/2 doxycycline inducible plasmids and differentiated 
into endothelial cells. Upon overexpression of Hey1 or Hey2 in embryonic stem cells and 
ESC-derived endothelial cells, RNA-Seq analysis was performed to identify potential 
downstream target genes of Hey1 and Hey2. 
6.2.1 Generation of stable embryonic stem cell lines for endothelial cell selection 
Murine embryonic stem cells can be differentiated into the endothelial lineage by expression 
of an integrated resistance gene under the control of endothelial specific promoters as 
published previously (Marchetti et al., 2002). Plasmids expressing a blasticidin resistance 
gene under the control of endothelial specific promoters, e.g. VE-Cadherin or Tie1, were 
co-electroporated together with a specific transposase in a ratio of 1:6 into ΔHey1/2 murine 
embryonic stem cells and E14 Hey wildtype stem cells leading to a transposon based 
genomic integration. After selection with hygromycin, individual stable clones were picked 
and grown up separately. Presence of the endothelial specific promoters VE-Cadherin or 
Tie1 was verified by PCR (Fig. 14A). Subsequently, cells are named ∆Hey1/2-(VE-Cad-bsd) 
and E14-(Tie1-bsd). In addition, genotyping of ES cells was performed by PCR using specific 
primers to distinguish between Hey1 wildtype and Hey1 deficient cells as described 
previously (Fischer et al., 2005). Hey1 wildtype cells showed a band at 150 bp, while Hey1 
deficient cells show a specific band at 260 bp. Genotyping of ES cells confirmed the Hey1 
deficient state of ∆Hey1/2-(VE-Cad-bsd) cells (Fig. 14B). 
 
Fig. 14 PCR analysis of stable ES cells expressing endothelial specific selection markers (A) 
and genotyping of Hey deficient and Hey wildtype ES cells (B). ES cells were harvested and DNA 
was extracted using the base/neutral solution buffer system. PCR was performed using specific 
primers for the integrated transgene VE-Cadherin (337 bp) or Tie1 (553 bp) (A). For genotyping of ES 
cells Hey1 specific primers were used to distinguish between Hey1 wt (150 bp) and Hey1 deleted 
(260 bp) cells. * indicates primer dimers. For negative controls water was used as template instead of 
DNA. 
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The undifferentiated state of ES cells can be determined by high expression of alkaline 
phosphatase. ∆Hey1/2-(VE-Cad-bsd) and E14-(Tie1-bsd) cells were stained with alkaline 
phosphatase staining solution and observed for alkaline phosphatase positive cells. As 
shown in Fig. 15 ES cell colonies were positive for alkaline phosphatase staining, which 
confirmed their pluripotent state.  
 
Fig. 15 Alkaline phosphatase staining of ∆Hey1/2-(VE-Cad-bsd) and E14-(Tie1-bsd) cells. Cells 
were stained with alkaline phosphatase staining solution and a representative picture of alkaline 
phosphatase positive cells is shown. 
6.2.1.1 Establishment of a directed ESC-EC differentiation method 
As already mentioned above, murine embryonic stem cells can be directly differentiated into 
endothelial cells using selection markers driven by an endothelial specific promoter 
(Marchetti et al., 2002) as well as by the use of chemically defined medium formulations 
(Blancas et al., 2011). A directed differentiation model for endothelial cells was established 
by combining selection marker driven enrichment of endothelial cells and the use of 
chemically defined mediums (Fig. 16). Two chemically defined media formulations 
supplemented with specific growth factors like VEGF, BMP4 and bFGF were used during 
differentiation. Cells were differentiated in 2D culture systems for 14 days in the absence of 
LIF with an induction phase of four days. After four days the culture medium was changed 
and bFGF was added to the culture dish (Fig. 16). From day seven for E14-(Tie1-bsd) or day 
eight for ∆Hey1/2-(VE-Cad-bsd) on, selection with blasticidin was started to enrich the culture 
for endothelial cells and to prevent overgrowth of the culture dish with embryonic stem cells. 
A time course model of the developed differentiation protocol is shown in Fig. 16. 
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Fig. 16 Schematic model of directed differentiation of embryonic stem cells into endothelial 
cells. ES cells were differentiated in 2D culture systems for 14 days with an induction phase of four 
days. After induction a second phase of four days with another specific medium, named LdSK, was 
following, before selection with blasticidin was started. Selection of E14-(Tie1-bsd) cells was started 
from day seven, while selection for ∆Hey1/2-(VE-Cad-bsd) cells was started from day eight on. 
Time points for starting selection were chosen according to relative mRNA expression levels 
of VE-Cadherin and Tie1 measured by qRT-PCR during differentiation of ES cells before 
selection markers were stably integrated into the cells. Expression levels of VE-Cadherin and 
Tie1 represented as ∆∆ ct values at different time points during differentiation compared to 
their undifferentiated counterparts are shown in Fig. 17. VE-Cadherin and Tie1 were not 
detectable in Hey1/2 deficient cells before day eight of differentiation, thus this time point was 
chosen to start selection with blasticidin (Fig. 17). For E14 ES cells selection with blasticidin 
was already started on day seven of differentiation because of higher doubling times of E14 
ES cells when compared to Hey1/2 deficient ES cells (Fig. 17). 
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Fig. 17 Relative expression levels of VE-Cadherin and Tie1 during differentiation of ∆Hey1/2 
and E14 ES cells. Cells were harvested at the indicated time points and marker expression was 
analyzed by qRT-PCR. Quantification was done with Hprt as a housekeeping gene and calculated 
against undifferentiated ES cells, which is represented in ∆∆ ct values. 
Respective pictures of ∆Hey1/2-(VE-Cad-bsd) and E14-(Tie1-bsd) cells during differentiation 
from day eight to 14 are shown in Fig. 18. Both cell lines were able to differentiate into 
endothelial cells in 2D culture systems to a similar extent and showed typical endothelial cell 
morphology at day 14 of differentiation. At day eight of differentiation many ES cell like 
colonies were still present in the culture dish. During differentiation of E14-(Tie1-bsd) cells, 
ES cell-like colonies were present for a longer time in the culture dish when compared to 
differentiation of ∆Hey1/2-(VE-Cad-bsd) cells. Therefore, selection with blasticidin was 
already started one day earlier than for ∆Hey1/2-(VE-Cad-bsd) cells. ES cells started dying 
with further addition of blasticidin and were removed from the culture dish by medium 
change. This selection process allowed a selective enrichment of embryonic stem cell 
derived endothelial cells until day 14 of differentiation (Fig. 18). 
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Fig. 18 Differentiation of ∆Hey1/2-(VE-Cad-bsd) and E14-(Tie1-bsd) ES cells. Cells were 
differentiated for 14 days and selected with blasticidin from day seven for E14-(Tie1-bsd) cells and 
from day eight for ∆Hey1/2-(VE-Cad-bsd) cells on. Pictures were taken every second day during the 
selection phase to observe endothelial specific colonies. 
6.2.1.2 Characterization of embryonic stem cell derived endothelial cells 
After establishment of a directed differentiation method for endothelial cells, cells were 
characterized using quantitative real-time PCR, immunofluorescence as well as a functional 
test. ESC-derived endothelial cells from ∆Hey1/2-(VE-Cad-bsd) and E14-(Tie1-bsd) cell lines 
were harvested after 14 days of differentiation and total RNA was extracted. Endothelial as 
well as pluripotency marker genes were analyzed using qRT-PCR in comparison to 
undifferentiated ES cells at day 0 of differentiation (Fig. 19). Endothelial marker genes like 
VE-Cadherin, Vegfr2, Tie1 and Tie2 were upregulated in both cell lines when compared to 
their undifferentiated counterparts showing ∆∆ ct values up to 15 cycles. On the other hand, 
as expected, pluripotency marker genes like Nanog, Oct4 and Sox2 were strongly 
downregulated showing ∆∆ ct values up to ten cycles compared to undifferentiated ES cells. 
Taken together, the data demonstrate that both, ∆Hey1/2-(VE-Cad-bsd) and E14-(Tie1-bsd) 
endothelial cells, expressed endothelial marker genes at comparable and high levels, while 
expression of pluripotency marker genes was strongly reduced (Fig. 19). 
Results 
50 
 
Fig. 19 Relative expression levels of endothelial and pluripotency marker genes of ESC-derived 
∆Hey1/2-(VE-Cad-bsd) and E14-(Tie1-bsd) endothelial cells. Cells were harvested after 14 days of 
differentiation and marker gene expression was analyzed by qRT-PCR. Quantification was done with 
Hprt as a housekeeping gene and calculated against undifferentiated ES cells, which is represented in 
∆∆ ct values. Results are an average of three biological repetitions. 
To confirm endothelial marker expression seen on mRNA level, protein expression of 
PECAM-1 and VE-Cadherin was investigated. ESC-derived endothelial cells were fixed on 
day 14 of differentiation and stained with antibodies against PECAM-1 (CD31) and 
VE-Cadherin. The immortalized mouse brain endothelioma cell line bEnd5 was used as a 
positive control (Wagner and Risau, 1994, Rohnelt et al., 1997). Endothelial cells derived 
from ∆Hey1/2-(VE-Cad-bsd) and E14-(Tie1-bsd) embryonic stem cell lines exhibited typical 
membranous staining of PECAM-1 and/or VE-Cadherin when compared to the positive 
control bEnd5 (Fig. 20). The respective negative control was only incubated with the primary 
antibody without the following incubation of the secondary antibody and showed no 
expression of PECAM-1 and VE-Cadherin on the cell surface. Cell nuclei were co-stained 
with Hoechst dye (Fig. 20). 
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Fig. 20 Expression of PECAM-1 and VE-Cadherin in embryonic stem cell derived endothelial 
cells. ∆Hey1/2-(VE-Cad-bsd) and E14-(Tie1-bsd) embryonic stem cells were differentiated into 
endothelial cells, fixed on day 14 of differentiation, stained with antibodies to PECAM-1 (A, C) or 
VE-Cadherin (B) and co-stained with Hoechst dye (A-C). 
Functional endothelial cells are able to build capillary like structures when plated on a 
basement membrane matrix in vitro (Arnaoutova and Kleinman, 2010). To assess the 
biological functionality, ESC-derived endothelial cells were plated in Ldsk culture medium 
supplemented with 400 ng/ml VEGF and 50 ng/ml bFGF on Matrigel and the formation of 
capillary like structures was investigated under an inverted cell culture microscope (Fig. 21). 
Human umbilical vein endothelial cells (HUVECs) were used as a positive control and built 
tubes as early as three hours after plating on Matrigel (Fig. 21C). ESC-derived endothelial 
cells did not show any tube formation after plating on Matrigel, even not after longer 
incubation times on Matrigel (data not shown). As endothelial progenitor cells can be 
differentiated into mature endothelial cells by fluid shear stress (Obi et al., 2012), adherent 
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∆Hey1/2-(VE-Cad-bsd) and E14-(Tie1-bsd) ESC-derived endothelial cells were incubated on 
an orbital shaker to promote maturation. After 72 hours of incubation and shaking, cells were 
again plated on Matrigel and the formation of tubes was investigated. Capillary like structures 
were built after six hours, however at a later time point and to a lower extent when compared 
to HUVECs, which were not exposed to shear stress (Fig. 21A,B). 
 
Fig. 21 Tube formation of ∆Hey1/2-(VE-Cad-bsd)-, E14-(Tie1-bsd)-derived endothelial cells and 
HUVECs. 1.5 x 105 cells were seeded in a well of a 96 well plate onto 50 µl gelled Matrigel and 
investigated for tube formation after three to six hours under an inverted cell culture microscope. 
Characterization of embryonic stem cell derived endothelial cells showed that cells lacking 
Hey1 and Hey2 are still able to differentiate into endothelial cells. Taken together, no 
differences in endothelial marker gene expression on mRNA level as well as on protein level 
were evident when compared to Hey1/2 wildtype cells. These data somehow suggested that 
Hey1 and Hey2 seem not to be essential in this in vitro setting. However, the in vitro 
differentiation system was used as a starting point for more detailed characterizations and 
challenges of endothelial cells. To investigate Hey1 and Hey2 mRNA expression levels 
during endothelial cell differentiation relative quantification was done in E14-(Tie1-bsd) Hey 
wildtype cells at different time points during differentiation (Fig. 22). Cells were harvested 
starting on day seven of differentiation and subsequently every second day from day eight 
on. Relative Hey1 and Hey2 expression was measured by qRT-PCR and presented as ∆∆ ct 
values resulting from undifferentiated ES cells at day 0 of differentiation with Hprt as a 
housekeeping gene. Both, Hey1 and Hey2, are enriched at least more than two cycles 
compared to the undifferentiated state. Hey1 expression was increased with ongoing 
differentiation with up to 5.7 cycles at day 14 of differentiation, while Hey2 was less strongly 
enriched with up to 3.5 cycles (Fig. 22). 
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Fig. 22 Relative expression levels of Hey1 and Hey2 during differentiation of E14-(Tie1-bsd) 
cells. Cells were harvested starting from day seven of differentiation every second day. Hey1 and 
Hey2 mRNA levels were analyzed by qRT-PCR. Quantification was done with Hprt as a 
housekeeping gene and calculated against undifferentiated ES cells, which is represented in ∆∆ ct 
values. Results are an average of three biological repetitions. 
6.2.2 Generation of Hey inducible embryonic stem cell lines 
To further investigate the impact of Hey1 and Hey2 on endothelial cell differentiation, Hey1 
and Hey2 were re-expressed in a Hey deficient background using Hey1/2 deficient cells. 
Flag-Strep-tagged Hey1 and Flag-tagged Hey2 under the control of a tetracycline dependent 
promoter were incorporated into ∆Hey1/2-(VE-Cad-bsd) embryonic stem cells using the 
sleeping beauty transposase system as described previously (Mates et al., 2009). 
Flag-Strep-tagged Hey1 or Flag-tagged Hey2 plasmids were co-transfected together with a 
transposase (SB100X) in a ratio of 1:1, which led to integration of the transgene to a 
genomic target site. After selection with puromycin, individual clones were picked and grown 
up separately. Individual clones were induced with 1 µg/ml doxycycline for 48 hours and 
harvested for western blot analysis. Induction with doxycycline led to a strong overexpression 
of Hey1 and Hey2, respectively (Fig. 23). Without addition of doxycycline to the cell culture 
medium expression of Hey1 and Hey2 was not detectable. Tubulin was used as a loading 
control (Fig. 23). Subsequently, cells are named ∆Hey1/2-(VE-Cad-bsd)-pSB-FS-mHey1 and 
∆Hey1/2-(VE-Cad-bsd)-pSB-Flag-mHey2.  
 
Fig. 23 Western blot analysis of Hey inducible embryonic stem cell lines. ∆Hey1/2-(VE-Cad-bsd)-
pSB-FS-mHey1 and ∆Hey1/2-(VE-Cad-bsd)-pSB-Flag-mHey2 embryonic stem cells were induced with 
1 µg/ml doxycycline for 48 hours. Tubulin served as a loading control. α-Flag was diluted 1:2000, 
α-Tubulin 1:10000. 
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6.2.2.1 Differentiation and characterization of Hey re-expressing endothelial cells 
After stable integration of inducible plasmids containing Hey1 or Hey2, embryonic stem cells 
were differentiated into endothelial cells as described before (6.2.1.1). Respective pictures of 
∆Hey1/2-(VE-Cad-bsd)-pSB-FS-mHey1 and ∆Hey1/2-(VE-Cad-bsd)-pSB-Flag-mHey2 cells 
from day eight to 14 during differentiation are shown in Fig. 24. Both cell lines are able to 
differentiate in 2D culture systems into endothelial cells similarly and show typical endothelial 
cell morphology at day 14 (Fig. 24). 
 
Fig. 24 Differentiation of ∆Hey1/2-(VE-Cad-bsd)-pSB-FS-mHey1 and ∆Hey1/2-(VE-Cad-bsd)-pSB-
Flag-mHey2. Cells were differentiated for 14 days and selected with blastidicidin from day eight on. 
Pictures were taken every second day during the selection phase to observe endothelial specific 
colonies. 
At day 14 of differentiation embryonic stem cell derived endothelial cells were seeded on a 6 
well plate and on the following day doxycycline (1 µg/ml) was added for 48 hours to induce 
expression of Hey1 and Hey2. Flag-tagged versions of Hey1 or Hey2 are linked via an IRES 
site to a GFP coding sequence, which is also under the control of the tetracycline dependent 
promoter. Endothelial cells were investigated for GFP positive cells, which were only present 
after induction with doxycycline, however to a very low extent, as shown in Fig. 25. These 
data reflect that Hey1 and Hey2 expression could partially be restored in Hey deficient cells 
upon addition of doxycycline as demonstrated by GFP expression Fig. 25. 
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Fig. 25 Induction of ∆Hey1/2-(VE-Cad-bsd)-pSB-FS-mHey1 and ∆Hey1/2-(VE-Cad-bsd)-pSB-
Flag-mHey2 derived endothelial cells. Cells were differentiated for 14 days and selected with 
blasticidin from day eight on. At day 15 of differentiation cells were induced with 1 µg/ml doxycycline 
for 48 hours. Pictures in the upper lane were taken with bright-field mode, while pictures in the lower 
lane represent the corresponding fluorescent picture. 
In addition to the analysis of GFP expression levels, protein expression of Hey1 and Hey2 
was quantified in embryonic stem cells using Bradford reagent. Cells were induced with two 
different concentrations of doxycycline, 50 ng/ml and 1000 ng/ml, and harvested after 72 
hours of incubation for western blot analysis (Fig. 26). A total amount of 50 µg of protein was 
separated on a SDS-Page with tubulin serving as a loading control. Subsequently, proteins 
were transferred to a nitrocellulose membrane and incubated with the respective antibodies. 
Addition of doxycycline led to a stronger expression of Hey2 compared to Hey1 (Fig. 26). A 
quite low concentration of doxycycline (50 ng/ml) was already sufficient to induce Hey2 
expression, while Hey1 expression was only evident after induction with higher 
concentrations of doxycycline (1000 ng/ml). These data reflect a stronger overexpression of 
Hey2 compared to Hey1 in embryonic stem cells upon stimulation with doxycycline, although 
cells were induced with the same amount of doxycycline (Fig. 26). 
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Fig. 26 Western blot analysis of Hey inducible embryonic stem cell lines. ∆Hey1/2-(VE-Cad-bsd)-
pSB-FS-mHey1 and ∆Hey1/2-(VE-Cad-bsd)-pSB-Flag-mHey2 embryonic stem cells were induced with 
either 50 ng/ml or 1000 ng/ml doxycycline for 72 hours. Tubulin served as a loading control. Protein 
quantification was done using Bradford reagent and a total amount of 50 µg protein was loaded on a 
SDS-Page. α-Flag was diluted 1:2000, α-Tubulin 1:10000. 
After the establishment of Hey1 and Hey2 overexpressing embryonic stem cell lines, cells 
were used for further endothelial differentiation experiments to elucidate the role of Hey 
genes in vascular development. It is known from the literature that Hey expression leads to 
arteriogenesis and to the development of rather arterial than venous endothelial cells. 
Therefore, we expected different or opposing regulation of arterial and venous genes in 
endothelial cells upon Hey overexpression. To this end, ∆Hey1/2-(VE-Cad-bsd)-pSB-FS-
mHey1 and ∆Hey1/2-(VE-Cad-bsd)-pSB-Flag-mHey2 embryonic stem cells were 
differentiated into endothelial cells and induced with doxycycline (1 µg/ml) for 72 hours. Cells 
were harvested and gene expression analysis was performed using qRT-PCR (Fig. 27). The 
fold change was calculated from induced versus non-induced samples but did not show any 
significant change between arterial (Dll4, EphrinB2) and venous (CoupTFII, CoupTFII alt and 
EphB4) marker genes. The venous marker gene CoupTFII exists in two isoforms, whereby 
one isoform lacks a DNA binding domain and is referred as CoupTFII alternative (alt). Arterial 
genes were slightly induced upon Hey2 overexpression, while the venous genes, CoupTFII 
and CoupTFII alt, were slightly reduced, however with high standard deviations and thus not 
to a significant extent (Fig. 27). 
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Fig. 27 Relative expression levels of arterial and venous marker genes of ESC-derived 
endothelial ∆Hey1/2-(VE-Cad-bsd)-pSB-FS-mHey1 and ∆Hey1/2-(VE-Cad-bsd)-pSB-Flag-mHey2 
cells. After 14 days of differentiation cells were induced with 1 µg/ml doxycycline for 72 hours. Cells 
were harvested and gene expression was analyzed by qRT-PCR. Quantification was done with Hprt 
as a housekeeping gene. The fold change was calculated from doxycycline induced samples against 
non-induced controls. Results are an average of three biological repetitions. 
6.2.3 RNA-Sequencing of Hey inducible cell lines 
In order to determine potential vascular Hey1/2 downstream target genes, RNA-Sequencing 
was performed with ∆Hey1/2-(VE-Cad-bsd)-pSB-FS-mHey1 and ∆Hey1/2-(VE-Cad-bsd)-
pSB-Flag-mHey2 embryonic stem cells as well as embryonic stem cell derived endothelial 
cells that overexpress the respective gene. RNA-Seq analysis revealed that about 90 % of 
the reads of each sample aligned to the Mus Musculus genome (NCBI37/mm9). For further 
details see Table 1 in the appendix. 
6.2.3.1 RNA-Sequencing of Hey inducible embryonic stem cells and endothelial cells 
after Hey1/2 overexpression 
For RNA-Sequencing of ∆Hey1/2-(VE-Cad-bsd)-pSB-FS-mHey1 and ∆Hey1/2-
(VE-Cad-bsd)-pSB-Flag-mHey2 embryonic stem cells and endothelial cells, cells were 
induced with 1µg/ml doxycycline for 72 hours with the exception of ∆Hey1/2-(VE-Cad-bsd)-
pSB-FS-mHey1 endothelial cells, which were only induced for 48 hours. RNA was extracted 
and cDNA libraries were generated as described in 5.3.5. For reasons of simplification, 
∆Hey1/2-(VE-Cad-bsd)-pSB-FS-mHey1 and ∆Hey1/2-(VE-Cad-bsd)-pSB-Flag-mHey2 
embryonic stem cells are subsequently named ES Hey1+ and ES Hey2+, while endothelial 
cells are subsequently named EC Hey1+ and EC Hey2+. 
For analysis of raw data, genes with less than ten reads per million (RPM) were excluded 
from further analysis. Noise expression was calculated from reads mapping to non-exonic 
regions of the genome and a gene was considered as expressed with a value of ≥ 2.26 reads 
per kilo base per million (RPKM). This value is ten-fold higher than RPKM values for 
non-exonic regions of the genome. Analysis of RNA-Sequencing data revealed differences in 
overexpression intensities of Hey1 and Hey2 in both cell types. Hey1 was elevated 14-times 
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higher than Hey2 in embryonic stem cells after induction with the same amount of 
doxycycline (fold change Hey1: 343.17, Hey2: 23.77). Similar results were obtained in 
endothelial cells, where Hey1 was increased more than 4.7-fold compared to Hey2 (fold 
change Hey1: 15.27, Hey2: 3.26). RNA-Sequencing showed a stronger increase of Hey1 
than Hey2 in both, embryonic stem cells as well as endothelial cells, although protein 
expression in embryonic stem cells was higher for Hey2 than for Hey1 as shown by western 
blot analysis (Fig. 26).  
To identify Hey target genes the following selection criteria were used: a gene was 
considered as regulated if the fold change between control and induced sample was ≥ 1.8, 
while the RPKM value had to be ≥ 2.26 in at least one sample. Genes regulated by either 
Hey1 or Hey2 were clustered with Cluster 3.0, which resulted in 354 regulated genes in 
embryonic stem cells and 123 regulated genes in endothelial cells as illustrated by the 
respective heatmaps in Fig. 28A.  
 
Fig. 28 Heatmap of ES Hey1+/Hey2+ and EC Hey1+/Hey2+ (A) and GO term analysis (B). 
Clustering was done using Cluster 3.0 with at least one observation with an absolute value ≥ 1.8. GO 
term analysis was done using DAVID 6.7, while only biological processes were considered. A Cluster 
Enrichment Score of 1.3 was considered as significant (p-value ≤ 0.05). 
Upregulated genes are presented in green colors, while downregulated genes are shown in 
red colors. No expression of the respective gene is indicated in grey colors. The data reflect 
that nearly three times more genes were regulated in embryonic stem cells (n = 354) than in 
endothelial cells (n = 123) upon Hey overexpression (Fig. 28A). The entire list including fold 
changes of the target genes regulated by Hey1 and Hey2 in ES and endothelial cells is 
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provided in the appendix in Table 2. Regulated genes in embryonic stem cells and 
endothelial cells were analyzed for Gene Ontology (GO) terms using DAVID 6.7, while only 
biological processes were considered. An enrichment score of 1.3 was considered to be 
significant with a p-value ≤ 0.05. (Fig. 28B). The higher the value of the Cluster Enrichment 
Score, the higher is the number of regulated genes related to the respective GO term. For 
regulated genes in endothelial cells the major three GO terms are presented, as no 
significant enrichment was observed. Most enriched biological processes in endothelial cells 
were apoptosis, regulation of transcription and chromatin modification, however not to a 
significant extent. In contrast to endothelial cells, significant enriched biological processes in 
embryonic stem cells were embryonic development, apoptosis, cardiac muscle tissue 
development and cell growth as well as embryonic development (Fig. 28B). 
6.2.3.2 Comparison of embryonic stem cells and endothelial cells after Hey 
overexpression by RNA-Sequencing 
To further elucidate the role of Hey1 and Hey2 in regulating target genes, comparative 
analysis between embryonic stem cells and endothelial cells was performed regarding 
regulated genes by either Hey1 or Hey2. Respective heatmaps and GO term analysis were 
performed with the same selection criteria as described in section 6.2.3.1 and presented in 
Fig. 29. Comparison of the number of regulated genes by either Hey1 (n = 106) or Hey2 
(n = 382) in embryonic stem cells and endothelial cells revealed that 3.6-fold more genes 
were regulated by Hey2 than by Hey1, hypothesizing a more important role of Hey2 in target 
gene regulation (Fig. 29A). The entire list of regulated target genes including the fold 
changes is provided in Table 3 in the appendix. However, the higher number of genes 
regulated by Hey2 could also be due to higher protein expression upon induction with 
doxycycline as shown in Fig. 26. GO term analysis for genes regulated by Hey1 in embryonic 
stem cells and endothelial cells did not show any significant enrichment, as the number of 
the Cluster Enrichment Score remained below 1.3. The top three enriched terms upon Hey1 
overexpression were cell secretion, cell cycle and apoptosis related processes. In contrast to 
Hey1, genes regulated by Hey2 revealed five significantly enriched biological processes: 
Apoptosis, cytoskeleton organization, regulation of transcription, heart development and 
embryonic development (Fig. 29B). As expected, many developmental processes as well as 
regulation of transcription were represented, as already shown in a previous study upon 
Hey1/2 overexpression in HEK-293 cells (Heisig et al., 2012). According to the data derived 
from RNA-Sequencing in embryonic stem cells and endothelial cells one could hypothesize 
that Hey2 plays a more important role in the regulation of target genes than Hey1.  
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Fig. 29 Heatmap of ES/EC Hey1+ and ES/EC Hey2+ (A) and GO term analysis (B). Clustering was 
done using Cluster 3.0 with at least one observation with an absolute value ≥ 1.8. GO term analysis 
was done using DAVID 6.7, while only biological processes were considered. A Cluster Enrichment 
Score of 1.3 was considered as significant (p-value ≤ 0.05). 
6.2.3.3 Target gene validation in embryonic stem cells and endothelial cells 
Several Hey regulated genes in embryonic stem cells and endothelial cells were chosen and 
validated with qRT-PCR. First of all induction, of either Hey1 or Hey2 was verified. Both 
genes were significantly increased in the respective cell line when compared to the 
non-induced control. No expression of Hey1 was found in the Hey2 overexpressing cell line 
and vice versa, as both cell lines were generated on a Hey deficient background of Hey1 and 
Hey2 (Fig. 30). In embryonic stem cells most of the genes were regulated by both, Hey1 and 
Hey2. Fold changes for genes, which were upregulated (Smarca2, Krt19, Nptx2, Calcoco2, 
Icam1, Ptges) or downregulated (Sox1, EG434280, Serpine2, Perp, Fabp3, Skil) by Hey1 
and Hey2 could be confirmed very precisely (Fig. 30). Most of the Hey target genes showed 
a similar regulation by Hey1 and Hey2, which reflects their great redundancy in regulating 
target genes, as published in a previous study (Heisig et al., 2012). However, there were 
some genes, which were not regulated by Hey1 and thus regulated by Hey2 alone. Spred3 
and Fibronectin1 were upregulated, while Lefty1 and Lefty2 were downregulated by Hey2. 
No change in regulation was observed for these genes in the corresponding Hey1 
overexpressing cell line (Fig. 30). 
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Fig. 30 Validation of ES Hey1+ and ES Hey2+ target genes by qRT-PCR. Fold changes of RNA-Seq 
and qRT-PCR analysis are shown. p-value ≤ 0.05 = *; p-value ≤ 0.01 = **, p-value ≤ 0.001 = ***. 
Results are an average of three biological repetitions. 
In contrast to embryonic stem cells, target gene validation in endothelial cells was rather 
limited (Fig. 31). However, Hey1 and Hey2 overexpression was confirmed by qRT-PCR as 
both genes were significantly upregulated. Neither for genes, which were regulated by both, 
Hey1 and Hey2, (Dnajc4, Rarres1) nor for genes, which were regulated by Hey1 (Cxxc1, 
Psmb10) or Hey2 (Ddit3, Hdac8, C1d, Esm1, Mier3) alone, regulation could be confirmed by 
qRT-PCR. According to the data derived from qRT-PCR analysis, target genes of Hey1 and 
Hey2 in endothelial cells remained more or less unregulated after overexpression of the 
respective gene (Fig. 31). 
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Limited changes seen in target gene regulation in endothelial cells could be due to the lower 
overexpression of Hey1 and Hey2 when compared to embryonic stem cells or even could 
represent random regulations. 
 
Fig. 31 Validation of EC Hey1+ and EC Hey2+ target genes by qRT-PCR. Fold change of RNA-Seq 
and qRT-PCR are shown. p-value ≤ 0.05 = *. Results are an average of three biological repetitions. 
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7 Discussion 
7.1 Impact of bevacizumab treatment on human tumor cell lines in 
vitro 
7.1.1 Tumor cell expression of VEGF and VEGF receptors under hypoxia and 
bevacizumab treatment 
It is well known that VEGF receptors are mainly located on the cell surface of endothelial 
cells and angiogenic signaling is activated through binding of VEGF (Ferrara and Kerbel, 
2005). However, it is controversially discussed in the literature if VEGF receptors are also 
present on tumor cells and whether tumor cells could benefit from VEGF signaling. Autocrine 
and/or paracrine VEGF signaling loops in tumor cells could facilitate tumor growth and tumor 
spread by enhanced VEGF signaling (McMahon, 2000). Blocking of VEGF by bevacizumab 
treatment could therefore exhibit a direct impact on tumor cells. To this end, VEGF receptor 
expression was analyzed in several human tumor cell lines from four different tumor types. In 
line with previous studies (Duff et al., 2006, Seto et al., 2006, Ghosh et al., 2008, Soker et 
al., 1998) expression of VEGFR1, VEGFR2 and NRP1 was confirmed in a variety of human 
tumor cell lines measured by western blot and flow cytometry analysis. VEGFR1 and NRP1 
were expressed by almost all tumor cell lines investigated, while expression of VEGFR2, the 
major receptor involved in angiogenesis, was limited to four out of nine tumor cell lines. With 
the exception of one renal cell line (A498), incubation under hypoxia and the addition of 
bevacizumab did not alter receptor expression. Besides the presence of VEGF receptors on 
tumor cells, induction of VEGF under hypoxia further supports the hypothesis of a potential 
autocrine or paracrine stimulation of tumor cells. As summarized by Harris et al. hypoxia 
leads to a variety of gene expression changes and the production of several growth factors 
like VEGF through activation of HIF-1 (Harris, 2002). The induction of VEGFA and GLUT1 
under hypoxic conditions in this study clearly shows the responsiveness of tumor cell lines to 
the hypoxic environment, which has been demonstrated for several lung and breast 
carcinoma cell lines as reported before (Simiantonaki et al., 2008). Besides increased 
expression of VEGF in tumor cell lines due to hypoxia, secretion of VEGF from tumor cells is 
also important when evaluating possible autocrine and/or paracrine signaling loops. Thus, in 
future experiments quantification of secreted VEGF should be determined from culture 
medium of tumor cells with and without addition of bevacizumab under normoxic and hypoxic 
conditions, e.g. by VEGF ELISA assays. These experiments would provide insight in the 
amount of secreted VEGF from tumor cells and could probably be related to receptor 
activation in tumor cells. VEGF receptor activation in tumor cells is initiated by binding of 
VEGF to VEGFR2, which leads to autophosphorylation of VEGFR2 and induces downstream 
signaling. Thus, it would be interesting to investigate the activated form of VEGFR2 in tumor 
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cells using phospho-specific antibodies against the main autophosphorylation sites, Tyr1175 
and Tyr1214, of VEGFR2. Taken together, the presence of at least one receptor in each 
tumor cell line together with the hypoxic stimulation of VEGF provided the basis for an 
extended analysis of angiogenic gene expression and biological outputs of VEGF signaling 
after bevacizumab treatment to further investigate potential autocrine and paracrine functions 
of tumor cells. 
7.1.2 Angiogenic gene expression analysis under hypoxia and bevacizumab 
treatment 
In addition to protein expression analysis, VEGF and VEGFR expression was investigated on 
mRNA level to detect changes after bevacizumab treatment, which probably may not have 
been apparent on protein level. First of all, gene expression changes of different isoforms of 
VEGFA, which are generated according to alternative splicing, were investigated. Different 
isoforms of VEGFA are differing in their length and their amino acid content and may also 
exhibit varying functions (Harper and Bates, 2008). To investigate if bevacizumab treatment 
influences VEGFA expression in an isoform-specific manner, relative expression changes of 
three different isoforms, VEGFA189, VEGFA165 and VEGFA121, were evaluated after 
bevacizumab exposure. Overall, none of the tumor cell lines showed any regulation in 
response to bevacizumab treatment. Upon bevacizumab treatment one could expect a 
downregulation of VEGF on the one side or an opposing upregulation of VEGF on the other 
side because tumor cells could react to VEGF depletion with higher production of the growth 
factor to ensure their survival. However, VEGF expression was confirmed in every single 
tumor cell line investigated and thus we went on to evaluate tumoral VEGF receptor and 
co-receptor expression. VEGFR1 and NRP1 were present in nearly all tumor cell lines 
investigated in this study, while VEGFR2 expression was restricted to four cell lines (H552, 
HOP62, HCT-116, MDA-MB-231), indicating that VEGFR2 expression is rather limited in 
tumor cells when compared to endothelial cells. A lack of expression of VEGFR2 under both, 
normoxic and hypoxic conditions, has been reported in a previous study with several 
colorectal, breast and lung carcinoma cell lines, claiming that a functional autocrine loop 
between VEGF and VEGFR2 is not possible in these cell lines (Simiantonaki et al., 2008). In 
contrast, our data demonstrate the simultaneous presence of VEGF receptors or 
co-receptors together with expression of VEGF in the same tumor cell line, which supports 
the theory of a functional autocrine signaling loop that could be inhibited by bevacizumab. 
For one breast tumor cell line, HS-578 T, a significant reduction of NRP1 was evident after 
bevacizumab treatment under hypoxia, in line with the endothelial control. The reduced 
expression of NRP1 upon VEGF depletion in HS-578 T could be due to impaired autocrine 
VEGF signaling. At least, a change in regulation of NRP1 due to hypoxia has been reported 
recently for two other breast carcinoma cell lines, MDA-MB-231 and SUM159, as well as for 
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HUVECs (Bae et al., 2008), indicating that NRP1 expression is changed in response to 
hypoxia. However, downregulation of NRP1 in HS-578 T was not seen on protein level, 
which could be due to alternative regulatory mechanisms or posttranslational modifications. 
The overall limited detection of autocrine signaling loops in the investigated tumor cell lines 
might also be due to alternative signaling of angiogenic ligands and receptors, such as 
VEGFR3 as well as VEGF-C and VEGF-D. VEGF-C and VEGF-D are the major ligands that 
activate VEGFR3, which is mainly involved in lymphangiogenesis (Takahashi and Shibuya, 
2005). Binding of the ligands VEGF-C and VEGF-D is not exclusively restricted to VEGFR3, 
but can also induce VEGFR2 and NRP2. Activation of VEGFR2 through alternative ligands 
besides VEGF-A could compensate for VEGF-A depletion by bevacizumab, leading to 
prolonged angiogenic signaling. It has been reported that VEGF-A depletion by bevacizumab 
in glioma cell lines led to an induced expression of VEGF-C and VEGF-D, indicating the 
amplification of other pro-angiogenic molecules, which would lead to escape mechanisms 
from anti-VEGF therapy (Grau et al., 2011). In addition, it has been shown that binding of 
other VEGF family members such as VEGF-B and PLGF could activate VEGFR1 and NRP1 
independently of VEGF-A, thereby rescuing VEGF signaling, which was blocked by 
bevacizumab (Takahashi and Shibuya, 2005, Fischer et al., 2008). 
7.1.3 Effects of bevacizumab treatment on tumor cell survival 
In order to determine already known VEGF-A dependent biological functions, which are 
impaired after VEGF depletion in endothelial cells (Wang et al., 2004), changes in apoptosis 
were investigated in tumor cell lines after treatment with bevacizumab. In endothelial cells 
VEGF-A can act as a survival factor and rescue cells from apoptosis suggesting that 
VEGF-A can also play a role in tumor cell survival, which in turn could be reduced by 
bevacizumab treatment. In contrast to endothelial cells, depletion of VEGF-A via 
bevacizumab did not increase apoptotic levels or change cellular survival in the investigated 
tumor cells, as measured by the presence of cleaved PARP via protein analysis and by 
propidium iodide staining via flow cytometry. However, it has been shown in the literature 
that VEGF and VEGFR1/2 are involved in the survival of tumor cells via autocrine signaling 
loops (Calvani et al., 2008, Lee et al., 2007). Depletion of VEGF by bevacizumab blocked the 
survival of certain colorectal cancer cells, which demonstrates their responsiveness to VEGF 
and its inhibition (Calvani et al., 2008). Loss of VEGF or knockdown of VEGFR1 using 
siRNAs in breast tumor cell lines led to an increase in apoptotic levels, indicating that 
expression of VEGF and VEGFR1 are essential for the survival of cancer cells (Lee et al., 
2007). Interestingly, decreased survival of breast tumor cells was only dependent on the 
depletion of VEGFR1, but not on the depletion of VEGFR2 or NRP1, which further highlights 
the importance of VEGFR1 in regulating tumor cell survival. However, decreased survival of 
tumor cells was only evident if the endogenous level of VEGFR1 was reduced, but not with 
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the addition of externally acting proteins like bevacizumab. This might be due to the location 
of VEGFR1, which is primarily located at nuclear membranes and therefore inaccessible for 
extracellular ligands (Lee et al., 2007). 
7.1.4 Proliferation and migration analysis of human tumor cell lines after 
bevacizumab treatment 
In endothelial cells proliferation and migration are dependent on active VEGF signaling. 
Active VEGF signaling in tumor cells could also be beneficial for tumor cell proliferation as 
well as for tumor cell migration and could be reduced by VEGF blocking. To investigate the 
impact of bevacizumab on tumor cell proliferation and migration, analysis was further 
extended to a screen including 30 tumor cell lines derived from four tumor types to identify 
possible cell line specific effects. Experiments were done under hypoxic conditions to induce 
VEGF-A expression and to mimic the in vivo state of tumors. Proliferation rates were 
determined for up to 72 hours but treatment with bevacizumab did not influence cell 
proliferation, which remained more or less unchanged in most of the tumor cell lines. The 
only significant change in proliferation was evident in one colorectal tumor cell line, HT-29, 
which showed reduced proliferation rates after bevacizumab exposure in line with the 
endothelial control. Endothelial cells showed a significant reduction in cell proliferation after 
72 hours of bevacizumab treatment and an opposing increase in proliferation rates when 
stimulated with rhVEGF. From the literature it is known, that bevacizumab treatment inhibits 
endothelial cell proliferation in a dose-dependent manner using a concentration range from 
0-500 ng/ml of bevacizumab and that a concentration of 100 ng/ml bevacizumab is sufficient 
to reduce proliferation of endothelial cells to a significant extent in vitro (Wang et al., 2004). 
However, in this study even higher, clinically relevant concentrations of bevacizumab (250 
µg/ml) were used to inhibit VEGF-A, but overall did not influence tumor cell proliferation. A 
lack of tumor cell response in terms of proliferation changes after bevacizumab treatment in 
vitro has been reported before and even longer exposure of tumor cells to bevacizumab did 
not significantly impair tumor cell growth (Grau et al., 2011). However, tumor cell lines are 
responsive to loss of VEGF as demonstrated by VEGF depletion via homologous 
recombination, resulting in decreased proliferation in vitro, but not by VEGF depletion using 
monoclonal antibodies like bevacizumab (Samuel et al., 2011). 
Limited changes in response to bevacizumab treatment were also evident when evaluating 
cellular migration in tumor cells. Across all investigated tumor cell lines no significant change 
in tumor cell migration was apparent after bevacizumab treatment, while cell migration in 
endothelial cells was strongly impaired. In endothelial cells migration is controlled through 
VEGFR1 signaling, which could additionally be enhanced by the co-expression of 
Neuropilin1 (Koch et al., 2011), while blocking of VEGFR1 completely abolished cellular 
migration (Kanno et al., 2000). This emphasizes a critical role of the VEGF/VEGFR1 pathway 
Discussion 
67 
in regulating cellular migration in endothelial cells and supposes that tumor cell migration 
might also be controlled by the VEGF/VEGFR1 signaling axis. Because most of the tumor 
cell lines investigated exhibited expression of VEGFR1 and NRP1, migration could be 
influenced upon VEGF depletion by bevacizumab. Although some tumor cell lines expressing 
NRP1 and high levels of VEGFR1 were highly motile, VEGF blocking via bevacizumab did 
not influence migratory potential. This raises the possibility that tumor cells might not be 
exclusively dependent on VEGF alone, but also on other ligands like PLGF and VEGF-B, 
which can specifically activate VEGFR1 and regulate tumor cell migration. Expression of 
VEGFR1 as well as the respective ligands VEGF-B and PLGF has been demonstrated in 
several pancreatic carcinoma cell lines and blocking of VEGFR1 led to reduced tumor cell 
migration and invasion (Wey et al., 2005). This further supports the involvement of VEGFR1 
in regulating tumor cell migration. Tumor cell migration and endothelial permeability are also 
dependent on the secretion of VEGF and thus tumor cells could contribute to VEGF signaling 
activation via secretion of VEGF. Indeed, VEGF secretion from tumor cell lines or primary 
tumors is able to enhance endothelial permeability, which is in turn blocked by the addition of 
bevacizumab (Prager et al., 2010, Yang et al., 2010). Interestingly, several tumor cell lines 
showed slightly higher migration rates after bevacizumab treatment when compared to non-
treated control cells, however not to a significant extent. Similar results, namely an increase 
in tumor cell migration, after chronic exposure with bevacizumab for up to three month was 
apparent by an in vitro study by Fan et al. Increased migration and invasion of tumor cells 
was abrogated by blocking of VEGFR1, which further underlines the essential involvement of 
VEGFR1 in regulating cellular migration (Fan et al., 2011).  
7.1.5 Conclusion 
In the 40 years since Judah Folkman first proposed treating angiogenesis as a novel cancer 
therapy, VEGF-A has been evolved as the major molecule involved in tumor angiogenesis. 
VEGF-A plays an essential role in generating endothelial cell changes, while blocking of 
VEGF by bevacizumab has shown direct anti-vascular effects in tumors (Willett et al., 2004). 
However, less is known about any direct anti-tumoral effects of bevacizumab and whether 
tumor cells are intrinsically affected by bevacizumab treatment. In this study, VEGF and 
VEGF receptor expression could be confirmed in a variety of tumor cell lines derived from 
different tumor types, supporting the theory of an autocrine and/or paracrine VEGF signaling 
loop. Blockade of VEGF by bevacizumab in vitro did not affect tumor cells in a unique 
manner and the overall measurable effect was rather limited when evaluating downstream 
outputs of VEGF signaling known from endothelial cells. Besides the limited or even 
complete lack of response in tumor cells to bevacizumab treatment, tumor cell lines exhibit a 
very high biological diversity according to their cell morphology differing in cell size and also 
in their proliferation ability with varying doubling times. This somehow reflects the 
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heterogeneity of tumor cells in vivo, which demonstrates the complexity of cancer therapy 
and the lack of a unique treatment for curing cancer. Although anti-angiogenic therapy has 
proven efficacy in patients leading to prolonged survival, further research is needed to 
elucidate the complex interaction between tumor cells and tumor endothelial cells. Besides 
VEGF-A, many other angiogenic ligands as well as angiogenic receptors are involved in 
tumor angiogenesis and also the intensive signaling crosstalk between different cells could 
contribute to increased tumor growth. For initial experiments in vitro, tumor cell lines from the 
well established NCI-60 panel provided a useful tool to study the direct impact of 
bevacizumab on tumor cells. However, data derived from the present study showed that 
tumor cells are not intrinsically affected by bevacizumab single treatment demonstrating that 
anti-VEGF-A based therapies remain a rather complex process between tumor and 
endothelial cells.  
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7.2 In vitro differentiation of Hey deficient and Hey re-expressing 
endothelia to delineate vascular Hey gene functions 
7.2.1 Hey deficient endothelia efficiently differentiate in vitro 
Hey deficient embryonic stem cells were used to study Hey dependent endothelial cell 
differentiation in vitro. Hey deficient embryonic stem cells were generated from blastocysts 
derived from Hey1fl/fl/Hey2-/- mice. The floxed Hey1 allele was recombined by treatment with 
a Cre recombinase, which resulted in homozygously deleted embryonic stem cells 
representing Hey1/2 double-knockout cells (Fischer et al., 2005). These cells are able to 
differentiate as 3D aggregates, so called embryoid bodies, into various cell types. Analysis of 
nine-day-old embryoid bodies indicated the formation of endothelial and smooth muscle cells 
as well as the formation of cardiomyocytes (Fischer et al., 2005). To selectively trigger the 
differentiation into a specific cell type and to circumvent the formation of several cell types 
from differentiating ES cells, we made use of a selection based system. A selection marker 
driven by an endothelial specific promoter was used to achieve a directed differentiation of 
ES cells into endothelial cells. This method has proven efficacy for the selection of 
cardiomyocytes (Klug et al., 1996) as well as for the selection of endothelial cells (Marchetti 
et al., 2002) before. Differentiation into endothelial cells was done with Hey knockout cells as 
well as E14 embryonic stem cells, which present Hey1/2 wildtype cells and served as a 
control. Both embryonic stem cell lines were stably transfected with a blasticidin resistance 
gene under the control of either the VE-Cadherin (Hey knockout cells) or the Tie1 promoter 
(E14 Hey wildtype cells), which are both vascular endothelial-specific promoters. Selection 
with blasticidin was started at day seven (E14) or day eight (∆Hey1/2) of differentiation 
because mRNA levels of VE-Cadherin and Tie1 were highly enriched at this day compared 
to undifferentiated ES cells, which indicated the formation of endothelial progenitor cells. The 
selection procedure using blasticidin as a selection agent highly enriched the culture for 
endothelial cells, while eliminating stem cells from the culture dish, which resulted in a 
relatively pure endothelial cell population after 14 days. Besides the efficient selection 
method, high yields of endothelial cells were obtained using chemically defined media 
formulations with specific growth factors as described in a previous study (Blancas et al., 
2011). VEGF and BMP4 were added to the culture medium as both growth factors enhance 
mesodermal development, in particular haematopoietic and endothelial cell determination, 
while inhibiting neuronal development (Johansson and Wiles, 1995, Chiang and Wong, 
2011). Endothelial cell differentiation in vitro is also enhanced by addition of bFGF, which is 
involved in the survival of endothelial precursor cells and was therefore added to the culture 
dish after the induction phase and after initial formation of EC progenitor cells (Vittet et al., 
1996, Chiang and Wong, 2011). The enhancing effect of EC differentiation due to the 
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addition of specific growth factors is often also mediated by the use of FBS in cell culture 
media, as FBS is supplemented with a large number of growth factors. However, the use of 
FBS in cell culture medium often leads to higher variability according to batch-to-batch 
variations and to limited reproducibility. To this end, serum-free formulations like KOSR have 
been explored and used not only for maintenance and establishment of embryonic stem cells 
(Cheng et al., 2004), but also for the differentiation of endothelial cells (Blancas et al., 2011). 
Serum-free media was therefore used for the culture of embryonic stem cells as well as for 
the differentiation into endothelial cells. Taken together, efficiency of endothelial 
differentiation in vitro was not altered between Hey knockout and Hey wildtype cells, which 
assumes that the loss of Hey1 and Hey2 does not affect the ability of stem cells to 
differentiate into endothelial cells in this system.  
7.2.2 ESC-derived endothelial cells show typical endothelial characteristics 
Before starting endothelial differentiation studies with Hey knockout and Hey wildtype ES 
cells, their pluripotency was investigated. Cells were stained for alkaline phosphatase 
expression, which is used as a pluripotency marker and confirms the stem cell character of 
ES cells. Hey knockout and Hey wildtype cells exhibited a similar staining pattern, which 
indicated that the loss of Hey genes does not impair the stem cell character and thus Hey 
genes were not involved in the maintenance of the stem cell status. This was also evident 
from comparative differentiation studies between Hey knockout and Hey wildtype ES cells as 
the ability of Hey knockout ES cells and Hey wildtype ES cells to differentiate into endothelial 
cells was not altered between both cell lines (7.2.1). As demonstrated before, Hey deficient 
cells were also able to differentiate into 3D aggregates and to form several cell types, which 
further indicates that Hey genes are dispensable for  ES cell differentiation (Fischer et al., 
2005). Consistent with this, differentiation of cardiomyocytes, endothelial cells and 
haematopoietic progenitor cells was not disturbed, when Notch signaling was blocked further 
upstream by loss of RBPkJ (Schroeder et al., 2003). Blocking of Notch signaling in human 
embryonic stem cells by gamma secretase inhibiton (GSI) even promoted differentiation and 
induced the formation of mesodermal cells (Jang et al., 2008). In addition to the unaltered 
differentiation potential of Hey knockout cells, gene expression analysis confirmed the 
pluripotent character of the investigated stem cell lines. Stem cells exhibited high expression 
of the pluripoteny marker genes Nanog, Oct4 and Sox2, which were strongly reduced in 
differentiated endothelial cells. Again, there was no obvious difference in Hey knockout and 
Hey wildtype cells. Embryonic stem cell derived endothelial cells exhibited typical endothelial 
characteristics as shown by marker gene expression on mRNA level as well as by 
immunofluorescent staining. Gene expression analysis revealed a strong induction of 
endothelial marker genes including receptor tyrosine kinases like Tie1, Tie2 and Vegfr2 as 
well as the cell adhesion molecule VE-Cadherin in endothelial cells when compared to 
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embryonic stem cells. Consistent with our findings, upregulation of these endothelial marker 
genes has been demonstrated before, however in an endothelial differentiation system using 
embryoid bodies (Vittet et al., 1996). To confirm endothelial marker expression in 
ESC-derived endothelial cells on protein level, cells were stained for PECAM-1 and 
VE-Cadherin. VE-Cadherin and PECAM-1 (CD31) are specific endothelial cell surface 
molecules, which were first described in the early 90s (Newman et al., 1990, Lampugnani et 
al., 1992). Until today, both proteins are commonly used in immunofluorescent stainings to 
identify and characterize endothelial cells. VE-Cadherin and PECAM-1 expression was 
confirmed in ESC-derived endothelial cells as shown by localization at the cell membrane of 
endothelial cells. Immunofluorescent staining was not altered between Hey knockout and 
Hey wildtype cells but confirmed the endothelial phenotype of ESC-derived endothelial cells. 
In order to determine the functionality of endothelial cells, the tube-forming ability is mainly 
used as a measure of functional endothelium (Arnaoutova et al., 2009). Embryonic stem cell 
derived endothelial cells were not able to form tubes after plating on Matrigel in contrast to 
HUVECs, which served as a control. Tube formation of Hey knockout and Hey wildtype 
endothelial cells only became evident when endothelial cells were incubated on an orbital 
shaker before seeding them on Matrigel. This observation could be due to the fact that 
embryonic stem cell derived endothelial cells may lack maturation in vitro when compared to 
primary isolated mouse endothelial cells (McCloskey et al., 2006). Nevertheless, 
ESC-derived endothelial cells were able to form tube-like structures after incubation on an 
orbital shaker, which in a way simulated shear stress. It is known from the literature that 
laminar shear stress induces differentiation of endothelial progenitor cells by activation of 
VEGFR2 and PI3K/Akt/mTOR signaling, which could contribute to maturation of endothelial 
cells (Obi et al., 2012). Taken together, ESC-derived endothelial cells exhibited typical 
endothelial characteristics, but lacked complete functionality in vitro. 
7.2.3 Re-expression of Hey proteins in Hey1/2 double knockout cells 
To investigate Hey protein functions during endothelial cell differentiation Hey1 and Hey2 
were re-expressed in Hey knockout ES cells. Therefore, stable embryonic stem cell lines 
expressing Hey1/2 inducible plasmids were generated. Stable integration was achieved by 
transfection of the cells using the sleeping beauty transposon system. In this two-component 
system the gene of interest, in this case Hey1 or Hey2, is positioned between inverted 
terminal repeats that are recognized by a specific transposase (SB100X). The specific 
transposase is supplemented in trans and mediates the integration to a genomic target site. 
This system was chosen as it has been shown to work efficiently in human and mouse 
embryonic stem cells before (Geurts et al., 2003, Davidson et al., 2009, Mates et al., 2009). 
Re-expression of Hey proteins was achieved using a doxycycline dependent expression 
system, which allows Hey protein expression in a reversible and controlled fashion by 
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addition and withdrawal of doxycycline. The doxycycline dependent gene expression system 
is based on the Escherichia coli tetracycline resistance operon, which was first described for 
the use in mammalian cells in 1992 (Gossen and Bujard, 1992). In the reverse fashion, the 
transactivator (rtTA) is composed of the repressor (rtetR) and the herpes simplex virus (HSV) 
VP16 transcripton activation domain driven by an appropriate promoter, the eukaryotic 
translation elongation factor 1 alpha (EF1α). In the absence of a tetracycline derivate 
(doxycycline) the transactivator can not bind to a specific DNA target site and transcriptional 
activation of the desired gene is suppressed. The addition of doxycycline results in binding of 
the transactivator to the tet operon (tetO), which leads to transcriptional activation (Gossen et 
al., 1995). Thus, this system allows the investigation of Hey proteins and their functions in ES 
cells and during the formation of endothelial cells by switching Hey on or off at defined time-
points during differentiation. Differentiation studies in embryonic stem cells using this gene 
expression system have already been used before and provided a powerful tool to study 
specific protein functions during ES cell differentiation (Niwa et al., 1998, Era and Witte, 
2000). Induction of Hey1 and Hey2 after addition of doxycycline was confirmed in the 
respective cell line by western blot analysis and whole transcriptome sequencing. Quite 
strikingly, the induction efficiency of Hey1 and Hey2 was much higher in embryonic stem 
cells than in ESC-derived endothelial cells. This could be due to the number of read counts 
for Hey1 and Hey2, which were more than 5-fold higher in ES cells than in endothelial cells 
when comparing the doxycycline-induced samples between both cell types (Read counts ES 
Hey1+: 349, EC Hey1+: 66, ES Hey2+: 319, EC Hey2+: 61). These data reflect that the 
efficiency of tetracycline dependent gene expression can vary between different cell types, 
although expression was induced using the same concentration of doxycycline. Differences 
seen in Hey transgene expression between ES and EC cells could be due to promoter 
silencing during endothelial differentiation or varying promoter strength in different cell types. 
Expression of the transactivator (rtTA3), which is essential for Hey transgene expression, is 
driven by the EF1α promoter. The EF1α promoter obviously led to a robust transgene 
expression in embryonic stem cells and according to the literature should also exhibit solid 
activity at stage-specific steps during mouse ES cell differentiation (Hong et al., 2007, Wang 
et al., 2008). However, ESC-derived endothelial cells showed lower Hey transgene 
expression when compared to ES cells. Further experiments using other promoters e.g. the 
CMV promoter for transgene control would show, if expression of transgenes could be more 
efficient and stable in endothelial cells using other promoters driving transgene expression. 
Transgene expression in endothelial progenitor cells and in HUVECs driven by the CMV 
promoter has shown higher efficacy than the EF1α promoter (Liu et al., 2006), further 
supporting the use of other promoters for stable transgene expression in endothelial cells. 
Furthermore, transgene silencing could also be due to DNA methylation and histone 
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modifications in the transgene driving promoter. Epigenetic silencing in the genome is often 
associated with methylation of specific CpG islands on the DNA as well as histone 
deacetylations, which lead to chromatin changes and transcriptional repression. These 
mechanisms could also be involved in controlling transgene expression in embryonic stem 
cells as well as during differentiation of ES cells (Rosenqvist et al., 2002, He et al., 2005).  
7.2.4 No significant change in arterial versus venous marker gene expression upon 
Hey overexpression in ESC-derived endothelial cells 
Hey1 and Hey2 are involved in the specification of arterial endothelial cells during embryonic 
development as demonstrated by analysis of yolk sacs from Hey1 and Hey2 mutant 
embryos, which revealed a significant downregulation of the arterial specific marker EphrinB2 
(Fischer et al., 2004). In contrast, CoupTFII, which has been described as the main 
transcription factor regulating venous endothelial cell fate determination (You et al., 2005), 
exhibited a significant upregulation during embryoid body differentiation of Hey deficient ES 
cells (Diez et al., 2007). Based on these data one would expect to detect differences in 
arterial versus venous marker gene expression in ESC-derived endothelial cells after Hey 
overexpression in the in vitro differentiation setting used in this study. However, Hey1 and 
Hey2 overexpression in ESC-derived endothelial cells did not significantly change expression 
of arterial (EphrinB2, Dll4) and venous (CoupTFII, CoupTFII alt, EphB4) endothelial marker 
genes as measured by qRT-PCR. The lack of a significant change could be due to the point 
of time when Hey overexpression was initiated. Hey induction with doxycycline was induced 
after 14 days of differentiation by the time when endothelial cells were nearly terminally 
differentiated and specification was probably already determined. Thus, for future 
experiments endothelial cell differentiation should be investigated in parallel with constant 
Hey overexpression during the whole time course of differentiation in comparison to Hey 
deficient cells. Moreover, specification of arterial and venous endothelial cells during 
embryonic development might not be solely dependent on Hey gene functions alone, but 
rather remains a complex process involving many other critical factors of different pathways. 
Several other genes like Sonic Hedgehog and VEGF as well as other transcription factors 
like Foxc1, Foxc2 and Sox have been implicated in arterial specification (Marcelo et al., 
2013, Kume, 2010). Recently, there have been two publications dealing with the molecular 
mechanisms determining arterial versus venous endothelial cell fate determination using 
primary freshly isolated arterial (HUAECs) and venous (HUVECs) endothelial cells (Korten et 
al., 2013, Aranguren et al., 2013). Consistent with the results of this study, overexpression of 
Hey2 in HUVECs did not influence expression of CoupTFII and other arterial and venous 
marker genes. However, CoupTFII was able to bind directly to the Hey2 promoter leading to 
transcriptional repression, which indicates a direct interaction of CoupTFII and Hey2. 
Transcriptional repression of Hey2 leads to suppression of the arterial program and to 
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formation of endothelial cells with a venous character, induced by expression of CoupTFII 
(Korten et al., 2013). Furthermore, overexpression of a combination of eight transcription 
factors in cultured HUVECs has been required to induce a conversion into an arterial 
phenotype, while overexpression of Hey2 alone did not reveal strong changes. This 
diminished the essential role of Hey2 as the current ‘golden standard’ in arterial cell fate 
determination (Aranguren et al., 2013).  
7.2.5 Whole transcriptome analysis revealed more Hey downstream target genes in 
embryonic stem cells than in endothelial cells 
In order to determine Hey target genes, RNA-Sequencing was performed in Hey 
overexpressing embryonic stem cells and ESC-derived endothelial cells. Overall, RNA-Seq 
analysis revealed nearly three-fold more Hey target genes in ES cells than in endothelial 
cells (ES: n = 354, EC: n = 123). Additionally, regarding regulated genes by either Hey1 or 
Hey2 in both cell types, more genes were regulated by Hey2 than by Hey1 (Hey1: n = 106, 
Hey2: n = 382). The identification of a larger number of target genes in embryonic stem cells 
might be due to varying overexpression intensities of Hey1 and Hey2. Hey overexpression 
was stronger in ES cells than in endothelial cells as shown by the higher number of read 
counts for Hey in embryonic stem cells (7.2.3). Although mRNA expression of Hey1 was 
higher than expression of Hey2, more target genes were regulated by Hey2 than by Hey1, 
independent of the cell type investigated. This could be a consequence of a stronger protein 
expression as shown by quantification and western blot analysis. Validation of several target 
genes in embryonic stem cells by qRT-PCR demonstrated that Hey1 and Hey2 more or less 
act in a redundant manner, which has been shown for the regulation of target genes of Hey1 
and Hey2 in HEK293 cells before (Heisig et al., 2012). Most of the regulated genes in Hey 
overexpressing ES cells play a functional role during embryonic development and/or are 
involved in transcriptional regulation. For example, Icam1 and Fibronectin1 were upregulated 
by Hey and their expression probably also plays a functional role in endothelial cells. Icam1 
is a cell surface molecule, which is typically expressed on endothelial cells but its expression 
is also be found on embryonic stem cells (Frenzel et al., 2009). Fibronectin1 is involved in 
cell adhesion and thus plays an important role in endothelial cell differentiation, as it is 
commonly used as a coating agent in differentiation processes in vitro (Blancas et al., 2011).  
Genes downregulated by Hey were for example Sox1, Skil and Lefty2, which all have been 
implicated in regulation of embryonic development before. Sox1 is a transcriptional regulator 
involved in the regulation of embryonic development and cell fate determinations. 
Overexpression of Sox1 in neural progenitor cells leads to neural lineage commitment and 
promotes neuronal differentiation by several different mechanisms. One of them is related to 
the direct binding of Sox1 to the Hes1 promoter, which leads to suppression of Notch 
signaling and Hes1. Hes1 is a potent inhibitor of neurogenesis and thus repression of Hes1 
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promotes neuronal cell development (Kan et al., 2004). Skil (SKI-like), also known as SnoN, 
is a member of the SMAD signaling pathway, which regulates cell growth and cell 
differentiation. Until today, a functional role for Skil has mainly been linked to tumorigenesis, 
while its role in embryonic development is not fully characterized yet. Recently, it has been 
reported that Skil is involved in embryonic angiogenesis by regulating interaction of ALK1 
and Smad1/5 in endothelial cells. The ALK1 receptor mediates TGF-ß signaling by activating 
downstream Smad proteins to promote angiogenesis (Zhu et al., 2013). Lefty2, left-right 
determination factor 2, plays an important role in left-right asymmetry determination of organ 
systems during development. Lefty proteins function in embryonic stem cells in regulating 
both, stemness and differentiation, as they can modulate expression of the TGF-ß family 
member, Nodal. Expression of Nodal is modulated by gene expression changes of Lefty, 
which results in impaired differentiation or impaired left-right asymmetry (Tabibzadeh and 
Hemmati-Brivanlou, 2006). Furthermore, expression of Nodal is induced upon active Notch 
signaling, indicating that the Notch pathway acts upstream of left-right determination in mice 
(Krebs et al., 2003). However, there were some target genes, which were only regulated by 
Hey2 and remained unregulated by Hey1 (Spred3, Fibronectin1, Lefty2), indicating a slightly 
more important role for Hey2 in target gene regulation. This was also evident from RNA-Seq 
analysis of ESC-derived endothelial cells, as more genes were regulated by Hey2 than by 
Hey1. However, regulation of target genes in endothelial cells could barely be confirmed by 
qRT-PCR, which could partially be due to clone-specific regulations of genes. Clonal 
diversity could reveal distinct gene expression profiles between endothelial cells derived from 
specific clones and also the ability to differentiate could be altered between different clonal 
sublines (Martinez et al., 2012). Thus, Hey regulated target genes in ESC-derived endothelial 
cells could to a certain extent result from clonal artifacts. Varying target gene output between 
different cells could also be due to increased noise expression of the regulatory protein 
rtTA3, which controls Hey transgene expression. It has been demonstrated before that 
increased noise in the transcription of regulatory proteins has led to increased cell-cell 
variability in target gene regulation and may be an important point to consider when 
evaluating cellular differentiation processes (Blake et al., 2003). For future experiments 
several individual ESC-derived endothelial clones should be taken to perform whole 
transcriptome analysis to identify Hey target genes in endothelial cells. This would then 
clarify if supposed endothelial Hey target genes could be confirmed in several individual 
clones or if Hey overexpression in ESC-derived endothelial cells does not influence target 
gene expression in this in vitro setting. However, GO term analysis revealed enrichment of 
biological processes mainly linked to embryonic development and transcriptional regulation, 
which is in line with previous Hey overexpression studies in HEK293 cells (Heisig et al., 
2012). Furthermore, RNA-Seq analysis from cells harvested at different time points during 
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endothelial cell differentiation in the presence and absence of Hey proteins would provide 
insight in stage-specific Hey target genes. In addition, ChIP-sequencing of Hey 
overexpressing ES cells and ESC-derived endothelial cells could be used to identify direct 
binding sites for Hey proteins throughout the genome. 
7.2.6 Conclusion 
Loss of Hey1 and Hey2 leads to impaired vascular development which results in early 
embryonic lethality in vivo (Fischer et al., 2004). Until today, less is known about potential 
vascular Hey target genes that could be involved in the outcome of the vascular phenotype 
observed in Hey deficient mice. As Hey proteins mainly act as transcriptional repressors, 
they could be involved in regulating target genes important for proper vascular network 
formation. In the present study an in vitro differentiation system for endothelial cells was 
established to identify vascular Hey target genes in embryonic stem cells as well as in 
endothelial cells. To this end, Hey deficient ES cells were used in comparison to Hey 
overexpressing ES cells, based on a doxycycline dependent overexpression system. 
According to gene expression analysis and immunofluorescent staining as well as tube 
formation ability, Hey deficient ES cells were able to differentiate into endothelial cells to a 
similar degree than Hey wildtype cells. This indicates that loss of Hey expression in vitro 
does not influence endothelial cell differentiation ability and thus, Hey deficient ES cells 
provide a powerful tool to study endothelial cell differentiation. Furthermore, doxycycline 
dependent Hey protein expression allowed a controlled re-expression of Hey in Hey 
knockout cells. Whole transcriptome analysis upon Hey overexpression in both cell types 
revealed many Hey downstream target genes in ES cells and less target genes in 
ESC-derived endothelial cells. The limited response of Hey proteins in regulating target gene 
expression in endothelial cells could be due to experimental setups as well as to clonal 
variations. It furthermore highlights the complexity of target gene regulation, which might not 
only be dependent on a single transcription factor alone. 
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9 Appendix 
9.1 Abbreviations 
°C degree Celsius 
µg microgram 
2D two-dimensional 
3D three-dimensional 
alt alternative 
APC allophycocyanin 
BC breast cancer 
bEnd brain endothelial cells 
bFGF basic fibroblast growth factor 
BMP4 bone morphogenetic protein 4 
bp basepairs 
BSA bovine serum albumin 
bsd blasticidin 
CADASIL cerebral autosomal dominant arteriopathy with subcortical infarcts 
and leukoencephalopathy 
cDNA complementary DNA 
ChIP chromatin immunoprecipitaton 
cm centimeter 
CMV cytomegalovirus 
CRC colorectal cancer 
Cre cyclization recombination 
ct value cycle threshold value 
D day of differentiation 
DEPC diethylpyrocarbonate 
DMEM Dulbecco’s Modified Eagle Medium  
DNA deoxyribonucleic acid 
dNTP deoxynucleoside-triphosphate 
dox doxycyline 
EC endothelial cell 
ECGS endothelial cell growth supplement 
EDTA ethylenediaminetetraacetic acid  
EF1α elongation factor 1 alpha 
ELISA enzyme-linked immunosorbent assay 
ES cells embryonic stem cells 
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FACS fluorescent-activated cell sorting 
FBS fetal bovine serum 
Fig. figure 
fl floxed 
GFP green fluorescent protein 
GO Gene Ontology 
h hour 
HEPES 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid 
HSV herpes simplex virus 
HUAEC human umbilical artery endothelial cell 
HUVEC human umbilical vein endothelial cell 
ID identification 
IRES internal ribosome entry site 
kb kilobase 
kDa kilo Dalton 
ko knockout 
KOSR knockout serum replacement 
LDL low density lipoprotein 
LIF leukemia inhibitory factor 
M molar 
mA milliampere 
MEM Minimum Essential Medium Eagle 
mg milligram 
min minute 
ml milliliter 
mM millimolar 
mRNA messenger RNA 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NEAA non-essential amino acids 
NCI National Cancer Institute 
ng nanogram 
nm nanometer 
NSCLC non-small cell lung cancer 
O2 oxygen 
PAGE poly acrylamide gel electrophoresis 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
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qRT-PCR quantitative realtime-PCR 
RCC renal cell carcinoma 
rh recombinant human 
RNA ribonucleic acid 
RNA-Seq ribonucleic acid-sequencing 
RPKM reads per kilo base per million 
rpm reads per million 
RPMI Roswell Park Memorial Institute 
rtetR reverse tetracycline dependent repressor 
rtTA3 reverse tetracycline dependent transactivator 
s second 
SDS sodium dodecyl sulfate 
siRNA small interfering RNA 
tetO tet operon 
UV ultraviolet light 
V volt 
VEGF vascular endothelial growth factor 
wt wildtype 
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9.2 RNA-Seq data 
Table 1 Raw reads and aligned reads mm9 genome.  
 reads 
aligned reads 
mm9 genome percentage 
ES Hey1 - 6642887 5886045 88.61 
ES Hey1 + 6738380 5985985 88.83 
ES Hey2 - 11044568 9777373 88.53 
ES Hey2 + 6935446 6264752 90.33 
EC Hey1 - 29509057 26781653 90.76 
EC Hey1 + 31806354 28935172 90.97 
EC Hey2 - 4593400 4125723 89.82 
EC Hey2 + 5310928 4733459 89.13 
 
Table 2 Target genes in ES Hey1+, ES Hey2+ (A) and EC Hey1+, EC Hey2+ (B). Analysis was 
performed as described in section 5.3.5 and revealed 354 target genes in ES cells and 123 target 
genes in endothelial cells. For each target gene Entrez ID, gene name and fold change after Hey1 and 
Hey2 overexpression are presented. If no number for the fold change is indicated, selection criteria 
were not fulfilled and the gene was excluded from analysis, n.e. = not expressed. 
A    B    
Entrez ID Gene fold change Entrez ID Gene fold change 
  ES 
Hey1+ 
ES 
Hey2+ 
   EC 
Hey1+ 
EC 
Hey2+ 
14980  -1.07 1.84 272396  -1.15 -1.81 
77633  1.31 -1.95 100043609  -1.05 -2.23 
108112  -1.10 1.93 100217431  2.01  
624713  1.62 -2.64 100302648  -1.82  
652925  1.08 -2.01 100503498  -2.05  
665037  1.72 4.15 100526469  -2.00  
751556  1.55 -2.07 100526479  -2.02  
100042464  -1.22 3.59 100628584  -1.95 -1.43 
100043040  1.97 1.25 100628588  -1.98  
100043813  1.41 -2.30 100628612  -2.80  
100049713   -2.06 100628620  -2.02  
100169889  -1.20 2.73 68332 0610010E21Rik -1.01 -1.96 
100316809  -2.22 1.90 68347 0610011F06Rik 1.83 1.04 
100415787  1.07 -2.38 66061 0610012D17Rik -1.89  
100499530  -2.22 1.90 85308 1500005A01Rik -2.01  
100503879  1.17 1.89 66278 1810013D10Rik -1.53 1.82 
100504114  -1.12 2.04 66273 1810020D17Rik -1.97  
100526469  1.31 -1.97 66282 1810029B16Rik -1.14 -2.01 
100526479   1.81 67892 1810063B05Rik 1.21 1.97 
100568459  1.20 1.81 67509 1810063B07Rik -1.05 -1.99 
101243624  1.67 -2.35 72429 2010203O07Rik -1.14 -2.29 
75394 0610040F04Rik -1.96 1.75 72093 2010320M18Rik -1.01 -2.71 
68618 1110012L19Rik -1.81 -1.47 76947 2310030N02Rik 1.35 -1.91 
66179 1110031I02Rik -2.15 -2.36 69627 2310031A18Rik 1.15 -2.24 
68742 1110032O16Rik -1.97 1.14 69642 2310046A06Rik 2.35 1.10 
69017 1500031I19Rik -1.48 2.01 75430 3200002M19Rik -1.19 2.08 
76927 1700021C14Rik 1.17 1.81 69277 3300002I08Rik 1.05 1.92 
66935 1700023B02Rik -1.96 1.16 319518 4930402E16Rik -1.04 1.96 
69513 1700030C10Rik -1.38 -1.93 73863 4930415O20Rik -2.16  
70011 1700030N03Rik  1.87 67651 4930527F14Rik 1.30 -2.40 
67105 1700034H14Rik 1.09 -1.97 71532 9030418K01Rik 1.21 -1.85 
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67524 1700095A21Rik -1.14 -2.11 330385 9530026P05Rik 1.98 1.38 
69186 1810027O10Rik 1.03 -1.89 619321 9530052E02Rik 1.67 -2.29 
66291 1810030N24Rik 1.36 2.33 194268 9930104L06Rik 1.02 -2.14 
76527 2010004A03Rik 1.50 2.51 381823 Apold1 1.37 -1.94 
69871 2010007H12Rik -1.08 1.84 26879 B3galnt1 -1.26 -2.20 
100910 2010209O12Rik -2.06 -1.04 414069 BC024978 -1.27 -1.85 
72093 2010320M18Rik -1.96 -1.41 14705 Bscl2 1.17 2.06 
70080 2210010C17Rik -2.07 -1.47 57316 C1d -1.14 -2.02 
69698 2310046K01Rik -1.24 1.82 654318 C530005A16Rik -1.31 -2.24 
71918 2310047A01Rik -1.08 -3.67 57895 Ccdc126 1.22 -1.88 
77032 2610029I01Rik 1.03 -1.85 12615 Cenpa -1.06 -1.81 
73242 2610110G12Rik -1.11 2.01 56464 Ctsf 1.06 1.86 
72481 2610203C22Rik 1.15 -1.85 72865 Cxx1c 1.89  
70435 2610204M08Rik -1.41 1.93 170716 Cyp4f13 -1.31 -1.83 
545428 2610301F02Rik 1.62 1.88 225995 D030056L22Rik -1.05 1.95 
70419 2810408A11Rik -2.03 -1.01 114585 D17H6S53E -1.00 2.08 
68034 2900009I07Rik 1.05 2.09 231630 D5Ertd40e -1.25 1.91 
73172 3110037I16Rik -1.87 -1.60 13198 Ddit3 1.01 -2.40 
67419 3632451O06Rik 1.63 -2.71 13368 Dffb -1.10 1.87 
432479 4930404N11Rik  1.84 57431 Dnajc4 1.64 2.01 
78108 4930414L22Rik 1.06 -2.20 77490 E130218I03Rik 1.10 2.27 
67585 4930455J16Rik -2.29 -1.78 55960 Ebag9 -1.19 -2.06 
75060 4930506C21Rik -1.14 2.12 620393 EG620393 1.13 2.09 
74726 4930523O13Rik -2.24 2.02 72205 Eml2 1.03 2.07 
75202 4930546H06Rik 1.64 2.50 71690 Esm1 1.02 -1.97 
223626 4930572J05Rik -2.09 -1.45 71436 Flrt3 -1.03 2.07 
78215 4930578N18Rik  1.90 14369 Fzd7 1.12 3.85 
70942 4931403E22Rik 3.25 3.04 80860 Ghdc 1.11 2.07 
74437 4933402E13Rik  3.84 73690 Glipr1 -1.32 2.27 
67531 5730408K05Rik -1.83 1.36 110304 Glra3 -1.01 1.81 
67412 6330407J23Rik -1.36 2.11 228730 Gm114 -1.47 1.81 
231842 6530401C20Rik  2.06 57441 Gmnn -1.21 1.83 
76219 6530401D17Rik 1.61 -1.83 14676 Gna15 1.28 2.46 
381062 9030025P20Rik 1.17 1.87 67371 Gtf3c6 -1.03 -1.83 
231717 A230106M15Rik -1.12 -1.86 70315 Hdac8 1.26 -2.08 
239559 A4galt 1.70 1.89 15213 Hey1 15.27 n.e. 
381272 A630095N17Rik  2.07 15214 Hey2 n.e. 3.26 
109202 A930024E05Rik -2.24 -1.13 15277 Hk2 -1.07 1.90 
76491 Abhd14b -1.02 2.24 15473 Hrsp12 -1.22 -1.95 
11433 Acp5 1.40 -2.14 15901 Id1 1.36 1.98 
433256 Acsl5 -1.33 -1.98 16336 Insl3 -2.34 -1.88 
11464 Actc1 -1.02 -5.74 170771 Khdrbs2 1.26 -2.19 
11474 Actn3 -1.83 -1.64 70394 Kptn -1.19 -1.89 
106672 AI413582 -1.76 3.02 17087 Ly96 1.04 -1.91 
100165 AI507597 1.06 1.83 26922 Mecr -1.32 -2.19 
11634 Aire 1.57 3.57 17299 Mettl1 -1.10 -1.80 
72041 Alkbh4 -1.38 1.81 100034361 Mfap1b -1.24 1.92 
232566 Amn1 -1.67 1.98 17314 Mgmt 1.23 -1.91 
69010 Anapc13 1.80 -1.33 218613 Mier3 1.10 1.91 
234396 Ankrd41 -1.47 1.89 64660 Mrps24 -1.16 -1.88 
12306 Anxa2 1.51 1.91 18030 Nfil3 -1.13 -2.95 
27052 Aoah 1.57 2.11 68501 Nsmce2 1.17 2.13 
64933 Ap3m2 1.87 2.75 52793 ORF9 -1.04 -2.50 
13498 Atn1 1.00 2.14 433287 OTTMUSG00000022109 1.44 -1.97 
320871 B230206H07Rik 1.39 2.38 73162 Otud3 1.34 -2.41 
319752 B230209E15Rik 1.16 -1.83 76498 Paqr4 -1.00 -1.82 
230991 B930041F14Rik -2.10 -1.09 319455 Pld5 1.01 -1.90 
233913 BC017158 -1.92 1.24 217430 Pqlc3 -1.06 1.82 
414069 BC024978 1.01 -2.12 77619 Prelid2 2.02  
277154 BC030046 -1.06 2.41 19171 Psmb10 -2.02 1.40 
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103220 BC030307 -1.40 -1.87 227746 Rabepk -1.61 -1.83 
238024 BC032265 -2.09 -1.08 218772 Rarb 1.09 2.28 
474160 BC033916 -1.07 -2.40 109222 Rarres1 -1.90 -2.29 
408058 BC048507 2.05 1.21 58175 Rgs20 -1.20 1.90 
381066 BC049807 1.51 2.19 218215 Rnf144b 1.14 2.12 
230676 BC059842 -1.11 1.96 622404 RP23-195K8.6 1.06 -1.91 
12159 Bmp4 -1.95 -1.76 101122 Rpusd3 -1.39 -2.29 
101831 C230052I12Rik -2.47 1.15 74648 S100pbp 1.30 -2.44 
97863 C78339 1.91 1.06 74729 Setmar -1.08 1.95 
76815 Calcoco2 1.83 2.13 59049 Slc22a17 1.30 1.99 
12337 Capn5 1.30 2.12 108652 Slc35b3 1.05 1.90 
12367 Casp3 1.08 -1.85 72027 Slc39a4 1.03 -2.10 
12372 Casq1 -1.66 2.92 242259 Slc44a5 -1.04 -1.80 
232664 Ccdc136 -1.28 -2.23 330959 Snapc5 -1.18 -1.91 
382073 Ccdc84 1.35 1.96 214616 Spata5l1 1.17 -2.20 
12505 Cd44 -1.51 -3.50 67249 Tbc1d19 1.16 1.94 
12509 Cd59a -1.19 2.13 67978 Tctn2 -1.52 2.02 
12512 Cd63 -1.65 -1.81 386612 Thoc6 1.13 -1.97 
260409 Cdc42ep3 -1.13 -2.02 67698 Tmem157 -1.23 -1.98 
239096 Cdh24 1.16 1.84 236792 Tmem32 1.26 2.11 
12578 Cdkn2a 2.21 1.38 233979 Tpcn2 -1.01 1.85 
26365 Ceacam1 1.03 -2.22 74019 Traf3ip1 -1.03 1.97 
231821 Centa1 -1.85 1.32 21912 Tspan7 1.03 -1.85 
216859 Centb1 -1.22 2.14 52808 Tspyl2 -1.10 2.25 
68567 Cgref1 -1.05 -1.97 233276 Tubgcp5 1.27 -1.80 
69065 Chac1 -1.27 -2.22 22172 Tyms-ps -1.88 -1.83 
68119 Cmtm3 1.80 1.20 22350 Vil2 -1.24 2.21 
72042 Cotl1 -1.23 -2.37 22365 Vps45 1.01 2.08 
12865 Cox7a1 2.50 1.56 434204 Whdc1 -1.16 -1.90 
12873 Cpa3 -1.86 -1.38 56220 Zfp386 -1.06 2.15 
12877 Cpeb1 2.00 1.14 68040 Zfp593 1.15 1.85 
12925 Crip1 1.03 1.94 69020 Zfp707 1.21 -2.29 
13032 Ctsc 1.19 1.80 67538 Zswim3 1.10 -1.91 
13034 Ctse -1.73 3.11      
435802 Cyp4a30b -1.18 -2.25      
12879 Cys1 1.09 -2.35      
320351 D230037D09Rik  -2.51      
654822 D330041H03Rik 1.15 1.90      
52480 D7Ertd715e 1.27 2.72      
228859 D930001I22Rik -1.51 -1.80      
13132 Dab2 -1.28 2.00      
240025 Dact2 -1.09 1.82      
72185 Dbndd1 -1.54 2.09      
13198 Ddit3 -1.08 -1.93      
230073 Ddx58 1.60 1.98      
209773 Dennd2a -1.06 -1.83      
13346 Des -1.19 -1.97      
107585 Dio3  3.94      
227697 Dolk 1.14 -1.86      
60364 Donson -1.84 -1.14      
13482 Dpp4 -1.12 -1.94      
56405 Dusp14 2.52 1.61      
320172 E230016M11Rik 1.01 -1.81      
68177 Ebpl -1.92 -1.16      
434197 EG434197 2.35 1.43      
434280 EG434280 -2.29 -2.69      
627821 EG627821  1.87      
665574 EG665574 1.61 1.84      
386655 Eid2 1.33 -2.05      
100038468 ENSMUSG00000074385 -1.09 -1.83      
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98845 Eps8l2 1.41 2.59      
13867 Erbb3 1.19 1.90      
14009 Etv1 1.10 1.89      
277978 Exoc3l 1.21 2.46      
791260 F930017I19Rik -1.82 -1.15      
14077 Fabp3 -1.65 -1.86      
327959 Fbxo39  2.31      
230903 Fbxo44 1.15 -2.07      
14226 Fkbp1b 1.97 1.37      
286940 Flnb -1.04 1.90      
226844 Flvcr1 -1.16 2.29      
54418 Fmn2 1.06 1.81      
14268 Fn1 1.06 2.46      
15221 Foxd3 -1.33 2.00      
54601 Foxo4 1.07 -1.99      
17873 Gadd45b -2.19 -1.21      
14473 Gc  2.90      
14620 Gjb3 1.61 2.13      
93692 Glrx 1.38 1.85      
229599 Gm129 -2.03 1.56      
208080 Gm514 -2.25 -1.70      
14676 Gna15 -1.22 -2.32      
215798 Gpr126 1.10 -2.44      
14766 Gpr56  10.24      
14804 Grid2 -1.03 1.91      
14865 Gstm4 -1.85 1.20      
14873 Gsto1 -1.07 1.95      
14872 Gstt2 -2.19 -1.10      
14964 H2-D1 1.03 1.89      
15114 Hap1 1.11 1.98      
67666 Hapln3  2.44      
171285 Havcr2 -1.02 -1.84      
15200 Hbegf -1.14 -2.09      
320473 Heatr5b -1.09 1.94      
69536 Hemk1 -1.02 1.87      
15213 Hey1 343.17 n.e.      
15214 Hey2 n.e. 23.77      
75828 Hormad2 -1.85 1.13      
53602 Hpcal1 -1.13 -2.57      
101502 Hsd3b7 -1.99 1.39      
15530 Hspg2 -1.39 1.89      
15894 Icam1 1.73 2.48      
50723 Icosl -1.10 1.81      
15903 Id3  2.85      
68713 Ifitm1 1.09 1.90      
16002 Igf2 -1.90 -2.49      
239114 Il17d -1.47 -2.33      
20403 Itsn2 1.30 -1.96      
16548 Khk 1.08 -1.80      
242721 Klhdc7a 1.56 2.28      
70394 Kptn -1.86 1.02      
16668 Krt18 2.02 1.76      
16669 Krt19 2.13 2.40      
16776 Lama5 -1.22 1.92      
214048 Larp2 -2.15 -2.01      
13590 Lefty1 1.41 -2.92      
320202 Lefty2 1.36 -2.22      
232798 Leng8 -1.32 1.98      
67803 Limd2 -1.12 -2.37      
217708 Lin52 2.18 -1.42      
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628308 LOC628308 -1.30 1.81      
628709 LOC628709 1.64 -2.63      
67774 Loh12cr1 -2.09 -1.12      
80749 Lrfn1 -1.81 1.24      
16971 Lrp1 -1.07 1.84      
100604 Lrrc8c -1.04 -2.02      
17035 Lxn 1.55 2.33      
26921 Map4k4 -1.21 -2.14      
226778 Mark1 -1.10 -1.81      
69572 Mfsd3 1.02 1.90      
17318 Mid1 -1.12 1.86      
214162 Mll1 1.02 1.89      
76915 Mnd1 -1.22 -1.83      
17888 Myh6  -9.20      
98932 Myl9  -1.93      
17937 Nab2 -2.27 -1.29      
18039 Nefl 1.10 2.26      
18073 Nid1 1.11 1.92      
77583 Notum -2.42 -2.45      
74091 Npl -1.18 -2.48      
53324 Nptx2 1.94 2.83      
106338 Nsun3  2.13      
18208 Ntn1 1.02 2.17      
229228 Nudt6  2.02      
77595 Nup210l 1.17 -2.27      
75475 Oplah 1.06 1.93      
14539 Opn1mw -1.07 -2.02      
52793 ORF9 1.13 -2.24      
217066 OTTMUSG00000001305 -1.98 1.78      
627585 OTTMUSG00000010105 2.27 1.08      
93737 Pard6g -1.29 -2.57      
30052 Pcsk1n 1.31 -1.89      
18574 Pde1b -1.23 2.29      
18616 Peg3 1.21 2.31      
64058 Perp -2.18 -2.78      
69129 Pex11c  2.03      
18639 Pfkfb1 -1.02 2.46      
66268 Pigyl 1.11 2.01      
18715 Pim2 1.26 1.97      
330890 Piwil4 -2.11 -2.42      
85031 Pla1a -1.02 3.33      
329502 Pla2g4e 1.57 -2.24      
18793 Plaur -1.06 1.88      
72469 Plcd3 -1.86 1.38      
269608 Plekhg5 1.32 2.10      
84094 Plvap -1.31 1.81      
67448 Plxdc2 -1.29 -2.54      
110312 Pmch 1.31 -1.98      
99011 Pomt1 -1.25 1.84      
18997 Pou4f2 1.23 2.11      
67905 Ppm1m -1.53 -1.95      
381813 Prmt8 -1.73 -3.27      
65116 Prrg2 -2.64 -1.03      
64292 Ptges 1.70 2.55      
19228 Pthr1 -2.25       
19245 Ptp4a3 -1.38 -1.84      
329384 Ptrh1 -1.64 -2.34      
19286 Pts -2.61 1.46      
226422 Rab7l1 -1.15 2.14      
67286 Rabl5 1.34 1.80      
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56089 Ramp3 1.45 3.19      
223864 Rapgef3 -1.03 1.83      
68895 Rasl11a 1.57 2.14      
54354 Rassf5 1.50 2.29      
26611 Rcn2 -1.14 -1.89      
226594 Rcsd1  2.82      
13650 Rhbdf1 -1.37 1.92      
242662 Rims3 -2.13 -1.38      
56532 Ripk3 -2.09 -1.29      
11858 Rnd2 -1.22 -2.17      
19881 Rom1 2.38 2.18      
26564 Ror2 -1.06 1.81      
57294 Rps27 1.41 -2.30      
56367 Scoc 1.42 -2.34      
69938 Scrn1 -2.03 -1.48      
20720 Serpine2 -2.13 -2.50      
53609 Sfrs16 -1.05 2.00      
20401 Sh3bp1 1.25 2.66      
20482 Skil -1.38 -2.14      
237831 Slc13a5  5.31      
71781 Slc16a14 2.28 2.10      
110877 Slc18a1 -1.05 -2.41      
55963 Slc1a4 -1.15 -1.90      
67554 Slc25a30 1.06 1.81      
71279 Slc29a3 1.15 2.23      
72027 Slc39a4 1.53 2.10      
20532 Slc3a1 -2.16 -1.10      
56774 Slc6a14 1.26 -1.88      
240332 Slc6a7 1.97 3.35      
11989 Slc7a3 -1.22 -1.89      
24059 Slco2a1 1.07 2.30      
67155 Smarca2 2.92 3.59      
104367 Snora65 1.28 2.63      
20664 Sox1 -2.31 -2.66      
20668 Sox13 -1.84 -1.60      
101809 Spred3 1.15 2.19      
20446 St6galnac2 -1.06 1.97      
29819 Stau2 -1.06 -1.91      
20907 Stx1a 1.16 2.00      
20909 Stx4a -2.12 1.16      
57429 Sult5a1 1.83 3.53      
68760 Synpo2l  3.07      
21407 Tcf15 -1.52 -2.17      
226896 Tcfap2d 1.09 -1.88      
21679 Tead4 1.33 1.96      
21752 Tert -1.14 2.00      
21803 Tgfb1 1.55 1.85      
69876 Thap3 -1.02 1.83      
66231 Thoc7 1.80 -1.54      
30058 Timm8a1 1.15 -1.84      
101883 Tmem149 -1.39 1.83      
224019 Tmem191c 1.45 1.80      
56277 Tmem45a 1.35 -2.25      
230657 Tmem69 1.24 -1.91      
75002 Tmprss12 -2.24 1.41      
67971 Tppp3 1.43 -1.80      
59005 Trappc2l 1.01 -2.09      
22041 Trf 1.25 1.84      
22044 Trh -1.12 -2.07      
66597 Trim13 -1.64 -1.93      
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235631 Tsp50 1.25 2.55      
235330 Ttc12 -1.08 2.50      
237930 Ttll6 -1.07 2.61      
22147 Tuba3b 1.59 -1.82      
637908 Vmn2r53 1.20 -1.88      
320808 Wdr22 -1.75 -1.93      
76646 Wdr38 -1.06 -2.42      
68980 Wdr53 -1.81 1.41      
103784 Wdr92 1.03 -1.82      
434204 Whdc1 -1.03 2.39      
73750 Whrn -1.82 -1.17      
320916 Wscd2 1.07 2.40      
67057 Yaf2 -1.29 -1.96      
235320 Zbtb16 2.04 1.90      
22724 Zbtb7b 1.21 1.93      
207259 Zbtb7c -1.22 1.92      
67106 Zbtb8os -1.17 -1.88      
230738 Zc3h12a -2.07 1.28      
71164 Zdhhc11 -1.83 -1.24      
239102 Zfhx2 -1.27 1.95      
69234 Zfp688 -1.02 -2.23      
218441 Zfyve16 1.12 1.86      
65100 Zic5 -2.22 1.04      
665902 Zscan4f 1.38 2.59      
 
Table 3 Target genes in ES Hey1+, EC Hey1+ (A) and ES Hey2+, EC Hey2+ (B). Analysis was 
performed as described in section 5.3.5 and revealed 106 Hey1 target genes and 382 Hey2 target 
genes. For each target gene Entrez ID, gene name and fold change after Hey1 and Hey2 
overexpression are presented. If no number for the fold change is indicated, selection criteria were not 
fulfilled and the gene was excluded from analysis.  
A    B    
Entrez ID Gene fold change Entrez ID Gene fold change 
  ES Hey1
+ EC Hey1+    ES Hey2
+ EC Hey2+ 
100043040  1.97 -1.31 14980  1.84 1.14 
100217431   2.01 77633  -1.95 1.21 
100302648   -1.82 108112  1.93  
100316809  -2.22  272396  -1.61 -1.81 
100499530  -2.22  624713  -2.64 1.54 
100503498   -2.05 652925  -2.01  
100526469  1.31 -2.00 665037  4.15 -1.01 
100526479   -2.02 751556  -2.07 1.06 
100628584   -1.95 100042464  3.59  
100628588   -1.98 100043609   -2.23 
100628612   -2.80 100043813  -2.30 1.09 
100628620   -2.02 100049713  -2.06  
68347 0610011F06Rik 1.12 1.83 100169889  2.73 -1.06 
66061 0610012D17Rik 1.05 -1.89 100316809  1.90  
75394 0610040F04Rik -1.96 1.43 100415787  -2.38 1.74 
68618 1110012L19Rik -1.81 -1.42 100499530  1.90  
66179 1110031I02Rik -2.15 -1.91 100503879  1.89  
68742 1110032O16Rik -1.97 1.14 100504114  2.04  
85308 1500005A01Rik -1.02 -2.01 100526469  -1.97  
66935 1700023B02Rik -1.96 1.02 100526479  1.81  
66273 1810020D17Rik -1.13 -1.97 100568459  1.81 -1.23 
100910 2010209O12Rik -2.06 1.04 101243624  -2.35  
72093 2010320M18Rik -1.96 -1.01 68332 0610010E21Rik -1.58 -1.96 
70080 2210010C17Rik -2.07  66179 1110031I02Rik -2.36 -1.38 
69642 2310046A06Rik  2.35 69017 1500031I19Rik 2.01  
70419 2810408A11Rik -2.03 -1.73 76927 1700021C14Rik 1.81  
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73172 3110037I16Rik -1.87 -1.17 69513 1700030C10Rik -1.93 -1.05 
73863 4930415O20Rik  -2.16 70011 1700030N03Rik 1.87  
67585 4930455J16Rik -2.29 1.78 67105 1700034H14Rik -1.97 -1.50 
74726 4930523O13Rik -2.24 -1.15 67524 1700095A21Rik -2.11  
223626 4930572J05Rik -2.09 -1.98 66278 1810013D10Rik 1.23 1.82 
70942 4931403E22Rik 3.25 1.05 69186 1810027O10Rik -1.89 -1.34 
67531 5730408K05Rik -1.83 -1.62 66282 1810029B16Rik 1.44 -2.01 
330385 9530026P05Rik 1.07 1.98 66291 1810030N24Rik 2.33  
109202 A930024E05Rik -2.24 -1.08 67892 1810063B05Rik -1.09 1.97 
11474 Actn3 -1.83 1.34 67509 1810063B07Rik -1.15 -1.99 
69010 Anapc13 1.80 -1.28 76527 2010004A03Rik 2.51  
230991 B930041F14Rik -2.10 1.08 69871 2010007H12Rik 1.84 -1.01 
233913 BC017158 -1.92 -1.05 72429 2010203O07Rik 1.23 -2.29 
238024 BC032265 -2.09 1.03 72093 2010320M18Rik -1.41 -2.71 
408058 BC048507 2.05 1.11 76947 2310030N02Rik 1.30 -1.91 
12159 Bmp4 -1.95 1.08 69627 2310031A18Rik  -2.24 
101831 C230052I12Rik -2.47 3.20 69698 2310046K01Rik 1.82  
97863 C78339 1.91 1.01 71918 2310047A01Rik -3.67 -1.01 
76815 Calcoco2 1.83  77032 2610029I01Rik -1.85 -1.35 
12578 Cdkn2a 2.21 1.05 73242 2610110G12Rik 2.01 1.43 
231821 Centa1 -1.85  72481 2610203C22Rik -1.85 -1.19 
68119 Cmtm3 1.80 -1.01 70435 2610204M08Rik 1.93 1.02 
12865 Cox7a1 2.50  545428 2610301F02Rik 1.88  
12873 Cpa3 -1.86 -1.71 68034 2900009I07Rik 2.09 -1.09 
12877 Cpeb1 2.00 1.03 75430 3200002M19Rik 1.01 2.08 
72865 Cxx1c  1.89 69277 3300002I08Rik 1.03 1.92 
60364 Donson -1.84 1.38 67419 3632451O06Rik -2.71 -1.15 
56405 Dusp14 2.52 1.33 319518 4930402E16Rik 1.34 1.96 
68177 Ebpl -1.92 -1.14 432479 4930404N11Rik 1.84  
434197 EG434197 2.35 -1.32 78108 4930414L22Rik -2.20 1.04 
434280 EG434280 -2.29  75060 4930506C21Rik 2.12  
791260 F930017I19Rik -1.82 1.41 74726 4930523O13Rik 2.02  
14226 Fkbp1b 1.97  67651 4930527F14Rik -1.37 -2.40 
17873 Gadd45b -2.19 1.08 75202 4930546H06Rik 2.50 1.10 
229599 Gm129 -2.03 -1.54 78215 4930578N18Rik 1.90  
208080 Gm514 -2.25  70942 4931403E22Rik 3.04 -1.12 
14865 Gstm4 -1.85  74437 4933402E13Rik 3.84  
14872 Gstt2 -2.19  67412 6330407J23Rik 2.11  
15213 Hey1 343.17 15.27 231842 6530401C20Rik 2.06  
75828 Hormad2 -1.85  76219 6530401D17Rik -1.83  
101502 Hsd3b7 -1.99 -1.22 381062 9030025P20Rik 1.87 -1.06 
16336 Insl3  -2.34 71532 9030418K01Rik  -1.85 
70394 Kptn -1.86 -1.19 619321 9530052E02Rik 1.68 -2.29 
16668 Krt18 2.02 -1.56 194268 9930104L06Rik 1.20 -2.14 
16669 Krt19 2.13 1.43 231717 A230106M15Rik -1.86 -1.42 
214048 Larp2 -2.15 1.09 239559 A4galt 1.89  
217708 Lin52 2.18 1.21 381272 A630095N17Rik 2.07  
67774 Loh12cr1 -2.09 -1.05 76491 Abhd14b 2.24 -1.27 
80749 Lrfn1 -1.81 1.85 11433 Acp5 -2.14  
17937 Nab2 -2.27 1.18 433256 Acsl5 -1.98 1.01 
77583 Notum -2.42  11464 Actc1 -5.74  
53324 Nptx2 1.94  106672 AI413582 3.02 -1.10 
217066 OTTMUSG00000001305 -1.98  100165 AI507597 1.83  
627585 OTTMUSG00000010105 2.27 -1.28 11634 Aire 3.57  
64058 Perp -2.18 -1.09 72041 Alkbh4 1.81 -1.09 
330890 Piwil4 -2.11  232566 Amn1 1.98 1.06 
72469 Plcd3 -1.86 -1.02 234396 Ankrd41 1.89  
77619 Prelid2  2.02 12306 Anxa2 1.91 1.11 
65116 Prrg2 -2.64 -1.06 27052 Aoah 2.11  
19171 Psmb10 1.12 -2.02 64933 Ap3m2 2.75 -1.05 
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19228 Pthr1 -2.25  381823 Apold1  -1.94 
19286 Pts -2.61 1.29 13498 Atn1 2.14 -1.01 
242662 Rims3 -2.13  320871 B230206H07Rik 2.38  
56532 Ripk3 -2.09 -1.08 319752 B230209E15Rik -1.83 1.16 
19881 Rom1 2.38 1.08 26879 B3galnt1 -1.61 -2.20 
69938 Scrn1 -2.03 1.30 414069 BC024978 -2.12 -1.85 
20720 Serpine2 -2.13 1.04 277154 BC030046 2.41 1.02 
71781 Slc16a14 2.28  103220 BC030307 -1.87  
20532 Slc3a1 -2.16 -1.15 474160 BC033916 -2.40  
67155 Smarca2 2.92 1.03 381066 BC049807 2.19 -1.15 
20664 Sox1 -2.31  230676 BC059842 1.96 1.26 
20668 Sox13 -1.84 1.19 14705 Bscl2 -1.06 2.06 
20909 Stx4a -2.12 -1.05 57316 C1d 1.01 -2.02 
57429 Sult5a1 1.83 -1.04 654318 C530005A16Rik 1.05 -2.24 
66231 Thoc7 1.80 1.05 76815 Calcoco2 2.13  
75002 Tmprss12 -2.24  12337 Capn5 2.12  
68980 Wdr53 -1.81 -1.44 12367 Casp3 -1.85 1.16 
73750 Whrn -1.82 1.05 12372 Casq1 2.92 -1.67 
230738 Zc3h12a -2.07 1.33 57895 Ccdc126 -1.03 -1.88 
71164 Zdhhc11 -1.83 1.09 232664 Ccdc136 -2.23  
65100 Zic5 -2.22  382073 Ccdc84 1.96 1.33 
    12505 Cd44 -3.50 -1.07 
    12509 Cd59a 2.13 1.02 
    12512 Cd63 -1.81 1.09 
    260409 Cdc42ep3 -2.02 -1.12 
    239096 Cdh24 1.84 -1.01 
    26365 Ceacam1 -2.22  
    12615 Cenpa 1.08 -1.81 
    216859 Centb1 2.14  
    68567 Cgref1 -1.97 -1.35 
    69065 Chac1 -2.22  
    72042 Cotl1 -2.37 1.05 
    12925 Crip1 1.94  
    13032 Ctsc 1.80  
    13034 Ctse 3.11  
    56464 Ctsf -1.12 1.86 
    435802 Cyp4a30b -2.25  
    170716 Cyp4f13 1.31 -1.83 
    12879 Cys1 -2.35  
    225995 D030056L22Rik -1.10 1.95 
    114585 D17H6S53E -1.47 2.08 
    320351 D230037D09Rik -2.51 -1.32 
    654822 D330041H03Rik 1.90 1.19 
    231630 D5Ertd40e -1.19 1.91 
    52480 D7Ertd715e 2.72  
    228859 D930001I22Rik -1.80 1.05 
    13132 Dab2 2.00 1.14 
    240025 Dact2 1.82  
    72185 Dbndd1 2.09 -1.02 
    13198 Ddit3 -1.93 -2.40 
    230073 Ddx58 1.98 1.27 
    209773 Dennd2a -1.83 -1.13 
    13346 Des -1.97  
    13368 Dffb -1.13 1.87 
    107585 Dio3 3.94  
    57431 Dnajc4 1.12 2.01 
    227697 Dolk -1.86 1.21 
    13482 Dpp4 -1.94  
    77490 E130218I03Rik 1.15 2.27 
    320172 E230016M11Rik -1.81 1.03 
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    55960 Ebag9 1.34 -2.06 
    434280 EG434280 -2.69  
    620393 EG620393 1.19 2.09 
    627821 EG627821 1.87  
    665574 EG665574 1.84  
    386655 Eid2 -2.05 -1.06 
    72205 Eml2 1.34 2.07 
    100038468 ENSMUSG00000074385 -1.83  
    98845 Eps8l2 2.59  
    13867 Erbb3 1.90  
    71690 Esm1  -1.97 
    14009 Etv1 1.89 1.29 
    277978 Exoc3l 2.46 -1.15 
    14077 Fabp3 -1.86  
    327959 Fbxo39 2.31  
    230903 Fbxo44 -2.07  
    286940 Flnb 1.90 1.05 
    71436 Flrt3 1.23 2.07 
    226844 Flvcr1 2.29 1.03 
    54418 Fmn2 1.81  
    14268 Fn1 2.46 1.07 
    15221 Foxd3 2.00  
    54601 Foxo4 -1.99 -1.06 
    14369 Fzd7 1.36 3.85 
    14473 Gc 2.90  
    80860 Ghdc -1.13 2.07 
    14620 Gjb3 2.13  
    73690 Glipr1 -1.06 2.27 
    110304 Glra3 1.03 1.81 
    93692 Glrx 1.85 1.13 
    228730 Gm114 -1.29 1.81 
    57441 Gmnn -1.25 1.83 
    14676 Gna15 -2.32 2.46 
    215798 Gpr126 -2.44 1.04 
    14766 Gpr56 10.24  
    14804 Grid2 1.91 1.36 
    14873 Gsto1 1.95 1.02 
    67371 Gtf3c6 -1.07 -1.83 
    14964 H2-D1 1.89 1.34 
    15114 Hap1 1.98  
    67666 Hapln3 2.44  
    171285 Havcr2 -1.84  
    15200 Hbegf -2.09 -1.28 
    70315 Hdac8 -1.01 -2.08 
    320473 Heatr5b 1.94 1.11 
    69536 Hemk1 1.87  
    15214 Hey2 23.77 3.26 
    15277 Hk2 1.22 1.90 
    53602 Hpcal1 -2.57 1.03 
    15473 Hrsp12 -1.52 -1.95 
    15530 Hspg2 1.89 1.12 
    15894 Icam1 2.48 1.13 
    50723 Icosl 1.81  
    15901 Id1 -1.09 1.98 
    15903 Id3 2.85 -1.06 
    68713 Ifitm1 1.90  
    16002 Igf2 -2.49 -1.01 
    239114 Il17d -2.33  
    16336 Insl3 1.45 -1.88 
    20403 Itsn2 -1.96 -1.02 
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    170771 Khdrbs2 -1.34 -2.19 
    16548 Khk -1.80 -1.38 
    242721 Klhdc7a 2.28  
    70394 Kptn 1.02 -1.89 
    16669 Krt19 2.40  
    16776 Lama5 1.92 1.43 
    214048 Larp2 -2.01  
    13590 Lefty1 -2.92  
    320202 Lefty2 -2.22  
    232798 Leng8 1.98 1.01 
    67803 Limd2 -2.37 1.03 
    628308 LOC628308 1.81 -1.35 
    628709 LOC628709 -2.63  
    16971 Lrp1 1.84  
    100604 Lrrc8c -2.02 -1.01 
    17035 Lxn 2.33 -1.00 
    17087 Ly96  -1.91 
    26921 Map4k4 -2.14 -1.09 
    226778 Mark1 -1.81  
    26922 Mecr 1.24 -2.19 
    17299 Mettl1 1.12 -1.80 
    100034361 Mfap1b -1.08 1.92 
    69572 Mfsd3 1.90  
    17314 Mgmt -1.36 -1.91 
    17318 Mid1 1.86 1.19 
    218613 Mier3 1.07 1.91 
    214162 Mll1 1.89 -1.02 
    76915 Mnd1 -1.83  
    64660 Mrps24 -1.04 -1.88 
    17888 Myh6 -9.20  
    98932 Myl9 -1.93 1.10 
    18039 Nefl 2.26 -1.31 
    18030 Nfil3 -1.24 -2.95 
    18073 Nid1 1.92 1.13 
    77583 Notum -2.45  
    74091 Npl -2.48 1.77 
    53324 Nptx2 2.83  
    68501 Nsmce2 -1.23 2.13 
    106338 Nsun3 2.13  
    18208 Ntn1 2.17 -1.53 
    229228 Nudt6 2.02  
    77595 Nup210l -2.27 1.42 
    75475 Oplah 1.93  
    14539 Opn1mw -2.02 1.05 
    52793 ORF9 -2.24 -2.50 
    433287 OTTMUSG00000022109 1.35 -1.97 
    73162 Otud3 1.07 -2.41 
    76498 Paqr4 1.15 -1.82 
    93737 Pard6g -2.57 1.34 
    30052 Pcsk1n -1.89  
    18574 Pde1b 2.29  
    18616 Peg3 2.31 -1.19 
    64058 Perp -2.78  
    69129 Pex11c 2.03 -1.15 
    18639 Pfkfb1 2.46  
    66268 Pigyl 2.01 -1.62 
    18715 Pim2 1.97 -1.15 
    85031 Pla1a 3.33  
    329502 Pla2g4e -2.24 -1.59 
    18793 Plaur 1.88 -1.24 
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    319455 Pld5 -1.48 -1.90 
    269608 Plekhg5 2.10 -1.03 
    84094 Plvap 1.81 -1.26 
    67448 Plxdc2 -2.54 1.17 
    110312 Pmch -1.98  
    99011 Pomt1 1.84 1.46 
    18997 Pou4f2 2.11  
    67905 Ppm1m -1.95 1.05 
    217430 Pqlc3 1.83 1.82 
    381813 Prmt8 -3.27  
    64292 Ptges 2.55  
    19245 Ptp4a3 -1.84 -1.21 
    329384 Ptrh1 -2.34 -1.10 
    226422 Rab7l1 2.14 1.31 
    227746 Rabepk 1.16 -1.83 
    67286 Rabl5 1.80 1.33 
    56089 Ramp3 3.19  
    223864 Rapgef3 1.83 -1.13 
    218772 Rarb -1.24 2.28 
    109222 Rarres1  -2.29 
    68895 Rasl11a 2.14  
    54354 Rassf5 2.29 1.40 
    26611 Rcn2 -1.89 -1.15 
    226594 Rcsd1 2.82 -1.03 
    58175 Rgs20 -1.08 1.90 
    13650 Rhbdf1 1.92 1.00 
    11858 Rnd2 -2.17  
    218215 Rnf144b 1.56 2.12 
    26564 Ror2 1.81  
    622404 RP23-195K8.6 1.68 -1.91 
    57294 Rps27 -2.30 1.09 
    101122 Rpusd3 1.26 -2.29 
    74648 S100pbp 1.08 -2.44 
    56367 Scoc -2.34 1.03 
    20720 Serpine2 -2.50 1.17 
    74729 Setmar -1.37 1.95 
    53609 Sfrs16 2.00 -1.03 
    20401 Sh3bp1 2.66  
    20482 Skil -2.14 -1.02 
    237831 Slc13a5 5.31  
    71781 Slc16a14 2.10  
    110877 Slc18a1 -2.41  
    55963 Slc1a4 -1.90 1.18 
    59049 Slc22a17 1.52 1.99 
    67554 Slc25a30 1.81 1.30 
    71279 Slc29a3 2.23 1.14 
    108652 Slc35b3 1.07 1.90 
    72027 Slc39a4 2.10 -2.10 
    242259 Slc44a5 -1.00 -1.80 
    56774 Slc6a14 -1.88  
    240332 Slc6a7 3.35  
    11989 Slc7a3 -1.89  
    24059 Slco2a1 2.30  
    67155 Smarca2 3.59 1.26 
    330959 Snapc5 -1.15 -1.91 
    104367 Snora65 2.63  
    20664 Sox1 -2.66  
    214616 Spata5l1 1.79 -2.20 
    101809 Spred3 2.19 -1.16 
    20446 St6galnac2 1.97  
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    29819 Stau2 -1.91 1.28 
    20907 Stx1a 2.00 1.11 
    57429 Sult5a1 3.53  
    68760 Synpo2l 3.07  
    67249 Tbc1d19 -1.18 1.94 
    21407 Tcf15 -2.17  
    226896 Tcfap2d -1.88 -1.34 
    67978 Tctn2 -1.10 2.02 
    21679 Tead4 1.96 1.13 
    21752 Tert 2.00  
    21803 Tgfb1 1.85 1.08 
    69876 Thap3 1.83 -1.10 
    386612 Thoc6 -1.03 -1.97 
    30058 Timm8a1 -1.84  
    101883 Tmem149 1.83  
    67698 Tmem157 -1.35 -1.98 
    224019 Tmem191c 1.80  
    236792 Tmem32 -1.20 2.11 
    56277 Tmem45a -2.25  
    230657 Tmem69 -1.91 1.51 
    233979 Tpcn2 1.24 1.85 
    67971 Tppp3 -1.80  
    74019 Traf3ip1 -1.05 1.97 
    59005 Trappc2l -2.09 1.06 
    22041 Trf 1.84  
    22044 Trh -2.07  
    66597 Trim13 -1.93  
    235631 Tsp50 2.55  
    21912 Tspan7 -1.25 -1.85 
    52808 Tspyl2 -1.19 2.25 
    235330 Ttc12 2.50 1.07 
    237930 Ttll6 2.61  
    22147 Tuba3b -1.82  
    233276 Tubgcp5 1.27 -1.80 
    22172 Tyms-ps -1.03 -1.83 
    22350 Vil2 -1.01 2.21 
    637908 Vmn2r53 -1.88  
    22365 Vps45 1.14 2.08 
    320808 Wdr22 -1.93 1.00 
    76646 Wdr38 -2.42 -1.76 
    103784 Wdr92 -1.82 -1.10 
    434204 Whdc1 2.39 -1.90 
    320916 Wscd2 2.40  
    67057 Yaf2 -1.96 1.02 
    235320 Zbtb16 1.90  
    22724 Zbtb7b 1.93 1.09 
    207259 Zbtb7c 1.92  
    67106 Zbtb8os -1.88 1.08 
    239102 Zfhx2 1.95 -1.16 
    56220 Zfp386 1.08 2.15 
    68040 Zfp593 -1.19 1.85 
    69234 Zfp688 -2.23 -1.08 
    69020 Zfp707 1.56 -2.29 
    218441 Zfyve16 1.86 -1.11 
    665902 Zscan4f 2.59  
    67538 Zswim3 -1.09 -1.91 
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